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1 ABSTRACT 
Spinal muscular atrophy (SMA) is a devastating childhood motor neuron disease caused by 
mutations in the survival motor neuron 1 gene (SMN1). SMN1 and SMN2 are nearly identical 
genes producing the survival of motor neuron (SMN) protein. SMN protein plays a crucial 
role in mRNA splicing and β-actin mRNA transport along the axons. In SMA the mutation 
leads to the loss of SMN1, which cannot be fully compensated by the SMN2 gene, which 
predominantly produces a truncated protein. The loss or reduction of SMN protein leads to 
motor axonal defects and motor neuron cell death. There are currently no treatments 
available but therapies have focused on increasing SMN through replacing SMN1 or 
increasing full length SMN from SMN2. The actin-binding protein Plastin 3 (PLS3) has 
been reported as a modifier for SMA, making it a potential therapeutic target. Recently, it 
was shown that the overexpression of the PLS3 gene improved axonal outgrowth in SMN-
deficient motor neurons of SMA Zebrafish and cultured motor neurons from mouse 
embryos.  
 
Gene therapy using viral vectors was carried out in vitro and in vivo to assess whether the 
overexpression of PLS3 could rescue neuronal loss in SMA and be developed as a therapy. 
The SMNΔ7 mouse model produces low levels of SMN, modelling severe SMA disease 
with an average lifespan of 12 days and loss of motor neurons. This study has established 
that the SMNΔ7 mice have little or no detectable PLS3 from birth, making it a good model 
for developing PLS3 gene therapy. Lentiviral vectors were able to upregulate PLS3 
expression in different cell lines. Transduction of NSC34 cells with LV-PLS3 vector led to a 
five-fold increase in expression of PLS3 compared to controls. In smn-deficient MNs, 
expression of PLS3 restored axonal length and showed a strong neuroprotective effect. 
 
Pre-clinical in vivo proof-of-concept studies using adeno-associated virus serotype 9 
(AAV9) encoding PLS3 in SMNΔ7 mice showed high transduction efficiency and 
overexpression of PLS3 specifically targeted to neurons in the central nervous system 
(CNS). This led to a small but significant increase of lifespan by 54%. However, PLS3 was 
not able to prevent disease onset. Although there was no improvement of phenotype, this 
study has demonstrated the potential use of PLS3 as a target for gene therapy, possibly in 
conjunction with other modulators of disease.  
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1.1 Spinal Muscular Atrophy 
Spinal Muscular Atrophy (SMA) is a childhood form of motor neuron disease 
characterized by the loss of alpha motor neurons (MNs) of the anterior horns in the 
spinal cord, resulting in symmetrical muscular weakness and hypotonia (Simic et al., 
2008). It is a relatively common lethal autosomal recessive disease (the second after 
cystic fibrosis), with an early onset, usually in childhood (Prior et al., 2009, Cherry 
and Androphy, 2012). The prevalence of the disease is 1/6,000 - 1/10,000 of 
children, where about 50% of those affected die before the age of two (Aschauer et 
al., 2013).  
1.1.1 Disease classification and clinical features 
Werdnig first described SMA in 1891, and in 1995 the survival of motor neuron 
(SMN) gene was identified as the causative gene for SMA (Lefebvre et al., 1995). 
95% of SMA cases result from the deletion of SMN1 (Prior et al., 2009), while 5% 
of the cases are caused by small mutations (splice mutants, small deletions and 
missense mutations) in the SMN1 gene (Alías et al., 2009) leading to the reduction 
of the SMN protein (Prior et al., 2009, Cherry and Androphy, 2012).  
The clinical severity of SMA can vary widely, ranging from death in infancy to 
disability in adulthood. The disease has been classified into: Type I, Type II, Type 
III and type IV, depending on the clinical manifestations and age at onset of disease 
(Table 1-1) (Hua et al., 2011, Wertz and Sahin, 2015). Type I is the most severe 
through to type IV which is the least severe. 
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Table 1-1 Classification of spinal muscular atrophy 
Type Age of disease onset  Clinical symptoms 
Werdnig-Hoffmann disease 
(SMA Type I)  
New born - 6 months   Never sit without help 
                                                                                                                 
Chronic SMA (SMA Type II)  
 
6 - 18 months  Sit but cannot stand or walk 
Kugelberg-Welander  
disease (SMA Type III)         
 
After18 months without aid Stand and walk 
Adult type (SMA Type IV)  >18 years  Stand and walk without aid 
(Hua et al., 2011, Wertz and Sahin, 2015) 
SMA Type I (Werdnig-Hoffmann disease) is lethal in children; the onset of the 
disease occurs by 6 months leading to death before the age of 2 years, usually due to 
respiratory failure (Schreml et al., 2013, Wertz and Sahin, 2015). Those affected 
never develop the ability to sit without aid (Dubowitz, 1999).  
SMA Type II (chronic SMA) is the intermediate form of the disease in terms of its 
severity, with age of onset from 6 - 18 months. Children are able to sit unsupported, 
however they never acquire the ability to stand or walk independently (Wadman et 
al., 2012a, Wertz and Sahin, 2015).They survive beyond the age of 2 and can live 
into adolescence or even longer (Russman et al., 1996).  
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SMA Type III (Kugelberg-Welander disease) is the mild form of the disease. The 
onset of the disease starts after 18 months (Kinali et al., 2002, Wertz and Sahin, 
2015) and patients are usually able to walk, although most of them lose the ability to 
walk around puberty  (Kinali et al., 2004). The life expectancy of these patients can 
be normal (Russman et al., 1996). 
SMA Type IV was added to the disease classification in order to account for patients 
with adult onset (>18 years) and mild symptoms. Patients with SMA type IV are able 
to walk and do not suffer from respiratory and nutritional problems (Aschauer et al., 
2013, Wertz and Sahin, 2015). 
In cases where SMN1 is deleted copy number of SMN2 modulates the severity of 
SMA (Lefebvre et al., 1995) (Table 1-2), with the majority of patients retaining 
between 2 and 4 copies of SMN2 (Chang et al., 2001, Locatelli et al., 2015). 
Nevertheless, the expressed SMN protein amount from SMN2 gene does not provide 
sufficient protection from SMA (McAndrew et al., 1997). However, there are 
families with identical SMN2 copy numbers that may have radically different disease 
severity (Oprea et al., 2008), implying that additional factors must also contribute to 
disease. [ 
Table 1-2  SMA severity correlated to SMN2 copy number 
 SMA Type Severity SMN2 copies 
Type I Severe One or two 
Type II Intermediate Three 
Type III Mild Three or four 
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(Chang et al., 2001) 
1.2 Survival of motor neuron (SMN) 
1.2.1 SMN gene 
The human SMN gene is located on chromosome 5 region 5q11.2 - 5q13.3 and 
encodes SMN, a 294 amino acid protein implicated in Ribonucleic acid (RNA) 
splicing as part of the small nuclear ribonucleoprotein (snRNP) complex(Sahashi 
and Sobue, 2014), stabilisation of the axonal growth cone in neurons, and the 
formation of neuromuscular junctions (Melki et al., 1990). 
In humans the SMN gene exists in two copies, the telomeric copy (SMN1) and the 
centromeric copy (SMN2) (Zheleznyakova et al., 2011). The two SMN isoforms have  
99.9% sequence homology, have equivalent promoters (Echaniz-Laguna et al., 
1999), and express RNA (Lefebvre et al., 1995) and protein ubiquitously (Coovert et 
al., 1997). Of the functional full length SMN (FL-SMN) protein, 90% is derived 
from SMN1, while the rest (10%) is produced by SMN2 (Helmken et al., 2003, 
Locatelli et al., 2015).  SMN2 is an inverted repeat of SMN1 with a single mutation 
(cytosine -thymine (C-T) at position 6 of exon 7) that results in 90% of its translated 
product being truncated and non-functional (Lorson et al., 1999). The mutation in 
SMN2 disrupts the exonic splice enhancer site (ESE) (Cartegni and Krainer, 2002) 
and forms an exonic splicing silencer site (ESS) (Kashima and Manley, 2003, 
Sahashi and Sobue, 2014), which results in the splicing out of exon 7(Sahashi and 
Sobue, 2014). The SMN2 gene, therefore, generates mostly a transcript lacking exon 
7 (SMNΔ7) (Figure 1.1) (Lefebvre et al., 1995, Sahashi and Sobue, 2014). This 
gives rise to a truncated and highly unstable protein with a severely decreased 
oligomerisation efficiency and reduced functional activity (Locatelli et al., 2015). 
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Approximately 10% of SMN2 transcripts are able to undergo correct splicing to 
include exon 7 and producing FL-SMN (Cho and Dreyfuss, 2010, Locatelli et al., 
2015).  
     
 
Figure 1.1. SMN1 and SMN2 Splicing 
The two SMN human gene copies are located on chromosome 5 in the 5q13 region and differ 
by a single nucleotide exchange (C-to-T) on exon 7. This mutation affects SMN2 splicing 
resulting in SMNΔ7 mRNA, lacking exon 7. When translated a truncated, unstable, and 
easily degraded protein is produced. Despite this around 10% of SMN2 transcripts undergo 
correct alternative splicing to form fully functional full length protein. SMN, survival motor 
neuron, full-length SMN protein (FL-SMN), exonic splice enhancer site (ESE) and exonic 
splicing silencer site (ESS) 
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1.2.2 SMN protein 
SMN is a ubiquitously expressed protein crucial for cell survival, independently of 
cell type. In humans, high levels of the protein are found in the spinal cord, kidney, 
liver and brain tissues (Coovert et al., 1997). The SMN protein is 38 kDa in size and 
is localized in the cytoplasm and in structures in the nucleolus known as "gemini of 
coiled bodies" (gems), that associate with nuclear coiled bodies (Young et al., 2000, 
Borg and Cauchi, 2014). 
SMN is involved in pre-mRNA splicing (Pellizzoni et al., 1999) and it also binds to 
heterogeneous nuclear ribonucleoprotein (hnRNP-R) (Rossoll et al., 2002). 
1.2.2.1 The role of SMN protein in snRNPs assembly 
95% of mammalian genes produce more than one mRNA from a single transcript 
through the process of alternate splicing, whereby different exons are removed to 
generate different proteins or isoforms (Chen and Manley, 2009, Borg and Cauchi, 
2014). Splicing is carried out by the spliceosome, a large RNA-protein complex 
composed of five small nuclear ribonucleoprotein particles (snRNPs) and many 
proteins, which recognise splice sites, bind and catalyse the removal of introns 
(Figure 1.2). SMN protein is essential in snRNP assembly in every cell type, 
including neurons (Avila et al., 2007, Burghes and Beattie, 2009, Li et al., 2014). 
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Figure 1.2. Role of SMN protein in snRNP assembly 
The SMN complex (SMN protein and Gemins 2-8) mediates the assembly of Sm core 
proteins onto U-snRNAs, forming active snRNPs that enter the nucleus to perform pre-
mRNA splicing. Survival motor neuron (SMN), small nuclear ribonucleoprotein particles 
(snRNPs) and heptameric ring of Sm proteins (sm protein). This diagram was adapted and 
modified from (Workman et al., 2009) 
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SMN along with other proteins known as Gemins 2–8 form the SMN complex, 
which allows a heptameric ring of Sm proteins (proteins to associate onto snRNA) 
(Pellizzoni, 2007, Tisdale et al., 2013), allowing for the cytoplasmic assembly of 
snRNPs (Fischer et al., 1997). snRNPs are RNA-protein complexes that, along with 
other proteins and unmodified pre-mRNAs, form the spliceosome, a large protein 
complex involved in splicing pre-mRNAs (Figure 1.2) (Tarn and Steitz, 1997, Li et 
al., 2014). Once the snRNPs are formed they get transferred into the nucleus where 
they carry out pre-mRNA splicing (Pellizzoni, 2007, Li et al., 2014). Therefore, 
SMN has been shown to be essential in the formation of snRNPs. 
1.2.2.2 The function of SMN protein in motor axon growth 
SMN protein granules are located in growth cones and axons of MNs (Sharma et al., 
2005, Fallini et al., 2012, Dombert et al., 2014) where it forms a ribonucleoprotein 
complex (Zhang et al., 2006). SMN was shown to be involved in the transport of 
RNA complexes containing hnRNP-R, Sm-like proteins (lsm), and β-actin mRNA 
within MNs to the axon tips (Todd et al., 2010, Ting et al., 2012). Defects in the 
mRNA transport process cause alterations of synapses and the formation of truncated 
axons (Figure 1.3) (Rossoll et al., 2002, Fallini et al., 2012).    
This finding was supported by the work done in zebrafish where knockdown of the 
smn gene lead to axonal defects (McWhorter et al., 2003). The reduced axonal 
growth resulting from smn protein deficiency in MNs was correlated with reduced β-
actin protein and mRNA levels in growth cones (Rossoll et al., 2003). Furthermore, 
lsms were found in a RNP complex in axons (Young et al., 2001). It has been 
postulated that the reduced level of Smn protein affects the assembly of lsm proteins 
resulting in a reduced transportation of mRNA and β-actin to the axon tip, which in 
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turn reduces specific gene expression at the synapse causing its alteration (Workman 
et al., 2009). On the other hand, several SMA mouse studies showed no axon 
outgrowth defect in vivo (Murray et al., 2009).  Murray et al, have shown in 
Smn−/−;SMN2 mice, a model of severe SMA that reduced Smn levels have no 
detectable effect on morphology of pre-symptomatic development in either 
vulnerable or stable motor units, indicating that abnormal pre-symptomatic 
developmental processes are unlikely to be a prerequisite for subsequent pathological 
changes to occur in vivo (Murray et al., 2009). The potential implications for 
developmental versus a degenerative mechanism of SMA disease pathogenesis is 
still unclear. 
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Figure 1.3. Role of SMN protein in axons  
SMN was shown to be involved in the transport of RNA complexes such as hnRNP-R, Lsm, 
mRNA and β-actin within MNs to the axon tips. Disruption of this transport can cause 
alterations of the synapse. Survival motor neuron (SMN), Sm like protein (Lsm), 
hetregenous nuclear ribonucleoprotein (hnRNP-R) and messenger ribonuclear protein  
 (mRNA). This diagram was adapted and modified from (Coady and Lorson, 2010) 
 
 
Additionally, a role of Smn in neuromuscular junction (NMJ) development was also 
suggested (Kariya et al., 2008, McGovern et al., 2008, Kong et al., 2009). 
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Furthermore, pre-synaptic defects such as impaired synaptic vesicle release, 
intermediate filament aggregates, and poor terminal arborisation have been identified 
in motor neurons when SMN is absent or depleted (Kariya et al., 2008, McGovern et 
al., 2008, Kong et al., 2009, Ting et al., 2012). Moreover, β-actin mRNA and protein 
staining was reduced in growth cones and distal axons (Rossoll et al., 2003). These 
findings suggest a crucial role for Smn in neurodevelopment.  
1.2.3 Motor Neuron Dysfunction in SMA  
The key clinical feature of SMA is the selective and progressive loss of motor 
neurons. Loss of innervation of muscles has been described throughout the body in 
various affected muscle fiber types, which was thought to be due to defects in 
synaptic maturation or maintenance (Swoboda et al., 2005, Ling et al., 2011). Due to 
poor synapse formation and lack of differentiation, SMA patients usually show 
abnormal migration of MNs towards the ventral roots of spinal cords before later 
succumbing to necrosis (Simic et al., 2008, Shababi et al., 2014). Several SMA 
animal models, such as Drosophila, zebrafish and mouse are characterized by axon 
degeneration and neuromuscular junction (NMJ) defects (Chan et al., 2003, 
McWhorter et al., 2003, Rossoll et al., 2003, Jablonka et al., 2004, Winkler et al., 
2005, Boon et al., 2009, Martinez et al., 2012). In the SMAΔ7 mouse model, defects 
in axonal transport of synapse proteins have been reported, suggesting the presence 
of defects in NMJs and synapses of MNs (Dale et al., 2011). A mild SMA mouse 
model showed altered NMJ morphology and reduced neurotransmitter release 
(Wadman et al., 2012b, Ruiz and Tabares, 2014). Defects have also been seen in the 
structure of the pre- and post-synaptic apparatus with accumulation of vesicles and 
changes in receptor clustering reported (Martínez-­‐Hernández et al., 2013). To date, 
Chapter 1: Introduction 
12 
 
two main hypotheses have been proposed to simplify the molecular mechanism 
behind the death of motor neurons: (a) Loss of splicing activity and (b) dysfunction 
in transportation of mRNA to the axon tips.  
SMN has been shown to be crucial in catalyzing the formation of snRNPs. In SMA 
there is enough SMN produced by SMN2 to allow cell survival, but a lack of snRNPs 
caused by low SMN levels may restrict or modulate the splice sites selected. This 
could produce a lack of certain proteins due to other splice variations being favored. 
Gabanella et al. showed that the activity of snRNP assembly is reduced dramatically 
in the spinal cords from SMA mice and this assembly correlates with the disease 
severity (Avila et al., 2007). Some snRNPs are down-regulated by the disease; 
however, this change is not motor-neuron-specific and is only seen at late stage of 
the disease (Zhang et al., 2008, Bäumer et al., 2009) suggesting this is not solely 
responsible for disease.  
Axonal growth defects and synaptic alteration are due to impaired trafficking and 
reduced transportation of molecules such as β-actin mRNA, which results in reduced 
specific gene expression at the synapse (Rossoll et al., 2003, Workman et al., 2009, 
Fallini et al., 2012, Shababi et al., 2014). SMN may be involved in RNA metabolism 
and transportation. In the cell body of motor neurons, mRNAs are packaged into 
translationally silent messenger ribonucleoproteins (mRNPs) and transported along 
the axon to distant parts of the cell to be produced on demand. In SMA there is a 
disruption of β-actin localisation in the neuronal growth cones suggesting transport 
impairment. The role of SMN in mRNA localisation and axonal transport is not 
clear(Fallini et al., 2012), but SMN may form part of the mRNP complex, similar to 
the snRNP complex; therefore, a lack of SMN prevents efficient formation of 
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mRNPs and disruption of transport to the distal parts of the neurons (Di Penta et al., 
2009).   
Depleted SMN protein levels in the growth cone of MNs also causes reduced axonal 
length (Oprea et al., 2008). Zebrafish expressing low levels of SMN display 
significant motor defects and shorter axons with fewer branches (Hao et al., 2012). 
This leads to abnormalities at both the NMJ and the synapse. SMN protein over-
expression can restore MN synapses and NMJ defects (Wadman et al., 2012b, 
Shababi et al., 2014). Surprisingly, SMN deficiency appears to affect only some 
muscles; for example, NMJ defects have been reported in the diaphragm but not in 
the soleus muscle (Voigt et al., 2010, Mikesh et al., 2011). The loss of innervation of 
affected muscles is thought to be due to the defects in synaptic maturation or 
maintenance (Ling et al., 2011).  
1.2.4 Other SMA disease modifiers 
Many proteins in the nucleus, growth cones and MN axons interact with SMN. Some 
of these have been reported to act as SMA disease modifiers (Oprea et al., 2008). 
Actin protein levels in growth cones of SMN-deficient MNs are reduced, suggesting 
that it may be important in the pathology of MNs in SMA. (Rossoll et al., 2003, 
Ning et al., 2010). Rossoll and colleagues suggested a role for SMN in the transport 
of these complexes, such as hnRNP-R, Lsm and β-actin mRNA within MNs (Rossoll 
et al., 2002).    
In MNs, SMN has been shown to associate with various molecules involved in RNA 
binding such as hnRNP-R, Plastin3 (PLS3) and Profilin II (Giesemann et al., 1999, 
Oprea et al., 2008, Chen et al., 2010, Akten et al., 2011, Fallini et al., 2011). The 
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RNA-binding proteins PLS3 and hnRNP-R were reported to co-localize with SMN 
in MNs and also associate with β-actin mRNA (Rossoll et al., 2003, Oprea et al., 
2008). In addition, hnRNP-R protein was previously identified as one of the proteins 
involved in RNA processing, where hnRNP-R binds RNA (Rossoll et al., 2002). 
Interestingly, PLS3 or hnRNP-R knockdown causes axon defects similar to SMN 
deficiency while PLS3 or hnRNP-R overexpression led to an increase in axonal 
length (Rossoll et al., 2003, Oprea et al., 2008).  
Profilin II is expressed predominantly in MNs; profilins are known to control β-actin 
dynamics and bind strongly to SMN (Bowerman et al., 2009). Furthermore, it has 
been shown that profilin II and hnRNP-R interact with both SMN and β-actin. 
Profilin II and PLS3 have been implicated in SMA actin dysregulation, where 
knockout of profilin II upregulates PLS3 expression in SMA mice. However, 
restoration of PLS3 protein and depletion of profilin II does not rescue SMA 
phenotype (Bowerman et al., 2009). This suggests that other actin dynamics 
regulators must contribute to rescue the SMA phenotype.  
Silencing of the Phosphatase and tensin homolog (PTEN), known to act as a 
regulator of cell growth, rescued axon length defects in cultured Smn-deficient MNs 
(Ning et al., 2010). Subsequently, a study reported that PTEN depletion led to an 
increase in survival of Smn-deficient MNs (Ning et al., 2010). Recently, another 
study by the same group showed that systemic suppression of PTEN was able to 
decrease SMA severity and prolong survival in a SMA mouse model (Little et al., 
2014). A single injection of self-complementary adeno-associated virus serotype 9 
expressing small interfering RNA (siRNA) against PTEN (scAAV9-siPTEN) at 
post-natal day 1 resulted in a 3-fold extension of the life span of SMNΔ7 mice, 
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revealing that PTEN can act as a disease-modifier in SMNΔ7 mice (Little et al., 
2014). 
1.3 Plastin3 
Fimbrins/plastins are a family of extremely conserved actin-bundling proteins (Arpin 
et al., 1994). The discovery of PLS3 as a potential disease modifier has opened up 
new prospects of understanding the exact mechanism of SMA pathology 
(Ackermann et al., 2012) and has shed light on the role of PLS3 in protecting against 
the disease. Eukaryotic cells express a large amount of actin-binding proteins 
(Delanote et al., 2005). According to Bretscher & Weber many biological processes 
involve a dynamic network of proteins in eukaryotic cells within the actin 
cytoskeleton, including cell motility, cell substrate adhesion, intracellular transport, 
endocytosis and exocytosis, cytokinesis, and cell morphology (Bretscher and Weber, 
1980). Furthermore, increasing evidence has shown that actin cross-linking or actin-
bundling proteins may control actin dynamics in addition to structuring the cortical 
actin cytoskeleton (Giganti et al., 2005).  
1.3.1 Human Plastin Gene 
Two ubiquitous plastin isoforms have been identified in humans, (L and T). The T 
isoform has been found in cells of all solid tissues, which have replicative potential 
such as fibroblasts, epithelial cells, melanocytes, and endothelial cells. In contrast, 
the L isoform is expressed in the hematopoietic cell line only (Lin et al., 1993).  
The T-plastin and L-plastin isoforms were mapped to chromosomes X and 13, 
respectively. Each gene was composed of 16 exons and was approximately 90 kbp in 
size. The T-plastin and L-plastin proteins have 83% identical C-terminal amino acids 
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(Otto, 1994). A potential calcium-binding site was localised to the N terminal part of 
the protein (De Arruda et al., 1990, Castresana and Saraste, 1995). The PLS3 gene is 
a protein-coding gene encoding a T-plastin, PLS3. Alternate splicing results in 
multiple transcript variants of PLS3 (Ackermann, 2011). Several diseases are 
associated with PLS3, including cutaneous T-cell lymphoma and osteoporosis 
(Yokobori et al., 2013).  
1.3.2 Plastin3 protein 
In 1979 a family of 70 kDa cytoplasmic polypeptides named plastins were 
discovered (Matsudaira and Burgess, 1979). There are three types of plastins, PLS1 
(I-­‐plastin), PLS2 (L-­‐plastin) and PLS3 (T-­‐plastin), all of which are differentially 
expressed and have similar modular structural domains (Lyon et al., 2013). They are 
evolutionarily conserved, versatile modulators of the actin cytoskeleton and thus 
play an important part in cell migration, adhesion and endocytosis (Lyon et al., 
2013).  
As a general rule it can be concluded that members of the plastin family have been 
identified in cellular regions containing polarized actin filaments and in areas with 
high actin filament turnovers (Arpin et al., 1994). In addition to solid tissues with 
replicative potential PLS3 is also found in muscle, brain, spinal cord, uterus, and the 
oesophagus (Delanote et al., 2005).  
1.3.2.1 Plastin protein structure 
PLS3 can be subdivided into three modules  a pair of actin-binding domains (ABDs), 
variable spacer domains, and a regulatory domain (Castresana and Saraste, 1995). 
Furthermore, there are two N-­‐terminal EF hand motifs which are variably implicated 
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in Ca2+ binding, and two C-­‐terminal actin binding domains (ABDs) each made up of 
two calponin homology (CH) domains (Delanote et al., 2005) (Figure 1.4). 
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Figure 1.4. Plastin protein isoforms structure  
Domain organization in plastin isoforms of different types. A scale (in amino acids) is drawn 
on top of the figure. The protein has an N-terminal headpiece of ~100 amino acids 
containing two EF-hand Ca2+-binding motifs and two actin-binding domains (ABDs) 
consisting of ABD1 (residues~ 100–300) and ABD2 (residues ~400–600), and each ABD 
contains two calponin-homology (CH) domains. Note that human T- and L-plastin contain a 
nuclear export signal (NES). Modified from (Delanote et al., 2005) 
 
The process of bundling actin filaments requires that each ABD bind to an individual 
actin filament (Volkmann et al., 2001). As a consequence, plastin without the 
Chapter 1: Introduction 
18 
 
C-­‐terminal ABD (ABD2) cannot bundle actin (Giganti et al., 2005). The CH 
domains are shared by signalling and cytoskeletal proteins such as dystrophin, α-
actinin, and spectrin. The tandem CH domain is generally involved in actin binding 
(Delanote et al., 2005).  
Giganti and colleagues recently investigated the calcium sensitivity of T-plastin 
(Giganti et al., 2005). The two calmodulin-like calcium-binding domains in plastins, 
known as EF hands, suggest that actin-binding or other functions of plastins could be 
regulated by calcium. The somewhat weak homology in the calcium binding 
domains of T- and L-plastin isoforms could suggest that their actin binding activities 
are differentially regulated by calcium (Namba et al., 1992). This activity could 
contribute to the maintenance and assembly of the actin cytoskeleton of plasma 
membrane protrusions in vivo. 
1.3.3 The role of PLS3 in SMA  
PLS3 is a key regulator that restores processes depending on actin dynamics in SMA 
MNs. Three studies in humans have shown a correlation between PLS3 expression 
and SMA severity in pre- and post-pubertal females, with higher levels of PLS3 
being associated with a reduction in SMA disease severity, even after correcting for 
SMN copy number (Oprea et al., 2008, Hao et al., 2012, Yanyan et al., 2013). 
A transcriptome-wide differential expression analysis performed on total RNA from 
lymphoblastoid cells taken from SMN1-deleted patients with discordant disease 
outcomes revealed a significant association between disease severity and PLS3 
expression. Further analysis of blood samples from a diverse population of SMA 
patients and from healthy controls confirmed this association (Oprea et al., 2008). 
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Stratified analysis of blood samples from SMA type I, II and III patients 
demonstrated that only post-pubertal females show an inverse correlation between 
circulating PLS3 and SMA severity, suggesting a role for PLS3 as an age- and sex-
specific modifier of SMA. The researchers suggest that this sex-specific effect may 
be due to PLS3 mapping to Xq23 (Stratigopoulos et al., 2010, Bernal et al., 2011).  
Since PLS3 expression has been shown to be modulated by SMN in SMA patients 
with SMN1 deletions and in zebrafish and down regulation of Pls3 over time when 
Smn is depleted early Pls3 depletion may affect the development of motor neuron 
axons in these models and may affect motor neuron survival, contributing to the 
SMA phenotype.  
In a smn-/- zebrafish model, Pls3 mRNA splicing and protein stability are unaffected, 
but Pls3 protein levels overall are reduced, therefore, SMN is involved in translation 
of Pls3, although the mechanism is unknown. Partially restoring Pls3 in these 
animals rescued presynaptic defects and motor behaviour, suggesting that Pls3 is not 
merely a correlate of SMN expression, but instead plays a significant role in SMA 
pathology (Hao et al., 2012). Unfortunately, a full restoration of Pls3 was not 
possible and therefore researchers were unable to test the effect on survival (Hao et 
al., 2012). Pls3 orthologs act as SMN modifier genes in C. elegans and Drosophila, 
possibly involving endocytosis and RNA processing pathways (Dimitriadi et al., 
2010). 
PLS3 overexpression stabilised axons, reduced axon pruning and counteracted the 
poor connectivity seen in SMA NMJs (Ackermann et al., 2012). PLS3 
overexpression also increased the number of vesicles available in the presynaptic 
pool. Ubiquitous overexpression modestly improved survival and motor function in 
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SMA mice. Hence, this may be a potential therapeutic target for SMA (Ackermann 
et al., 2012).   
Investigations into the function of PLS3 have begun to shed light on its role in 
protecting against SMA. Removal of the ability of PLS3 to bind to or cross-link actin 
filaments, by deleting one or both of its acting binding domains (ABD1/2) (Fig. 1.4), 
did not fully prevent the molecule from rescuing smn-/- mutant zebrafish. This 
suggested that PLS3 function might involve an additional role unrelated to its 
interaction with actin. Further deletion studies determined that the EF hand motifs, 
and specifically their interaction with Ca2+ ions, are essential for PLS3 function in 
MNs development (Lyon et al., 2013). This is supported by the observation in SMA 
of calcium dysregulation in the growth cone during motor axon outgrowth 
(McGivern et al., 2013).  
A crucial role of Pls3 down regulation in the pathology of SMA was proposed. It is 
important to demonstrate whether the restoration of Pls3 expression can rescue the 
axonal phenotype in spinal motor neurons cultured from a clinically relevant mouse 
model of SMA. In addition to furthering understanding of the function of Pls3, a 
potential use for Pls3 in gene therapy for SMA can be proposed. Since PLS3 
expression has been shown to be modulated by SMN in SMA patients with SMN1 
deletions and in zebrafish. However, there are some limitations that need to be taken 
in to consideration to achieve successful therapy for SMA, such as a clinical time-
window. This will need to combine therapies that both target pathways that rescue 
MN function and increase SMN levels or any other modifier such as PLS3.  
The use of PLS3 overexpression to extend lifespan demonstrates that PLS3 is a 
disease modifier of SMA and a good potential therapeutic target for SMA. PLS3 can 
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be used in a gene therapy approach but may be required to be delivered in 
combination with other disease modulators to give meaningful rescue to motor 
neurons and alleviate the disease phenotype sufficiently. Meeting these challenges 
will likely be essential to cure SMA, particularly in its most severe cases. 
1.4 Models of SMA 
To clarify the complex functions of the SMN protein and the pathology of SMA, the 
availability of SMA experimental models has been important. Several different 
models have been used, each with advantages and disadvantages to study different 
aspects of the disease.  
1.4.1 In vitro Models of  SMA 
In vitro models are mainly useful for early testing of potential therapies and 
understanding molecular pathways involved in SMA. SMA has been modelled in 
vitro using various techniques, including siRNA transfection or transduction with the 
aim of decreasing SMN protein levels in neuroblastoma spinal cord NSC-34 cells 
and primary neurons to disease levels (Acsadi et al., 2009). Purified motor neurons 
from the SMN mouse model have also been used as an in vitro model of SMA (Ning 
et al., 2010). SMA type I fibroblasts have been widely used as experimental tool in 
the field of SMA research (Coovert et al., 1997). 
1.4.2 Animal models of SMA 
In addition to cell models, animal models have also been used to understand the role 
of SMN protein in SMA (Rossoll et al., 2003, McGovern et al., 2008)}. The 
disruption of SMN has been investigated in various species including, Drosophila, C. 
elegans, zebrafish and mouse, with the aim of modelling the disease and gaining 
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fundamental knowledge about the molecular role of SMN protein (Schmid and 
DiDonato, 2007). All SMA models have a single Smn gene which corresponds to 
human SMN1 (hSMN1), the absence of which is lethal in all model organisms 
(Schmid and DiDonato, 2007); therefore, all models are heterozygous or have an 
insertion of human SMN2 to compensate for the loss of Smn.  
1.4.2.1 Mouse Models  
Mouse models are used extensively in studying SMA and the role of SMN protein. 
Mice have a single copy of the Smn gene, which is homologous to the human SMN1, 
and the knockout of this gene was shown to result in embryonic lethality (Schrank et 
al., 1997). Frugier et al. (2000) used the Cre-LoxP system to generate a transgenic 
mouse with a deletion of exon 7 in the Smn gene (Frugier et al., 2000). Mice 
expressing Cre-recombinase specifically under the Neuron-Specific Enolase (NSE) 
promoter were crossed to exon 7 knockout mice. This approach resulted in offspring 
with an average survival age of 25 days, suggesting that the pathological phenotype 
seen in the disease is a result of the SMN protein deficiency in MNs (Jao et al., 
2012). 
Another approach to study SMA was through introducing the human SMN2 gene 
along with its own promoter into Smn-/- mice by microinjecting a plasmid construct 
into mouse oocytes (Schrank et al., 1997). The expression of SMN2 in these mice 
rescued the embryonic lethality; however, the mice developed SMA phenotype 
(Foust et al., 2010). The severity of this phenotype depended on the gene copy 
number introduced into the mice; i.e. the most severe phenotype was observed in 
those with a low SMN2 gene copy number (Monani et al., 2000). 
In a different study, Smn-/-, SMN2+/+ model was used to indicate whether the lack of 
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smn protein is responsible for the maintenance or development of MNs (Schmid and 
DiDonato, 2007). In particular, it was seen that low levels of smn led to excessive 
cell death in the telencephalon region and to some morphological defects in the 
spinal nerves of the mutant embryos (Schmid and DiDonato, 2007). 
Previously, it was shown that the level of SMN∆7 was higher in Type I and Type II 
compared to Type III SMA patients (Sreedharan et al., 2008); therefore, it was 
important to check if the presence of SMN∆7 had a positive or a negative effect in 
SMA patients.  To do so, a Smn-/-, SMN2+/+, SMN∆7+/+ triple transgenic model was 
generated (Le et al., 2005) by introducing a SMN complementary deoxyribonucleic 
acid (cDNA) lacking exon 7 in a severe SMA mouse model described previously 
(Frugier et al., 2000). The lifespan of these mice increased up to 13 days compared 
to the 5 day lifespan of the Smn-/-, SMN2+/+ mice, suggesting that the expression of 
the SMN∆7 protein is not detrimental (Le et al., 2005). This triple transgenic mouse 
model is widely used for therapy development for SMA (see details in section 1.5).  
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Table 1-3 Mouse models of SMA  
Genotype 
 
Lifespan 
 
Phenotype 
 
Reference 
 
Smn-/-; SMN2+/+ 
 
(4-5) Days Severe defects in 
skeletal muscle and 
spinal cord MNs 
 
(Hsieh-Li et al., 2000) 
Smn-/-; SMN2+/+; 
SMNΔ7+/+ 
 
(13) Days Less severe than the 
Smn-/-;SMN2 model 
 
(Le et al., 2005) 
Neuron specific SMN 
mutation 
 
(25) Days Denervation of muscle 
and tremors  
 
(Frugier et al., 2000) 
Muscle specific SMN 
mutation 
 
(33) Days Paralysis due to severe 
muscle defects  
 
(Cifuentes-Diaz et al., 
2001) 
Smn-/-; SMN2+/+; 
SMN (A111G)+/+ 
 
 > 1 year  Moderate model  
 
(Madabusi, 2012) 
 
Although with these mouse models the key feature is neuronal defects there are also 
other changes caused in other organs by reduced SMN protein which indicates that 
SMN is important for different cell types in addition to MNs. Table 1.4 shows other 
organs affected by lack of SMN.   
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Table 1-4 Summary of multi-system phenotypes observed in SMA mouse 
models 
Organ  Mouse model  Observation  Reference 
Muscle  SMN2 and severe 
Taiwanese 
Molecular changes 
occur in muscle prior 
to, and independent of, 
motor degeneration 
(Monani et al., 
2000) 
(Mutsaers et al., 
2011) 
SMN2 Premature 
differentiation of 
skeletal muscle satellite 
cells and failure to 
efficiently form 
multinucleated 
myotubes 
(Hayhurst et al., 
2012) 
SMN Δ7 Decreased muscle fiber 
size 
(Hayhurst et al., 
2012) 
Conditional 
mouse model, 
restoration of 
SMN in muscle 
SMN has a role in 
muscle growth 
(Martinez et al., 
2012) 
Muscle-specific 
SMN knockout 
mouse 
Muscle-specific loss of 
SMN caused muscle 
necrosis with a 
dystrophic phenotype, 
led to muscle paralysis 
and death 
(Cifuentes-Diaz et 
al., 2001) 
Heart  SMN Δ7 Cardiac defects 
apparent at P7; 
bradycardia developed 
by P14 
(Bevan et al., 
2010) 
SMN2, SMN Δ7 Cardiac remodeling 
initiates embryonically 
and mice have 
physiological defects 
such as a drastically 
reduced heart rate; 
interventricular septum 
remodeling initiated at 
P3–P5 
(Shababi et al., 
2010b) 
Severe Taiwanese Interventricular septum 
thinning 
(Gogliotti et al., 
2012) 
Severe inducible 
mouse model 
Significant bradycardia 
from P3 
(Gogliotti et al., 
2012) 
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Lung  Severe Taiwanese Discoloration of the 
lungs suggestive of 
atelectasis or 
pulmonary infarction 
(Schreml et al., 
2013) 
Intestine   Intestinal edema (Schreml et al., 
2013) 
Liver  Severe Taiwanese Reduced expression of 
hepatic Igfals mRNA in 
neonatal liver 
 
(Hua et al., 2011) 
 Liver-specific 
SMN knockout 
mouse 
Liver-specific loss of 
SMN was 
embryonically lethal, 
and resulted in iron 
overload and liver 
atrophy 
(Vitte et al., 2004) 
Bone  Mild  Taiwanese Osteoporotic bone 
phenotype with 
decreased levels of 
osteoblast 
differentiation markers 
(Hsieh-Li et al., 
2000) 
(Shanmugarajan et 
al., 2009) 
Pancreas   2B1 Abnormalities in 
pancreatic islet cells 
with more α cells than β 
cells; fasting 
hyperglycemia, 
hyperglucagonemia, 
and glucose resistance 
(Bowerman et al., 
2012) 
 
1.5  Therapeutic strategies in SMA  
Currently there is no cure for SMA, and therefore treatment is centered on increasing 
the quality of life of patients through relieving secondary symptoms. To date the 
pathogenesis of SMA is not completely understood (James and Sumner, 2011) 
however a lot of effort has been made in trying to understand the molecular 
mechanism of the disease in order to target different therapeutic approaches (Coady 
and Lorson, 2010, James and Sumner, 2011, Castro and Iannaccone, 2014). Based 
on the evidence that SMN expression levels correlate with the disease severity in 
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humans (Farag, 2010), therapeutic development for SMA is mainly focused on 
increasing SMN protein levels by: (a) enhancing SMN2 gene transcription (Rossoll 
et al., 2003); (b) modulating SMN2 splicing (James and Sumner, 2011) ; (Figure 
1.5)(c) gene therapy based SMN replacement using viral vectors. Other therapeutic 
procedures focus on neuroprotection and cell replacement (Farag, 2010). 
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Figure 1.5. Therapeutic strategies for SMA 
The diagram represents the action of ASOs or small nucleotide drugs to: (A) Increase the 
expression levels of SMN transcripts and SMN protein (both full length and truncated). (B) 
Activate inclusion of exon 7 upon splicing of SMN2 pre-mRNA therefore increasing SMN  
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In clinical trials, various compounds have been tested for their ability to increase 
SMN2 expression (Chang et al., 2001, Coady and Lorson, 2010, James and Sumner, 
2011). Some successes have been achieved in finding molecules that have the ability 
to increase the amount of full length SMN protein produced from the remaining 
SMN2 gene(Castro and Iannaccone, 2014). However, to date, therapies have been 
tested in type II and III patients but not the most severe type I patients. Therapies 
have showed marginal or no success in milder phenotypes, and therefore are unlikely 
to have any effect on the more severe cases (Coady and Lorson, 2010). 
The biggest limitation to SMN therapy is the optimal window for therapy and the 
delay in diagnosis. Previous SMN replacement studies have shown that delaying 
treatment significantly reduces the phenotype rescue and the survival improvement. 
However early diagnosis is difficult in human patients, leading to a delay in 
treatment. This shows that there is a need to identify other therapeutic strategies 
which could be used in conjunction with SMN replacement which could potentially 
reverse some of the damage done in early stages of disease. This will be addressed 
further in section 1.3.3.  
1.5.1 Drug Treatment Approaches 
1.5.1.1 Enhancing SMN2 gene transcription 
Increasing the expression of the SMN protein from SMN2 gene is one of the main 
potential therapeutic strategies that could be used in targeting the disease (Chang et 
al., 2001). Familial studies performed on individuals suffering from SMA (type II 
and III) showed that both gene copies of SMN1 were absent in these patients as well 
as in asymptomatic patients (Rossoll et al., 2003). In each of the studied families, 
there was an individual who was lacking the SMN1 gene but showed no SMA 
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symptoms. It was shown that these individuals had 4-5 copies of SMN2 gene and 
showed normal levels of SMN protein in their fibroblasts (Rossoll et al., 2003). In 
other studies involving mice, it was found that Smn-/- mice with two cDNA copies of 
the SMN2 gene inserted, showed a longer survival time (about 3 weeks after birth) 
(Pagliardini et al., 2000).  
A screening assay of more than 555,000 compounds was performed in order to 
identify small drugs that would interact with the FL-SMN2 mRNA, and the results 
yielded two compounds - Trichostatin A (TSA) and Sodium Butyrate, which were 
found to increase the levels of SMN protein in patient-derived cells (Jarecki et al., 
2005). These two compounds belong to a class of histone deacetylase (HDAC) 
inhibitors resulting in the up regulation of about 2% of the total genes (Bowerman et 
al., 2009). Further experiments showed that TSA treatment in Smn-/-;SMN2+/+ 
transgenic mice resulted in a 1.5 to 2 fold increase in SMN protein levels and SMN2 
transcript levels; however, the effect on life span was not reported (Sendtner, 2010). 
On the other hand, sodium butyrate was shown to increase the lifespan of Smn-/-; 
SMN2+/+ transgenic mice by 4-5 days compared to untreated littermates (Chang et 
al., 2001).  
Another HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA) was found to 
reduce motor neuron degeneration and increase SMN protein levels, which resulted 
in about a 30% increase in the lifespan of the Smn-/-; SMN2+/+ transgenic mice 
(Riessland et al., 2010). 
 Valproic acid, an HDAC inhibitor used as an anti-epileptic drug (Brichta et al., 
2003, Sumner et al., 2003), was shown to elevate the SMN protein levels in SMA 
fibroblast cells by either activating the SMN promoter or preventing the exon 7 
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skipping of SMN2 during transcription (Vance et al., 2009). In a study where the 
smn-/-; SMN2+/+ transgenic mice were used, valproic acid was reported to normalize 
motor function, reduce motor neuron death and increase spinal SMN protein levels 
(Strong et al., 2007).  
Another study using the drug D156844, which belongs to the 2,4-
diaminoquinazoline family, revealed an increase in the survival of the SMN∆7 mice 
by 21-30% by enhancing overall SMN expression in these mice (Butchbach et al., 
2010). 
In summary, these drugs rely on increasing the SMN protein expression through 
increase of the endogenous SMN2 gene in the CNS which can ameliorate the 
phenotype and survival of SMNΔ7 SMA mice if expression is induced prior to 
motor neuron loss.   
1.5.1.2 Modulating SMN2 splicing 
The quite unique genetic situation of SMA patients, who lack functional SMN1 but 
carry the misspliced SMN2 copy gene, creates the possibility of correcting SMN2 
splicing by antisense oligonucleotides or drugs (Wirth et al., 2015).  
The antisense oligonucleotides (ASO) approach has been used to silence specific 
splicing sites in SMN pre-mRNA, specifically targeting SMN2 exon 7, to increase 
the amount of FL-SMN produced. When administered systemically, ASO was 
shown to increase the inclusion of exon 7 in SMN2 in liver, kidney and muscles. 
However, ASOs do not cross the blood brain barrier (BBB) so no change in the 
SMN protein level was observed in the spinal cord (Saunders et al., 2009). 
Therefore, in order to prove the potential therapeutic benefits of this approach in 
SMA, a new method of delivering ASO across the BBB was required (Long et al., 
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2008). In order to overcome the BBB problem the ASO is injected directly into the 
CNS so that it does not have to cross the BBB. 
The discovery of intronic splicing silencer N1 (ISS-N1) is a promising target for 
ASO therapy. One study assessed a morpholino (MO) oligomer against ISS-N1 and 
delivered this MO to SMNΔ7 SMA pups at postnatal day 0 (P0) by 
intracerebroventricular (ICV) injection. Significant survival from 15 days to more 
than 100 days was observed when administered early on. Delayed CNS MO 
injection showed moderate efficacy and mild survival advantage, suggesting that 
early CNS ASO administration is essential for SMA therapy. Following ICV 
treatment an increase of F-L SMN2 transcript as well as SMN protein in neural 
tissue was observed, but only minimally in peripheral tissue. This suggests that SMN 
CNS increases will have a major impact on SMA, and an early increase of the SMN 
level will results in correction of motor phenotypes (Porensky et al., 2012).  
In another recent study Singh NN et al, reported that an antisense oligonucleotide, 
ISTL1 was able to fully correct SMN2 exon 7 splicing and restore high levels of 
SMN in SMA patient cells through sequestration of ISS-N2 (Singh et al., 2015). 
Hydroxyurea is another compound that was used with an aim to modulate the SMN2 
splicing pattern allowing the formation of the full length protein (Grzeschik et al., 
2005). A study where lymphoblastoid cells from SMA patients were subjected to 
different concentrations of hydroxyurea showed that a high dose of the compound 
significantly increased the level of full length SMN mRNA and therefore the levels 
of SMN protein (Grzeschik et al., 2005). The exact mechanism of how hydroxyurea 
works in SMA is still unknown, however, it is thought that it changes the SMN2 
splicing pattern giving rise to the full length SMN protein (Lorson and Androphy, 
Chapter 1: Introduction 
33 
 
2000, Coady and Lorson, 2010). 
1.5.2 Gene therapy  
Gene therapy is the transfer of nucleic acid to repair or replace aberrant genes to stop 
or cure disease. An advantage of using gene therapy is the selective and long-term 
treatment of cells and tissues (Davidson and Breakefield, 2003). Various gene 
therapy approaches have been developed such as using viral vectors, which aim 
towards efficiently transferring the desired therapeutic gene to the target tissue 
(Davidson and Breakefield, 2003).  
A trans-splicing system has been employed to introduce more full length SMN from 
SMN2 by introducing therapeutic RNA with the SMN1 sequence and antisense RNA 
to block the splice site to discourage spicing of exon 7. In studies by Coady and 
Lorson (2010) and Lorson and Androphy (2000),  Smn-/-;  SMN2+/+  neonate  mice 
were injected with plasmids co-expressing these two RNAs, resulting in a 70% 
increase in the survival of these mice compared to untreated controls (Lorson and 
Androphy, 2000, Coady and Lorson, 2010).  
Introduction of naked DNA for gene therapy is not as efficient or targeted as viral 
delivery. Several viral vectors have been developed, each having distinct advantages 
and disadvantages. The two most common viral vectors undergoing pre-clinical trials 
in treatment of SMA are derived from lentivirus and adeno-associated virus (AAV) 
(Passini et al., 2010). 
1.5.2.1 Lentivirus Gene Therapy  
Lentiviruses (LVs) belong to the Retroviridae family that possesses a positive single-
strand RNA genome, which integrates into the host genome. There are several 
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serotypes of lentivirus that have the ability to infect different natural hosts, including 
humans and primates (Azzouz et al., 2004a, Nanou and Azzouz, 2009). 
Lentiviral vectors (LV) can transduce both dividing and non-dividing cells, including 
neurons (Azzouz et al., 2002), which make them particularly appealing for 
neurodegenerative diseases where the target cell is the neuron. They are efficiently 
used for gene transfer into various types of neurons in the nervous system (Martin-
Rendon et al., 2001). The integration into the host genome results in stable and long-
term gene expression (Deglon et al., 2000). LV has a large cloning capacity, about 8-
10 kb of gene sequence can be packaged, allowing larger genes to be targeted for 
gene therapy. Another key feature of LV is the low immunogenicity, decreasing 
potential for adverse reactions.  
The major disadvantage of LV vectors is safety concerns due to random integration; 
integration into the host genome has the potential for oncogenesis (growth of 
tumorous cells). The safety and design of these vectors are being refined and could 
be widely used for human clinical trials in the near future (Valori et al., 2010). An 
ongoing phase I/II trial for a Parkinson’s disease treatment (ProSavin Oxford 
BioMedica) has shown a long-term safety profile using an LV vector (Palfi et al., 
2014). Another disadvantage is that the large-scale production of LV is not possible 
with the current technology. 
1.5.2.2 Adeno-Associated Viruses (AAV)  
Adeno-associated viruses (AAV) belong to the Parvoviridae family of viruses. They 
are small, single-stranded, nonpathogenic DNA viruses that require a helper virus 
(such as adenovirus) for their replication and life cycle completion (Davidson and 
Breakefield, 2003).  
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Similar to LVs, AAV vectors can transduce both dividing and non-dividing cells 
with good efficiency, making them attractive for neurodegenerative diseases. In 
addition, AAV show no or little immunogenicity, making them very safe. There are 
several serotypes of AAV which target different tissues with varying efficiency and 
stability of expression (McCarty et al., 2001). In adults, a luciferase reporter gene 
delivered via different AAV serotypes produced low expression with AAV2, 3, 4 
and 5; moderate expression with AAV1, 6 and 8; and high expression with AAV7 
and 9 (Zincarelli et al., 2008). Interestingly, AAV9 can strongly transduce MNs in 
the Central nervous system (CNS) following intravenous administration, along with 
other tissues such as cardiac tissue and skeletal muscle (Benkhelifa-Ziyyat et al., 
2013). AAV vectors have stable gene expression levels even though they do not 
integrate into the host genome.  
A drawback to the use of AAV vectors is their small cloning size capacity (about 4.5 
kb) and their inability to efficiently transduce all cell types (Davidson and 
Breakefield, 2003).  
In addition to conventional AAV, self-complimentary viruses are also being used 
commonly in gene therapy. AAV can be altered to package two copies or dimeric 
inverted repeats of small genomes, resulting in self-complementary adeno-associated 
virus (scAAV) (McCarty et al., 2001). The scAAV vector is more efficient in cell 
transduction due to faster initiation of gene expression, as the need for 
complementary strand synthesis is bypassed. 
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1.5.3 Gene therapy approaches in SMA disease 
1.5.3.1 Lentivirus–Mediated Gene Therapy in SMA 
Sustained SMN protein expression is important for cell survival, therefore, a 
lentivirus-based gene therapy approach to replace the SMN1 gene in SMA patients is 
an attractive therapeutic strategy (Nanou and Azzouz, 2009).  
Equine Infectious Anaemia Virus (EIAV)-based LVs were found to transduce MNs 
upon intramuscular injection. Azzouz and colleagues expressed SMN cDNA in 
lentiviral vectors in order to restore SMN protein levels in cell culture (Azzouz et al., 
2004b). The virus was injected in various muscles (the gastrocnemius and facial 
muscle) of SMA mice and showed transduction of ~70% MN leading to reduction of 
motor neuron death and extended life span by an average of 20–38% (Azzouz et al., 
2004b). 
 Earlier reports of gene therapy using LV in an SMA mouse model showed 
promising results, with successful retrograde delivery of SMN-expressing lentivirus 
(pseudotyped with rabies G protein) to motor neurons in the lumbar spinal cord after 
delivery into multiple muscles (Azzouz et al., 2004b). Although the LV showed 
promising results, the use of the lentiviral vectors in the clinic is limited due to their 
risk of insertional mutagenesis. However, they are very useful for in vitro studies due 
to their long-term expression and high efficiency of transduction. Another major 
obstacle is the production of the large amount of virus required for muscle delivery 
in human therapeutics (Arnold and Burghes, 2013). 
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1.5.3.2 Adeno-Associated Viruses (AAV) - Gene Therapy in SMA 
Several studies have proven the efficacy of AAV vectors in animal models of 
neurodegeneration (Table 1-5). Valori et al. (2010) used scAAV9 to introduce SMN 
into an SMA model: scAAV9 vectors were injected into mice at postnatal day 1, 
which resulted in a 100% rescue of treated animals, increasing life expectancy from 
27 to over 340 days (median survival of 199 days) (Valori et al., 2010). The scAAV9 
therapy allowed for a complete correction of motor function, prevented MN death 
and rescued the weight loss phenotype close to normal (Valori et al., 2010). 
Another study by Foust et al. (2010) showed that scAAV9 was able to infect 
approximately 60% of MNs when it was inserted intravenously to newborn mice 
(Foust et al., 2010). In this study, scAAV9 was delivered to postnatal day 1 SMA 
mouse pups resulting in the rescue of motor function and increased the life span 
(Foust et al., 2010). Moreover, following intramuscular injection of AAV9 it has 
been shown to cause a widespread transduction in the spinal cord and peripheral 
tissues (Cearley and Wolfe, 2006, Benkhelifa-Ziyyat et al., 2013). A unique 
transduction characteristic for AAV9 is the variation in capsid surface regions 
(DiMatteo et al., 2008), which may increase cell entry allowing more vector 
genomes to enter the cell and therefore more protein to be produced (Cearley and 
Wolfe, 2006). 
Interestingly, it was shown that AAV9 might be used in human patients after 
successful transduction of MNs in neonatal macaques (Foust et al., 2010). Recently, 
transgene expression in neurons in both the CNS and PNS was generated after fetal 
administration of AAV9 to macaques (Mattar et al., 2012). It was also reported that 
the AAV9 vector genome was able to undergo axonal transport (Cearley and Wolfe, 
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2006). This may be useful in severe SMA cases in order to provide prenatal 
treatment.  
Table 1-5 Successful preclinical studies using the vector-based gene therapy approach 
for SMA treatment  
Vector 
 
Mouse model Routes/sites of 
administration 
 
Dose Timing 
Post-natal 
day 
Impact on 
survival 
(increase) 
Ref. 
EIAV-SMN  
 
SMNΔ7 IM: Hindlimb, 
gastrocnemius, 
diaphragm, 
muscles 
(facial,intercost
al, tongue) 
4.0 -7.0 _ 
108 TU 
2 20%  (Azzouz et al., 2004b) 
scAAV9-SMN  IV: Temporal 
facial vein 
IV or ICV 
5.0 _ 1011 
vg 
1 Complete 
rescue 
(Foust et al., 2010) 
scAAV9-
SMNopti  
IV: Temporal 
facial vein 
1.0 _ 1011 
vg 
1 400%  (Valori et al., 2010) 
IV: Temporal 
facial vein  
4.5 _ 1010 
vg 
1 1350%  (Dominguez et al., 2011) 
IM: triceps 
muscles 
gastrocnemius 
and Limbs 
 
7 _ 1010 
vg 
1 1260%  (Benkhelifa-Ziyyat et al., 
2013) 
SMN2 Trans-
Splicing Vector  
 
 (smn−/−, 
hSMN2+/+) 
ICV 1.14 _ 
1012 
(plasmid 
copies) 
1 75%  (Coady and Lorson, 2010) 
SMN Trans-
Splicing/IGF-1 
Dual Vector 
SMNΔ7 ICV  
 
10 µg 
(plasmid 
DNA) 
2 Trans-
splicing: 
50%  
IGF: 75%  
Dual: 100%  
(Shababi et al., 2010a) 
scAAV8-SMN  ICV: Lumbar 
intraparenchym
al 
1.7 _ 1010 
vg 
0 880%  (Passini et al., 2010) 
AAV8-SMN 
 
ICV: Lumbar 
intraparenchym
al 
5.0 _ 1010 
vg 
0 230%  (Passini et al., 2010) 
scAAV9-SMN ICV   1 × 1011 
vg 
 
2 475% (Shababi et al., 2015) 
Adapted from (Tam et al., 2014) 
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1.6 Clinical trials 
Many of the successful preclinical therapeutic studies have been translated into 
clinical trials. However, to date none of the treatments have proven to be effective 
for all SMA types (Passini et al., 2010, Wadman et al., 2012a). A number of drug 
compounds that have been tested in early clinical trials based on neuroprotective 
effects seen in preclinical studies, such as gabapentin, showing mixed results. One 
clinical trial in Italy showed that gabapentin was a potent treatment for SMA when 
tested on 120 type II or III SMA patients for 12 months (Merlini et al., 2003). On the 
other hand, a placebo-controlled clinical trial with type II or III SMA in the United 
States showed no improvement in 84 patients (Miller et al., 2001).   
 
 
Figure 1.6. SMA therapeutics pipeline as of February 2015  
Current pre-clinical and clinical trials in progress for SMA therapies. Drug name and 
company shown (Taken from SMAfoundation.org) 
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Several clinical trials are currently ongoing ( 
Figure 1.6), and showing promising results. Of particular interest is the drug 
Olesoxime, a mitochondrial pore modulator. Trophos Pharmaceuticals has shown 
promising results in large, multicentre clinical trials with Olesoxime. They are 
currently finishing phase 3 clinical trials and initiating the regulatory process of 
manufacture.  
A gene therapy clinical trial based upon the pre-clinical work by Foust and 
colleagues (Foust et al., 2010) is beginning phase I trials using scAAV9 in SMA 
type I patients. The primary objective of this study is to evaluate the safety and 
efficacy of scAAV9.CB.SMN, which aims to replace the missing SMN1 
(ClinicalTrials.gov Identifier: NCT02122952).  
Recently, ISIS Pharmaceuticals has completed Phase I and proceeded to a Phase II 
clinical trial of ISIS-SMNRx, an ASO designed to increase SMN protein expression 
by restoring exon 7 inclusion in SMN2 transcripts (Clinicaltrials.gov ID: 
NCT01839656). A total of 28 patients have been recruited, 15 with type II SMA and 
13 with type III SMA and will receive SMNRx as a single-dose treatment 
administered intrathecally (Mulcahy et al., 2014). 
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1.7 Project Aims 
The aim of this thesis is to investigate the role of PLS3 as a therapeutic target for 
SMA. The PLS3 gene will be modulated using viral vectors to mediate 
neuroprotection in experimental models of SMA. 
The first stage will assess the expression pattern of Pls3 in the SMNΔ7 mouse 
model, to explore the changes in Pls3 expression when SMN is depleted. Once this 
has been established, a lentiviral vector will be used to overexpress PLS3 and 
evaluate the neuroprotective effects of PLS3 in MNs isolated from SMNΔ7 mice.  
Secondly an AAV9 vector will be used to overexpress PLS3 in the CNS in vivo in 
the SMNΔ7 mouse model. The aim will be to determine whether PLS3 
overexpression can improve SMA survival and rescue the disease phenotype within 
the CNS.  
This study is part of a large programme of work with the ultimate goal of taking 
these viral vectors to the clinic to identify specific therapeutic targets for SMA.  
The project specific aims can be summarised as follows: 
1-Assess the expression pattern of Pls3 in SMNΔ7 mouse model  
2-Evaluate the neuroprotective effects of PLS3 in an in vitro model of SMA 
(purified MNs).  
3-Generate a pre-clinical proof-of-concept using adeno-associated vector serotype 9 
(AAV9) encoding PLS3 in SMNΔ7 mouse model of SMA. 
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2.1 Materials Equipment 
The list of the main equipment used in this project is given in (Appendix 1).  
2.1.2 Reagents and chemicals 
All the analytical grade chemicals, solvents, consumables and reagents were supplied 
by Thermo Fisher Scientific Inc. (Loughborough, UK) or Sigma (Cambridge, UK).  
2.1.3 Buffers and solutions  
All the solutions, dyes and in-house prepared buffers used for different 
experiments are listed with their ingredients in the text below. 
2.1.4 Cells and media 
All cell lines used in this study with their relevant information are listed in Table 
 2.1. 
Table 2-1 List of Cell lines used in this study 
Cell line Full name Culture medium 
HEK293T cells Human embryonic kidney cell line Dulbecco’s modified 
Eagle Medium (DMEM) NSC34 cells A hybrid mouse motor neuron-
neuroblastoma cell line 
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2.1.5 Ethics statement  
All in vivo experiments were regulated under the UK Home Office Animals 
(Scientific Procedures) Act 1986. With the approval from the University of Sheffield 
Ethical Review Sub-Committee, and the UK Animal Procedures Committee 
(London, UK), the Studies in this project were conducted under Project License 
(40/3640). 
Table 2-2 List of Primary Antibodies used 
Target 
Protein 
 
Host Supplier Cat No. Use Dilution 
Primary Antibodies   
Human PLS3  Rabbit  Abcam  ab45769 WB + IF  1:500 
Mouse PLS3 Rabbit Aviva ARP56623_P050 WB  1:500 
α-Tubulin  Mouse  Calbiochem Cp06 WB  1:1000 
GFP  Chiken Abcam  ab13970 IHC + IF  1:200 
β-actin Rabbit Abcam ab8227 WB 1:2000 
GABDH  Mouse  Calbiochem CB1001 WB 1:2000 
AAV VP1,2,3 Rabbit ARP 03-61084 WB 1:250 
NeuN Mouse Millipore MAB377 IF 1:500 
CGRP Mouse Abcam ab47027 IF 1:500 
 
Table 2-3 List of Secondary Antibodies used 
Target 
Protein 
 
Host Supplier Cat No. Use Dilution 
Secondary Antibodies   
Rabbit-A568 Goat Invitrogen A11036 IF+IHC  1:1000 
Mouse-A594  Goat  Invitrogen  A1105  IF + IHC  1:2000 
Mouse-A350  Goat  Invitrogen  A11045  IF  1:2000 
Mouse-A488  Goat  Life tech  A11017 IF  1:2000 
Chicken-A488 Goat Life tech A-11039 IF 1:2000 
Mouse-HRP  Goat  Bio-Rad  170-6516  WB  1:3000 
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2.1.6 Maps of the LV and AAV Plasmids  
The Maps of the LV-PLS3 Plasmid and AAV-PLS3 used in this project are given in 
Appendix 2.  
2.1.7 DNA Preparation 
All the plasmid DNAs were generated with QIAprep Spin Miniprep (QIAGEN, 
27106) and QIAGEN Plasmid plus Mega (QIAGEN, 12981) kits, according to 
manufacturer’s protocol and eluted in nuclease free water (NF-H2O) or elution buffer 
(EB). During viral production all ultra-centrifugation steps were performed by using 
the Optima L-100K Ultracentrifuge (Beckman Coulter). The plasmid DNA 
concentrations were measured using the Nanodrop1000 (Labtech), (ND-1000 v3.2.1 
software). The plasmid purity and exact band size were detected by electrophoresing 
the samples on 1% agarose gels. Then the gels were visualized using the GENi 
imaging machine (Syngene, 12834038). 
2.1.8 Protein extraction and quantification:  
Protein extraction was accomplished by cell lysis solution (RIPA buffer) which is 
composed of 50 mM Tris-HCl pH 8, 150 mM NaCl, 2 mM 
(ethylenediaminetetraacetic acid, Melford) EDTA, 1% Igepal CA630 (Sigma) and 
0.1% sodium dodecyl sulphate (SDS) (Sigma), supplemented with 1% Protease 
Inhibitor Cocktail (Sigma). The cell pellet was resuspended in 50-150 µL of the lysis 
solution and incubated for 30 minutes on ice to lyse the cell. The cell debris was 
separated from the protein content by centrifugation at 13,000 g for 10 minutes, and 
then the supernatant was transferred into a clean 1.5 ml tube.  
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The extracted protein was measured by Bicinchoninic Acid Protein Assay (BCA) kit 
(Fisher). As per the manufacturer’s guidelines eight serially diluted protein standards 
in addition to 10 µL of (one in ten) diluted samples were added separately and in 
duplicates to the aliquoted BCA working reagent. Reagent A was added to reagent B 
in a 50:1 ratio, then aliquoted into a 96-well plate in a quantity of 100 µL per well. 
The plate was incubated for 30 minutes at 37 °C. During incubation copper II in the 
working reagent was reduced by the proteins of the samples and standards to copper 
I, which interacts with the bicinchoninic acid and forms a purple-blue complex. A 
spectrophotometer plate reader can detect the absorbed light by this complex at 570 
nm. The protein quantity is directly proportional to the absorbance value. Using the 
Excel programme (Microsoft), the absorbance values of a set of standard dilutions 
were plotted against their known concentrations in order to construct a reference 
standard curve. The unknown protein concentration of each sample was determined 
against the diluted standard curve value of Bovine Serum Albumin (BSA), based on 
the equation of the standard curve. To calculate the actual protein concentration in 
each sample, the results were multiplied by ten, which was the dilution factor.  
2.1.9 Spectrophotometry 
Fluorescence measurements were performed using a FLUOstar Omega plate reader 
(BMG Labtech) for all the assays that require microplate reader for either UV/Vis 
absorbance measurements. Using a Varian Cary Eclipse spectrofluorimeter the 
Fluorescence measurements were recorded.  
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2.2 In Vitro Experimental Work  
2.2.1 Cell Lines and Cell Culture  
HEK293T cells, a human embryonic kidney cell line, were used for transfection, 
western blots and LV/AAV production. The cells are immortalized by the adenoviral 
E1A/E1B protein and express the SV40 large T antigen. A hybrid mouse motor 
neuron-neuroblastoma cell line, NSC34 cells (Cashman et al., 1992), was used for 
transfection and western blots.  All cell lines, were cultured in tissue culture flasks 
(CELLSTAR, Greiner, Germany) in (DMEM with 4.5 g/L Glucose, L-glutamine, 
without Na Pyruvate, Lonza) supplemented with 10% fetal calf serum (FCS, 
Biosera), 100 U/ml of penicillin and 100 µg/ml streptomycin (penicillin G sodium 
and streptomycin sulphate in 0.85% saline, Invitrogen). The cells were incubated at 
37 °C in a CO2 incubator with 95% humidified and 5% CO2 air environment.  Twice 
a week the culture media were refreshed. Once the cells reached around eighty 
percent confluency they were ready to be either harvested or passaged. All 
experiments were performed on passage 15-25 cells. For AAV production HEK293T 
cells were used in order to produce higher viral titres. Primary motor neurons from 
SMN∆7 mouse embryos were kindly provided by Dr. Ke Ning (University of 
Sheffield) as described below.  
2.2.2 Primary Motor Neuron Culture 
Primary motor neurons were purified from the spinal cords of embryonic day 13 
(E13) mouse embryos and cultured at 37 °C with 5% CO2 at 95% humidity. Briefly, 
10 mm coverslips were coated overnight at 4 ºC with 5% poly-DL-ornithine 
hydrobromide 1x 500 mg dissolved in 10 ml Borate buffer 0.15 M pH 8.35, filtered 
through 0.22 µm sterile filter (Sigma, p-8638) in  35 mm dishes with 4x10 mm rings 
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(Greiner bio-one, 627170). Hank’s Balanced Salt Solution (HBSS) (Sigma, H8264) 
was used to wash out the poly-ornithine before coating the coverslips again with 2.5 
µg/ml laminin (Invitrogen, 23017-015) that was prepared by diluting 0.75 mg/ml 
laminin stock in 50 mM Tris pH 7.4, in HBSS. A pregnant mouse was sacrificed 
using Schedule 1 method of cervical dislocation at E13 and the embryos were 
collected. Dissected spinal cords were placed into dissection buffer (Beta-
Mercaptoenthanol – 10nM concentration (β-ME) (Invitrogen, 313500) in HBSS). 
The cells were suspended for 15min at 37 ºC with 0.1% trypsin for MNs – 
(Worthington, TLR3-3707). Trypsin inhibitor – Sigma, 500mg dissolved in 49ml 
HBSS and 1ml of 1M HEPES (Sigma, T-6522) and filtered through a 0.22 µm sterile 
filter then was used to deactivate trypsin. P75 panning antibody – p75 NGF receptor 
antibody (Abcam, ab8877) monoclonal antibody against extracellular domain of p75 
was used at a concentration of 1:5000 in 10 mM Tris, pH 9.5 to pre coat the plate 
before placing the cell suspension in order to select motor neurons. The primary 
motor neurons were detached by depolarizing solution (30 mM KCl + 0.8% NaCl, 
while the unattached cells were washed off with Neurobasal- medium (NB medium) 
GIBCO (Invitrogen), 1x Glutmaxx-1, 2% horse serum, 1x B27 with 0.2 µM β-ME).  
The primary motor neurons were plated on the pre-coated coverslips at concentration 
of 2000-5000 cells/coverslip in Gibco NB supplemented with 2% of B27 (Gibco, 
12587-010), 1% glutamax (GIBCO, 35050), 2% (v/v) horse serum donor (Linaris, 
SHD3250YK), 100 U/ml of penicillin and 100 µg/ml streptomycin, 0.2 µM β-ME 
and 0.5 mM L-glutamine (GIBCO, 35050), and incubated for 24 hours before 
transduction at 37ºC in a humidified incubator with 5% CO2.  
 
 
Chapter 2: Materials and Methods 
49 
 
2.2.3 Generation of Viral Plasmids 
The human gene of interest (PLS3) containing a Kozak sequence (GCCACC) was 
sub-cloned, using appropriate sites in the destination expression viral plasmids; SIN-
PGK-cPPT-WHV (Addgene, 12252) plasmid for the LV viral plasmids or pAAV 
CMV MCS (Addgene, 46954) for the AAV viral plasmids) with ampicillin 
resistance property (Figure 2.1). The LV /AAV viruses encoding for the reporter 
gene green fluorescent protein (GFP) were generated within our laboratory group 
prior to starting the project. The concentration of   LV-GFP was 2.45 E8 vp/ml and 
1.93 E11 vp/ml for AAV- GFP. The bacterial cell stocks which express these vectors 
were kept at -80°C in 30% glycerol. They were incubated in LB Broth (LBb) (Merck 
Millipore, 1102850500) with the suitable antibiotic (Carbenicillin (Carb) (substitute 
for Ampicillin) 50 µg/ml) (Sigma, C3416) or (Kanamycin, 50 µg/ml (Sigma, 
K4000). All constructs were sequenced by Core Genomic Facility, Medical School 
at the University of Sheffield (Appendix 3). 
2.2.3.1 PLV-PLS3 
A lentiviral Vector (LV) expressing PLS3 was generated by extracting the PLS3 gene 
from pcDNA3.1-PLS3-V5/His6 Vector, provided by Prof. Dr. Brunhilde Wirth, 
(Institute of Human Genetics, University Hospital of Cologne, Germany) and cloned 
into the lentiviral Vector SIN-PGK-cPPT-GDNF-WHV. 
Briefly, the lentiviral Vector SIN-PGK-cPPT-GDNF-WHV was isolated out of the 
glycerol stock, and purified using miniprep kit (QIAGEN), GDNF was cut out using 
BamHI and XhoI. To linearize the plasmid 1-3 µg of the extracted plasmid DNA was 
digested by mixing it with 0.5µl XhoI (NEB, R0146), 0.5µl BamHI (NEB, R0136), 2 
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µl NEB buffer 3 (NEB, B7003), 2 µl of 10x BSA; (NEB, B9001), and topped with 
nuclease-free water (NF-H2O) up to a total of 20 µl. The mixture was incubated for 2 
hours at 37ºC. Then at 1:4 ratio 4 µl DNA loading buffer blue (Bioline, bio37045) 
was mixed with 12 µl of the digestion mixture then the mixture was loaded on 1% 
agarose gel. The samples were electrophoresed at 120 V for 1hr. The band 
corresponding to the plasmid backbone was isolated and purified using (QIAquick) 
gel extraction kit according to the manufacturer’s protocol (QIAGEN). The final 
DNA sample was eluted in 50 µl of elution buffer (EB). The PLS3 insert was 
digested out of the pcDNA3 vector. After a restriction digest with the same enzymes 
and gel electrophoresis, the isolated insert was purified from the gel. PLS3 fragment 
was ligated into the linearized LV-vector, using  T4 DNA Ligase (NEB, M02025). 
The required concentration of the insert was calculated according to the equation 
below: 
 
 
Then 30ng of vector was used at vector to insert molar ratio of 1:3 and 1: 6. 0. 
Around 1-50ng of ligation mixture was used to transform NEB 5-alpha Competent 
Escherichia. coli (E. coli ) (High Efficiency) (BioLabs, C2987I) by incubating 100µl 
of cells on ice for 30 minutes. Heat-shock at 42 0C was applied for 30 seconds and 
the tubes were incubated on ice for 2 minutes. A volume of 0.9ml of preheated broth 
with Catabolite repression (S.O.C) medium (Sigma-Aldrich, S1797) was added to 
the tubes and incubated at 37 0C for 1 hour with shaking at 225-250 rpm. The cells 
were plated on selective media (Lysogeny broth agar plates supplemented with 50 
µg/ml carbenicillin), 200 µl of the transformation mixture was plated and incubated 
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at 37 0C overnight. The purified plasmid DNA from the colonies were analyzed by 
restriction analysis and sequenced. PGK promoters were used: PGK forward: 5-
GGGAATTCCGATAATCAAC-3 and PGK reverse: 5-
CCTTCGCTTTCTGGGCTCA-3. The reaction contained 100 ng of vector DNA and 
10pmol of the primer (Table 2.4). Sequencing service was provided by Core 
Genomic Facility, Medical School the University of Sheffield (Appendix3). 
Megaprep of the ligated construct from the transformed NEB 5-alpha cells was 
prepared and stored at -20 ºC. 
2.2.3.2 PAAV-PLS3  
A self-complementary adeno-associated virus (scAAV9) expressing PLS3 was 
generated by extracting the PLS3 gene from pcDNA3.1-PLS3-V5/His6 vector and 
cloning into scAAV CMV GFP (VPK-418-DJ: AAV-410, Cell Biolab ICN) between 
restriction sites BamHI and XbaI. Firstly, PLS3 was amplified using forward and 
reverse primers as follow:  the polymerase chain reaction (PCR) mix was prepared 
by mixing 1µl of DNA template, 400 nM of each primer; Forward primer PLS3-
BamHI-FOR: ACTAC GGATCC GCC ACC ATG GAT GAG ATG GCT ACC 
ACT and; Reverse primer PLS3-XbaI-REV: CGCGAC TCTAGA TTA CAC TCT 
CTT CAT TCC C; 10 µl of FIREPol 5x Master Mix and topped up to 50 µl with NF-
H2O. The PCR mixture was run on a GS2 thermal cycler (G-Storm). According to 
the following program: first the temperature was set for 3min at 95ºC then each cycle 
was started with denaturation for 30sec at 95 ºC, annealing at 60 ºC for 30sec and 
elongation for 30 sec at 72 ºC, and DNA was amplified in 35 cycles. An extra 
elongation period at 72 ºC for 7 minutes was made and finally held at 4 ºC. The PCR 
product was extracted and treated with the appropriate enzymes XbaI (NEB, 
R0146S) and BamHI (1µl XbaI, 1 µl BamHI, 4 µl buffer4, 4 µl H2O and all the 
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DNA) and incubated for 2 hours at 37 ºC. Then it was ligated into BamHI- XbaI 
digested scAAV-CMV full vector and transformed into competent E. coli cells. 
For the conventional AAV-PLS3 vector, the PLS3 gene was extracted from 
pcDNA3.1-PLS3-V5/His6 plasmid and cloned into pAAV CMV MCS.  
Firstly, PLS3 was PCR amplified as above, using primers: PLS3-EcoRI-FOR: GAT 
GCC GAATTC CAG CGT GCC ACC ATG GAT GAG ATG GCT ACC ACT and; 
PLS3-XbaI-REV: AGCAA TCTAGA TTA CAC TCT CTT CAT TCC C. The PCR 
product was treated with restriction enzymes EcoRI and XbaI and subcloned into 
EcoRI-XbaI digested pAAV CMV MCS vector. After ligation the mixture was 
transformed into NEB 5- alpha competent   E. coli as described above. The picked 
clones were analysed by restriction analysis as explained in section (2.3.3.2) and the 
purified plasmid DNA was sequenced. The primers for sequencing anneal to the 
CMV promoter and are represented in Table 2.4:  
Table 2-4 Sequencing primers for PLS3 constructs 
Gene Primer Sequence Concentration 
scAAV CMV 
FW: 
TCATATGCCAAGTACGCCCC  
Binds within CMV promoter/enhancer region 
100 nM 
scAAV-FW: TCGTGACCCCTAAAATGGGC  
Binds before the promoter region 
100 nM 
scAAV-PolyA 
REV: 
GCATCGAGTCAGGTCAGCTT 
 
100 nM 
PLS3seq1 FW: 
  
CCACCATGGATGAGATGGCT 
 
100 nM 
PLS3seq2 FW  TTTGAGGGCTGGGAAACCTC 
 
 
100 nM 
 
PLS3seq3 FW:   
 
CCTGCAAGATGCCCTGGTAA 
 
 
100 nM 
PLS3seq4 : TGATGGGCAGGGGAATGAAG 
 
100 nM 
 
Chapter 2: Materials and Methods 
53 
 
The reaction contained 100ng of vector  DNA and 10 pmol of each primer (Table 
2.4). Core Genomic Facility, Medical School, at the University of Sheffield provided 
the sequencing service (Appendix 3). Megaprep of the ligated construct from the 
transformed NEB 5-alpha cells was prepared and stored at -20 ºC. All the details 
were done as above (see section 2.3.3.2). 
2.2.3.3 LV viral production LV-PLS3  
For lentiviral production 3 x 106 HEK293T cells per 100mm2 dish were plated and 
transfected after 24 hours of plating with a mix of four plasmids: pMD.2G: plasmid 
encoding the vesicular stomatitis virus G (VSV-G) envelope, pCMVDR8.92; 
packaging plasmid encoding all the viral genes needed in trans, SIN-W-PGK; 
transfer plasmid containing (PLS3) and pRSV-Rev; plasmid encoding the rev protein 
of Human Immunodeficiency Virus (HIV)-1. Viral production was performed as 
previously described (Deglon et al, 2000). Briefly, the DNA mixture was prepared 
by mixing 3 µg of pRSV-Rev, 13 µg of pCMV∆R8.92, 13 µg pMD. G and 13 µg of 
SIN-W-PGK-PLS3 or SIN-W-PGK-GLE1 in 0.25 M CaCl2. The mixture was then 
added drop-wise to an equal volume of 2x HBS buffer pH 7.1 and allowed to stand 
for 20 minutes at room temperature. The mixture was added to the cells and 
incubated for 6 hours at 37 °C. Then the media was replaced with fresh media (10 
ml) and the cells were incubated for three days. At 72 hours post transfection, the 
viral supernatant was harvested, filtered through 0.45  µm filter and concentrated by 
ultracentrifugation for 90 minutes at 19,000 rpm and at 4 °C.  
The viral pellet was suspended in 1.8 ml Phosphate buffered saline (PBS) 
supplemented with 1% Bovine Serum Albumin (BSA) (Sigma), divided into 50 µl 
aliquots and stored at -80 °C. Finally, Lentiviral titration was performed by Enzyme 
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Linked Immunosorbent Assay (ELISA) which targets HIV-1 p24 antigen (ZMC No. 
0801111, ZeptoMetrix Corporation) as described below. 
2.2.3.4 Lentiviral titration by ELISA   
Lentiviral titration was performed by ELISA, which targets HIV-1 p24 antigen 
(ZMC No. 0801111, ZeptoMetrix Corporation) according to the manufacturer’s 
protocol. The Microplate wells were coated with a monoclonal antibody specific for 
the p24 gag gene product of HIV-1. Samples and standards were added to the plate 
and were incubated for two hours to allow the antigen capture and recognition by the 
antibody. Substrate solution was added and the reaction was stopped by acidification 
thereby obtaining a yellow colour. Within 15 minutes optical density was read for 
each well at 450nm using a microplate reader. The density of the colour is 
proportional to the amount of HIV-1 p24 antigen present. The absorbance values of a 
set of standard dilutions from 1/500 to 1/1562500 were plotted (Table 2.5). The viral 
particle number in each sample was determined against the diluted standard curve. 
The amount of viral protein determined by the assay was converted into the number 
of viral particles. According to the manufacturer 1ng/ml of p24 corresponded to 1.2 
x 104 transducing Units (TU) per ml.  This was used for final titre calculations. The 
titre was presented as Transducing Units per ml (TU/ml), which is equivalent to the 
functional viral particles per ml. The absorbance values of a set of standard dilutions 
were plotted (Table 2.5). The viral particles number per ml of each sample was 
determined against the diluted standard curve values, based on the following 
calculations.     
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Table 2-5 Absorbance, P24 and serial dilution values for LV-PLS3 titration 
Dilution series Mean Absorbance p24 (pg/ml) 
100 0.438 30.41 
500 0.235 14.73 
2500 0.143 5.01 
12500 0.086 0.15 
62500 0.0575 67.99 
312500 0.4555 12.77 
 
   
This was used for final titre calculations. Eg. The highest dilution, (1: 312500) was 
converted to undiluted reading of 12.77 pg/ml. Then the concentration of p24 antigen 
was multiplied by dilution factor to get its concentration in the stock sample 
(12.77x312500 =21,250,000 pg/ml of p24). According to the manufacturer’s 
protocol, 1ng/ml of p24 corresponds to 1.2 x 104 TU per ml. Therefore to convert 
ng/ml to TU/ml= 21,250 ng/ml x1.2x104 TU/ml = 2.55x108 TU/ml (Table 2.6). 
 
Table 2-6 Titres of LV-PLS3 stock  
Samples Absorbance P24 concentrations Titre TU/ml 
1 0.0575 67.99 2.55x108 
2 0.4555 12.77 2.44x108 
 
The unconcentrated vector has been produced at high titre, which is suitable for in 
vitro applications. 
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2.2.3.5 AAV9 Viral production of AAV-PLS3  
The AAV-PLS3 virus was prepared in house by the aid of the technical support of 
our lab group. A small scale AAV production for each vector was performed in order 
to test whether the PLS3 cassette could be successfully packaged into the AAV 
virion, prior to large-scale production. 
Large-scale viral vector stocks of AAV-PLS3 were generated by polyethylenimine 
(PEI), (PEI; iodixanol; 5xPBS-MK, pH 7.0) cell transfection method with a ratio 3:1 
(µg PEI/µg DNA). 30 confluent dishes of HEK293T cells around 80-90% cultured in 
15 cm dishes, in DMEM (10 % FBS, 1% pen/strep), 20 ml per plate were co-
transfected with the following plasmids: 13 µg of vector plasmid (AAV9-PLS3)/ 
AAV2/9 packaging plasmid and 26 µg of the helper plasmid (pDGM6). 33 µl of PEI 
(1 µg / µl) = 33 µg of DNA complex was added carefully to a single plate and 
distributed well by delicate agitation. Five days (120 hours) post transfection the 
supernatant was collected and treated with Benzonase (Sigma, E1014-5KU) at a 
concentration of 250 unit/µl for 2 hours at 37°C, during incubation the medium was 
mixed every half hour. Cell debris was removed by a short centrifugation (3850 x g/ 
3-5 minutes, Sigma 3-16PK, rotor 11180) in 8x 50 ml tubes, then the supernatant 
was transferred to the top part of the Nalgene filtering unit (0.22 µm vacuum filter – 
Thermo Scientific Nalgene Rapid-Flow filter unit), (Thermo scientific, 595-3320) 
and vacuum was applied. The resulting clarified supernatant containing virus was 
concentrated in Amicon Ultra-15 Centrifugal 100K Filters (Millipore, UFC910024). 
Supernatant containing virus was added onto the filter and centrifuged 3800 x g at 4 
oC until the volume of 27-28 ml is achieved. In order to purify the viral particles 
iodixanol gradient ultracentrifugation using Quick-Seal 39 ml tubes (Beckman 
Coulter #344326) was used. Several different percent concentrations of iodixanol 
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solutions (Sigma Aldrich, D1556-250ML), (stock is 60% w/v) were prepared in PBS 
with 2.5 mM KCl (PBS-MK) and 1mM MgCl2 ( 
 
Table 2-7). The PBS-MK stock was 5 x concentrations. All the solutions were 
prepared as follows in 50 ml  tubes:  
 
Table 2-7 Preparation of Iodixanol solutions    
Percentage 
Iodixanol 
Iodixanol 
60% stock 
5M NaCl 5 x PBS-
MK 
(See below) 
H2O Phenol 
Red 
15% 12.5 ml 10ml 10 ml 17.5 ml - 
25% 20.8 ml - 10 ml 19.2 ml 100 µl 
40% 33.3 ml - 10 ml 6.7 ml - 
54% 45 ml - - 5 ml 100 µl 
 
The centrifuge was set to 18⁰C. A tube with sterile PBS (for topping up the virus 
layer) was prepared. The iodixanol solutions were layered very carefully using 
disposable syringes (Figure 2.1).  
Then the tubes were transferred to the type 70 Ti rotor (Beckman Coulter) at 69,000 
RPM for 1 hour 20 minutes at 18°C using maximum acceleration and no brake. After 
centrifugation, the clear fraction of the 40% layer would contain the virus.  To isolate 
the fractions, the tubes were clamped in a retort stand and a 19-gauge needle was 
inserted into the top of the tube to introduce air. 
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Figure 2.1. The iodixanol solutions layers.   
Quick-Seal tubes prior to (left) and after (right) centrifugation. Solutions are layered very 
carefully using disposable syringes in the following order: 4 ml of 15% iodixanol / 1M NaCl 
in PBS-MK buffer (1x phosphate buffered saline (PBS), 1 mm MgCl2, and 2.5 mM KCl). 9 
ml of 25% iodixanol in PBS-MK buffer containing Phenol Red (slightly pink). 9 ml of 40% 
iodixanol in PBS-MK buffer. 5 ml of 54% iodixanol containing Phenol Red (slightly 
yellow). The space in the top of the tube is filled with PBS using syringe with a small gauge 
needle 
Fractionation was the best method to extract the pure virus sample and separate it 
from debris and empty capsids. A standard 19 gauge syringe needle was inserted 
approximately 1 cm from the bottom of the tube with the bevel pointing upwards, 
and was pushed half way into the tube, towards the upper portion of the 60% 
iodixanol layer. Placing the needle in this manner caused slow leakage of the 
solution through the needle out of its other end in a drop-wise fashion. The drops 
were collected in samples of approximately 250-500 µl in 1500 µl plastic tubes. 
Samples were collected until the entire 40% layer and the first half of the 25% layer 
have been collected.  
In order to assess the purity of the viral preparation, viral samples were run in  SDS 
Polyacrylamide gel electrophoresis (PAGE) gel and the gel was stained with 
SYBRO RUBY (Lonza, 50562) as described below. 6 µl of each fraction was diluted 
with water (1:1), combined with 4x Laemmli loading buffer (3 µL) and was boiled 
Chapter 2: Materials and Methods 
59 
 
for 5 minutes at 95 oC.  The viral samples were loaded onto a 10% SDS-
polyacrylamide gel (Bio-Rad, Hemel Hempstead, UK) and was run at 180 V for 40 
minutes. Then the gel was fixed for 20 minutes with 10% methanol / 7% acetic acid. 
The gel was placed into the staining container and wrapped in aluminium foil to 
protect from light during the staining process. The volume that was used to stain per 
gel was 50 ml /8 cm x 10 cm x 0.75 mm. The gel was gently agitated at room 
temperature overnight. To minimize background fluorescence the gel was transferred 
to a clean staining dish and washed with a 10% methanol / 7% acetic acid solution 
for 30 minutes for three times. The stained gel was visualized using a 300 nm UV 
and fluorescent imaging was performed using Syngene, GENi. A western blot 
analysis was also performed to detect AAV viral proteins (VP) by using an antibody 
against the AAV capsid proteins VP1, VP2 and VP3. Fractions containing pure virus 
were pooled together and were considered as high quality virus prep, while the rest 
were considered as low quality virus prep. The Pooled AAV fractions were 
concentrated and desalted in the final buffer PBS/35 mM NaCl by centrifuging 
through Amicon Ultra centrifugal filter device.  
The titre of all viral solutions was determined by quantitative polymerase chain 
reaction (Q-PCR) (See section 2.2.6.8) with serial dilutions of the vector plasmid 
DNA. HEK-293 cells at a density of approximately 105/ well (6-well plate) were 
transduced with two different volumes of the viral supernatant. Five days post 
transduction, protein was extracted and analysed by WB.  
2.2.3.6 Quantification of AAV by real-time PCR 
The standards (linearized plasmid, serially diluted tenfold; 10-1, 10-2, 10-3, 10-4, 10-5 
and 10-6 were prepared. The AAV samples were diluted in to three different 
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dilutions, 1 in 100, 1 in 1000 and 1 in 10,000 in water. Then master mix for each 
sample and standard in triplicate was Prepared (Primer Mix 1µL (Table 2.8), SYBR 
green master mix 12.5 µL and water 1.5 µL). 15µL of master mix was added to each 
well that will be used on plate. 10µL of sample or standard were added to each well 
in triplicate while 10µL of water to the negative control. The plate was sealed and 
centrifuged to remove air bubbles. QPCR was performed by MX3000-P Real-time 
PCR system (BIO-RAD), following the program below: 
 
95 C     10 min 
95 C     30 seconds 
60 C     1 min 
95 C     1 min 
55 C     30 seconds 
95 C     30 seconds 
 
The titer was calculated by multiplying the dilution factor and 100 to obtain titer/ml.  
Table 2-8 Primers used for qPCR 
Gene  Primer Sequence  Concentration  
FW: ATT TTA TGT TTC AGG TTC AGG GGG AGG TG 
 
100 nM 
REV: 
Poly A R 
GCG CAG AGA GGG AGT GGA CTA GT 
 
100 nM 
2.2.3.7 Designing qPCR primers 
 
All the Primers were designed to match the following criteria: the GC content range 
was 40% to 60%, a primer melting temperature (MT) between 58 °C to 65 °C, 
amplicon product size of 50 bp to 150 bp and 20 bp to 32 bp lengths.  
Then primers properties were assessed by Primer-Blast algorithm: 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/).  
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2.2.3.8 Transduction of HEK293T / NSC-34 cells with LV-PLS3/AAV-PLS3 
virus 
HEK239T cells / NSC34 were plated at a density of 150,000-250,000 cells /well in 2 
ml full medium on a 6-well plate and incubated overnight at 37ºC in CO2 incubator. 
The virus volume required for transduction was calculated using the following 
equation: 
 
 
 
The calculated virus volume was added to each well, after the removal of 1ml of the 
medium from each well. After 6 hours incubation the cells were toped up with 1ml 
of full medium and incubated for another 3-5 days. Protein was extracted and 
quantified as described in section (2.2.2).  
2.2.3.9 In vitro transduction and immunostaining of primary motor neurons 
Primary motor neurons (MNs) were isolated from E13 spinal cord from controls 
(Smn+/+; SMN2+/+ and Smn+/–; SMN2+/+), and SMA (Smn–/–; SMN2+/+) 
embryos. After 24h plating, MNs were transduced with LV-PLS3 / LV-GFP and no 
virus at an MOI of 20 and 40 for immunocytochemistry. The µl of the virus that 
must be added to transduce the cells at a specific MOI are estimated by the following 
formula: µls of virus= [(number of cells/well) x MOI] / titre. Transduction efficiency 
was assessed by counting the GFP positive cells under the fluorescence microscope 
after transduction with LV-GFP, and was found to be 70-80% at an MOI of 40. 
Plates were incubated at 37 oC and 5% CO2 for 7days and immunostained with anti-
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Tubulin and anti-PLS3. Double staining was performed with anti-tubulin (1:1000) 
and anti-PLS3 (1:500) for overnight at 4 °C. Then the secondary (1:200) was added 
for 2 hours at RT: goat anti rabbit A568 Alexa red (PLS3), goat anti mouse A350 
blue (Tubulin). Images were taken by confocal microscope. The axon length was 
measured by ImageJ plugin NeuronJ. 
2.2.3.10 Western Blot analysis 
Before being denatured, the extracted protein samples were added to laemmli buffer  
(2% SDS, 10% glycerol, 5% 2-mercaptoethanol, 0.002% bromophenol blue & 62.5 
mM Tris-HCl pH 6.8). The extracted protein samples were heated to 95 °C for five 
minutes in order to denature proteins. Then the samples were adjusted to 10µl with 
dH2O so that the samples contained either 20 µg or 40 µg of protein, and diluted 1:1 
with 2x loading buffer. The samples (20 µl) were loaded onto a 10% SDS-
polyacrylamide gel, Gel casting cassette (Bio-Rad, Hemel Hempstead, UK).  The gel 
was run at 180 V for 40 minutes. An electrical field of 120 V for 90 minutes on ice 
was applied to transfer the proteins onto a methanol-preactivated Polyvinylidene 
difluoride (PVDF) membrane (Milipore Immobilon). To check the transfer, the 
membrane was stained with Ponceau stain for 5minutes. After several washes with 
water, the membrane was blocked with 5% non-fat milk in TBST (40.03 g of NaCl, 
15.76 g of Tris base, 5 ml of Tween (Sigma) in 5 litres of dH2O), to prevent non-
specific binding of the antibodies to the membrane for 2 hours at room temperature. 
The primary antibody was diluted in 5% milk/TBST as described in table 2 and then 
the membrane was incubated with the primary antibody at 4 °C with overnight 
shaking (Table 2.2). After 24 hours incubation, the membrane was washed three 
times with TBST (15 minutes each time). After the washes, the membrane was 
incubated with the secondary antibody (horseradish peroxidase (HRP) conjugated) 
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for 2 hours at room temperature, as detailed in Table 2.3. Then the membrane was 
washed again three times with TBST (same conditions as before). To detect the 
protein of interest, the membrane was developed using ECL Plus chemiluminescence 
detection kit (Biological industries, 20-500-120) visualized using G-Box (Sygene). 
Quantification of the protein was carried out by Alpha Imager computer software 
using densitometry. Each western blot was also probed with an antibody 
(housekeeping gene GAPDH or cytoskeleton marker tubulin) to measure accuracy of 
protein loading per well. This provides a semi-quantitative method for normalising 
samples and allowing comparison but can have an error of up to 20% (Eaton et al., 
2013). The density of each band was integrated and the ratio between densitometric 
values for each sample was obtained. The variation in protein expression was 
calculated by a comparison between the samples and the controls. 
In addition to the above standard WB protocol applied in this study, some optimising 
of steps were done. For example, to test the Ab sensitivity different protein 
concentrations or Ab were used. Furthermore the incubation temperature was 
changed from 4 °C to room temperature.  
In addition, PLS3 (plastin 3, T isoform) Blocking Peptide, the middle region of 
protein made by Aviva Systems Biology, (100 µg)) (Catalog#: AAP00000) was used 
to enhance the antibody specificity.  
2.2.3.11 Immunocytochemistry 
Immunofluorescence staining was performed on HEK293T cells/ and primary motor 
neurons.  In a 6-well plate, the cells were plated onto glass coverslips at a density of 
5x104 cells per well. HEK293T cells were transduced for five days with LV-PLS3. 
Primary motor neurons were transduced for Seven days to investigate the effect of 
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PLS3 overexpression on axon length in WT, heterozygous, and SMA mouse 
embryos. After transduction, the cells were washed with Dulbecco's Phosphate 
Buffered Saline (DPBS), and fixed by incubating them for 15 minutes in 4% 
Paraformaldehyde (PFA) in PBS (pH 7.3) at room temperature. The cells were then 
washed once with DPBS and stored at 4 ⁰C untill the staining procedure was 
performed. Cell membranes were permeabilized by incubating the cells in cell 
staining blocking solution (0.3% Triton X-100 and 10% Goat serum in DPBS) for 2 
hours at room temperature (also prevent non-specific binding of the secondary 
antibody). Blocking solution was removed and cells were incubated with anti-rabbit 
PLS3 antibody (ab45769) diluted at 1:500 in PBS overnight (Table 2.2). The next 
day, after three times 10 minutes washes with PBS, to remove any unbound 
antibody, the cells were incubated with anti-rabbit fluorescent secondary antibody 
with an Alexa red 568 conjugate (Invitrogen A1105) diluted at 1:200 in PBS for 1 
hour in the dark at room temperature. Finally, the cells were washed again for three 
times for 10 minutes in PBS and were mounted on glass slides using Vectashield 
hard set mounting medium with diamidino-2-phenylindole (DAPI) (Vector 
laboratories). Confocal microscope images of chosen fields were obtained using a 
Leica SP5 microscope system at 63x magnification and were analysed using ImageJ 
software. 
2.2.3.12 Real-time Quantitative-PCR for PLS3 expression 
One ml of TRIzol reagent per 50-100 mg of tissue (Life Technologies, 15596-026)  
was added to harvest the tissues following the manufacturer’s protocol. The Direct-
zol™ RNA MiniPrep (Zymo research, R2052) was used to isolate of RNA. Simply, 
one volume ethanol (95-100%) was added to one volume sample homogenate (1:1) 
Chapter 2: Materials and Methods 
65 
 
in TRI Reagent. Then the samples were applied to the Zymo-Spin™ IIC Column and 
centrifuged for 1 minute. After transferring the column into a new Collection Tube, 
400 µl Direct-zol™ RNA PreWash3 was added to the column and centrifuged for 1 
minute. 700 µl RNA Wash Buffer was added to the column and centrifuged for 1 
minute. To ensure complete removal of the wash buffer, the column was centrifuged 
for an additional 2 minutes in an empty collection tube. Then the column was 
transferred carefully into an RNase-free tube. 25 µl of RNase-Free Water4 was 
added to the column matrix directly and centrifuged at max speed for 1 minute. The 
eluted RNA was stored at -80°C or used immediately. 
By using NANODROP1000, the concentration of extracted RNA was measured. The 
PCR reaction consisted of; 25 µl of PCR mix; 1 µl of DNA template, 1.34 µM of 
forward primer and 1.34 µM of reverse primer 0.5 µM, 10 µl of (5x FIREPol Master 
Mix, Solis BioDyne) and topped up with NF-H2O to a final volume of 25 µl (Table 
2.9). Real-time PCR was performed by, CFX96 Touch Real-time PCR detection 
system (Bio Rad, CFX96) following the program below: 
50 C     10 min 
95 C      5 min 
95 C     10 seconds 
60 C     30 seconds 
 
The CFX Manager software was used to analyse the signal intensity and expression 
values were normalized to Glyceraldehyde 3-phosphate dehydrogenase (GAPDH). 
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Table 2-9 Primers used for Real time PCR (RT-PCR) 
Gene Primer Sequence 
 
Conc. 
FW-
PLS3  
PLS3- EcoRI -F – 5’ GAT GCC GAATTC CAG CGT GCC 
ACC ATG  GAT GAG ATG GCT ACC ACT  3’                           
100 µM 
REV-
PLS3 
PLS3-XbaI-R – 5’ AGCAA TCTAGA TTA CAC TCT CTT 
CAT TCC C  3’           
100 µM 
FW-
Mouse-
PLS3 
PLS3mouseF 5’ AATGAAGCACTGGCAGCTT 100 µM 
REV-
Mouse-
PLS3 
PLS3mouseR 5’GTGCGATTTGATTGAGCAGA 100 µM 
FW-
GAPDH  
Forward 5’GGAAGCTCACTGGCATGGC3’  
 
 
300 µM 
REV-
GAPDH 
Reverse – 5’ TAGACGGCAGGTCAGGTCCA 3’ 
 
300 µM 
2.3 In Vivo Experimental Methods  
2.3.1 Breeding and Genotyping of Transgenic Mice  
All in vivo experimental work was performed according to the UK Home Office 
Animals (Scientific Procedures) Act 1986. FVB.Cg-Tg (SMN2*delta7) 4299Ahmb 
Tg (SMN2) 89Ahmb Smn1tm1Msd/J SMNΔ7 mice (The Jackson Laboratory stock 
005025) were used for all in vivo studies. These mice are triple mutant mice on a 
FVB background.  They have two transgenes inserted, the human SMN gene lacking 
exon 7 and the full-length human SMN2 gene copy, while they are also lacking the 
murine Smn gene (Le et al., 2005). For breeding carrier animals were used and to 
detect the presence of the transgene PCR reaction was performed.  At the day of 
birth tail clips were taken and incubated for 1 hour at 65 oC in 15 µl DNA extraction 
buffer (DNA extraction solution 1.0. Epicentre Biotechnologies) and then inactivated 
at 98 oC for 5 minutes. The PCR reaction was then performed using three primers to 
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recognize Smn with two different reverse primers specific for either the mutated or 
the wild-type gene (Table 2.10).   
2.3.2 Housing  
All Mice were obtained and bred under specified pathogen free (SPF) or 
conventional conditions. They were kept in a 12-hour dark-light photocycle with free 
access to water and food at a standardised room temperature of 21°C at the animal 
facilities of the University of Sheffield. Each cage was lined with sawdust (ecopure 
chips premium) and paper wool (Datesand, UK) was used as bedding material.  
Table 2-10 Primers used for genotyping 
Primer Sequence Concentration 
Smn Wild-Type Reverse 5’ TTTCTTCTGGCTGTGCCTTT 3’ 1.34 µM 
Smn Targeted-Mutation 
Reverse 
5’ GGTAACGCCAGGGTTTTCC 3’ 0.5 µM 
Smn Forward 5’ CTCCGGGATATTGGGATTG 3’ 1.34 µM 
 
The PCR reaction composed of 1ul of template, 5µl PCR Mix  (5x FIREPol Master 
Mix, Solis BioDyne) 1.34 µM of forward primer and 1.34 µM or 0.5 µM of either 
Targeted-Mutation or wild type or revere primer, and H2O to a final volume of 25 
µl.  
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The PCR program was as follows: 
  -  95°C 3 minutes 
  -  95°C 30 seconds     
  -  52°C 30 seconds 
  -  72°C 30 seconds 
  -  72°C 7 minutes 
            - 10 °C forever 
 
The PCR mixture was electrophoresed at 140 V for 30 minutes on a 1.5% agarose 
gel with 0.5 µg/uL ethidium bromide. The bands were expected to be as follows 
(Wild-type at 800 bp, homozygous transgenic at 500 bp and hemizygous carriers 
were expected to have two bands, one at 800 bp and one at 500 bp. Using GENi 
imaging system (Syngene) the bands were visualized.  
2.3.3 Recruiting Experimental Mice 
For the AAV9-PLS3 study (Chapter 5) Mus musculus, smn delta 7 strain (FVB 
background) smn+/+, smn-/+ and smn-/- litter mates were used. This is a triple 
transgenic model of SMA, which more closely resembles the human disease. 
2.3.4 Viral Vector Delivery 
At postnatal day one the animals were injected in the cisterna magna under gas 
anesthesia (IsoFlo, 100% w/w isoflurane inhalation vapor, Abbott, liquid) using 
anesthesia apparatus (Burtons). 10µl of viral vector solution was injected to each 
animal using a 10 µl 33-Guage Hamilton syringe (ESS Lab). A few minutes after 
recovery the animals were rolled in sawdust from their cage and returned to the cage 
with their mother. All the injections were performed by Ian Coldicott, 
35 Cycles  
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research technician in our group.  
Table 2-11 Viral vector dose administered 
Virus Titre Dose 
AAV9-PLS3 3.89E13 vp / ml 1E10 virus particles 
AAV9-GFP  1.2E13 vp / ml 2E10 virus particles 
 
2.3.5 Behavioural and Clinical Assessment 
Mice were weighed daily and observed for normal behaviours and disease onset. 
After day 8 mice were checked for activity levels, grooming, respiration, gait and 
motor skills as indicators of disease onset. When mice showed severe respiratory 
distress they were humanely culled by cervical dislocation.  
2.3.6 Tissue Collection 
When the mice were deemed ready for sacrifice they were euthanized by 
intraperitoneal injection of 500mg/kg of sodium pentobarbital (sodium pentobarbital, 
20% w/v solution for injections, JML). Intracardiac perfusion of cold PBS 
containing 5 units/mL Heparin (2000 units/mL heparin, Sigma) was immediately 
performed for histological analysis followed by perfusion with 4% PFA using an in 
vivo perfusion system (AutoMate Scientific). Then the organs were collected and 
incubated overnight at 4 oC in 4% PFA. Only brain and spinal cord were further 
incubated in 30% sucrose in PBS for at least one day before being cryoembedded in 
optimum cutting temperature medium (OCT, Dako).  
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2.3.7 Histological Analysis  
Using a Leica cryostat brains were sectioned at 20µm and Lumbar spinal cords were 
sectioned at 10µm and mounted onto slides. 
2.3.7.1 Immunohistochemistry 
To assess Pls3 expression (Chapter 3) in brain and spinal cord, anti-PLS3 and a DAB 
peroxidase substrate kit (Vector) were used. First the tissue was incubated for 20 
minutes in 2% hydrogen peroxide in methanol to block endogenous peroxidase. 
Then the sections were washed in water for 1 minute followed by TBS for 5 minutes. 
Then the slides were incubated for 30 minutes with normal serum in TBS at room 
temperature to block any non-specific binding. 
Slides were then incubated with the primary antibody, polyclonal rabbit antibody 
against PLS3 (Abcam) at a dilution of 1:50 in TBS for 2 hours at RT. The sections 
were washed twice with TBS for 5 minutes then incubated with the secondary 
antibody for 30 minutes at room temperature. This was followed by  washs for 2x 5 
minutes in TBS before incubation for 30 minutes with the ABC reagent at room 
temperature. Then the slides were washed for a further 2x 5 minutes in TBS and 
incubated for 5 minutes in diaminobenzidine (DAB) at room temperature. A final 
wash for 5 minutes was done before being dehydrated through 70%, 95% and 
absolute ethanol, haematoxylin was used for counter staining. Then the slides were 
placed in xylene before being mounted with coverslips using Di-N-Butyl Phthalate 
in Xylene (DPX) and the images were taken with Nikon microscope using NIS-
Elements software (Improvision) at 40x magnification.  
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2.3.7.2 Immunofluorescence 
Immunofluorescence was performed to stain for neuronal or motor neuronal markers 
(Neuronal nuclei (NeuN) and Calcitonin-gene related peptide (CGRP) respectively) 
as well as for PLS3 and GFP. First the slides were washed for 10 minutes 5 times 
with PBS before being incubated with 10% normal goat serum (NGS) and 0.3% 
Triton X-100 (Sigma) in PBS for 2 hours at room temperature.  
For the Pls3 expression (Chapter 3) two primary antibodies were incubated together, 
for brain sections rabbit antibody against PLS3 (Abcam) alongside a mouse antibody 
against NeuN (Millipore) all diluted 1:200 in PBS and incubated overnight at 4 oC. 
Three washes were applied to all sections in PBS. Secondary antibodies were added, 
a goat Alexa fluor 594-conjugated anti-mouse antibody (Invitrogen) and a goat 
Fluorescein isothiocyanate (FITC)-conjugated anti-rabbit antibody (Jackson), 1:200 
in PBS for 2 hours at room temperature. Then all slides were washed 3 times for 10 
minutes in PBS.  Spinal cord sections were stained with rabbit antibody against 
PLS3 (Abcam) alongside either a mouse primary antibody against the 
nonphosphorylated neurofilament (SMI32) or CGRP diluted at 1:200 and a goat 
Alexa-Fluor594- conjugated anti-mouse antibody as described above.  
For AAV9- PLS3 study (chapter5), spinal cord Sections were stained with a rabbit 
antibody against PLS3 (Abcam) or with a chicken antibody against GFP (Abcam) 
alongside a mouse antibody against CGRP (Abcam), all of which were diluted 1:200 
and incubated at 4 oC overnight. A goat Alexa fluor 488-conjugated anti-mouse 
antibody (Invitrogen), or goat Alexa fluor 488-conjugated anti chicken (Life tech) 
and a goat FITC- conjugated anti-rabbit antibody (Jackson) used were as secondary 
antibodies. They were diluted at 1:200 and incubated for 2 hours at room 
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temperature. The Washing and blocking steps were performed for all slides as 
detailed above. Vectashield hard-set mounting medium with DAPI (Vector 
laboratories) was used for mounting. CGRP-Positive MNs were counted to assess 
PLS3 transduction. Images were taken with both a fluorescence microscope (Nikon) 
using NIS-Elements software (Impovision) at 100x magnification which were 
analysed using ImageJ software and with a confocal microscope using a Leica SP5 
microscope system.  
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3   CHAPTER 3: PLASTIN3 EXPRESSION IN SMNΔ7 MOUSE 
MODEL OF SPINAL MUSCULAR ATROPHY 
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3.1 Aims 
 
This chapter aims to assess the expression of pls3 mRNA and its corresponding 
protein distribution throughout the central nervous system in a SMA mouse model 
since PLS3 expression has been shown to be modulated by SMN in SMA patients 
with SMN1 deletions and in zebrafish. In this chapter characterization of Pls3 
expression and Pls3 protein levels in a SMA mouse model (SMNΔ7) at different 
time points of the disease were carried out to assess whether SMN dosage influences 
Pls3.   
3.2 Introduction    
PLS3 is detected in muscle, brain, spinal cord, uterus, oesophagus and preferentially 
expressed in mitotic cells such as fibroblasts, endothelial cells, epithelial cells, and 
melanocytes (Lin et al., 1993). PLS3 is highly expressed in fetal and adult human 
spinal cord, and is increased in rat cells during neuronal differentiation, suggesting a 
role in neuronal outgrowth (Giavazzi et al., 2006). Members of the plastin family 
have been identified in cellular regions containing polarised actin filaments, and in 
areas with high actin filament turnover (Delanote et al., 2005). Due to the fact that all 
plastin isoforms regulate the actin cytoskeleton, plastins have always been seen as 
cytoplasmic proteins (Lin et al., 1993). However, Delanote et al. have shown that 
endogenous PLS3, as well as overexpressed T- and L-plastin, had the ability to travel 
between the nucleus and cytoplasm in HeLa and Jurkat cells (Delanote et al., 2005). 
Recently a number of studies have suggested a role for PLS3 in regulating actin 
turnover in SMA (Oprea et al., 2008, Hao et al., 2012). PLS3 has roles in decreasing 
the disassembly rate of actin, which affects actin turnover and the length of actin 
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filaments (Giganti et al., 2005). Given that actin is the most abundant cytoskeletal 
protein found within the synapses of mature neurons (Matus et al., 1983, Sato-
Yoshitake et al., 1989) this activity makes PLS3 an interesting candidate for 
involvement in neurodegenerative diseases such as SMA. It has been reported that at 
the pre-synaptic terminal, actin has a crucial role in regulation and maintenance of 
synaptic vesicle pools, axonal vesicle trafficking, mobility of vesicles, and 
neurotransmitter release (Delanote et al., 2005, Giganti et al., 2005, Bowerman et al., 
2009, Ackermann et al., 2012). 
Therefore, actin-binding and actin-regulating proteins have an attractive regulation 
role of actin dynamics at the synapse, which is considered to be necessary for 
adequate NMJ function and maturation. Rossoll et al. (2003) reported dramatic 
reduction of β-actin mRNA and protein levels in cultured motor neurons isolated 
from a severe SMA mouse model (Rossoll et al., 2003). This disruption in the actin 
cytoskeleton may explain the degeneration of NMJs in the severe SMA mice which 
is a central event in SMA pathogenesis (Kariya et al., 2008, McGovern et al., 2008). 
SMN has also been shown to undergo a shift from nuclear to cytoplasmic and 
predominantly axonal localisation during maturation of the human CNS (Giavazzi et 
al., 2006), suggesting a role for SMN in neurodevelopment (Bowerman et al., 2009). 
T-­‐plastin seems to co-localize with SMN in granules throughout MN axons and 
growth cones (Sharma et al., 2005, Oprea et al., 2008). Both proteins have a similar 
cellular localisation and are believed to interact with each other, where they form a 
ribonucleoprotein complex (Zhang et al., 2006, Oprea et al., 2008). In vivo, in 
murine MNs, confocal microscope analysis showed co-localisation of Pls3 and Smn 
in granules throughout MN axons and growth cones, however in vitro assays showed 
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no direct interaction (Oprea et al., 2008). Suggesting that the interaction is indirect, 
possibly through complexes with other proteins, such as SMN and its binding partner 
hnRNP R. This complex interacts with β-actin mRNA causing translocation to the 
axons and growth cones of MNs (Rossoll et al., 2003).  
A potential association between PLS3 and SMN has been observed in SMA families 
(Oprea et al., 2008, Bernal et al., 2011, Yanyan et al., 2013), and in SMA models 
such as Smn knockout zebrafish and mice (Oprea et al., 2008, Bowerman et al., 
2009, Hao et al., 2012). In families with SMN mutations, siblings who were 
asymptomatic for SMA showed high levels of PLS3 whilst reduced PLS3 levels 
were reported in siblings affected by SMA, suggesting that overexpression of PLS3 
can overcome the loss of SMN. Further studies in zebrafish models in vivo and SMA 
PC12 cells in vitro showed that high Pls3 levels increased the amount of F-actin in 
motor neurons, resulting in improved axon outgrowth (Oprea et al., 2008). 
In this study Pls3 expression was assessed in SMNΔ7 mice, an SMA mouse model 
where Smn is depleted (Le et al., 2005). This is a triple transgenic mouse generated 
by overexpression of both human SMN2 gene (SMN2+/+) and the SMN1 gene lacking 
exon 7 (SMNΔ7), and lacking murine smn gene (smn-/-). The overexpression of 
human SMN genes provides a small amount of full length SMN protein but 
predominantly truncated, non-functional protein, as seen in human disease. The 
murine gene is removed to prevent murine SMN rescuing the lack of full length 
human SMN. Non-transgenic littermates used as control animals still have a copy of 
the human SMN genes, but also have both copies of the mouse gene (SMN2+/+, 
SMNΔ7+/+,smn+/+) therefore do not show disease.   
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SMNΔ7 mice, are a well-established model of SMA (Le et al., 2005), commonly 
used in disease research. They display progressive muscle weakness and die on 
average 2 weeks after birth, mimicking severe SMA in humans.  
 
It is not known whether levels of SMN directly influence PLS3 levels, however, it is 
known that PLS3 is a modifier of SMN (Oprea et al., 2008). This study will try to 
confirm this in the SMNΔ7 SMA mouse model, and to determine whether this is 
developmentally regulated. 
Both Pls3 mRNA and Pls3 protein expression was measured at three different time 
points: early (P1), mid- (P5) and late stages (P10) of the disease progression, to 
determine whether a correlation exists between disease severity and Pls3 expression.   
 
3.3 Results 
Protein expression was examined in the brain and spinal cord, due to the location of 
the motor neurons. The muscle from the thigh was also collected and examined 
being as the motor neurons have the end plates in the muscles. The thigh muscles 
were chosen as this muscle is commonly affected in disease and paralysis of hind 
limbs is an indicator of disease progression.  
 
3.3.1 Pls3 protein expression is downregulated in SMNΔ7 mice  
Firstly, pls3 levels within the brain, spinal cord and muscle of SMNΔ7 mice were 
compared to their wild type and heterozygous littermates (n = 6) at postnatal days 1, 
5 and 10 (P1, P5, P10). Tissue homogenates were prepared from SMN2+/+, 
SMNΔ7+/+,smn+/+ (defined as wild type) (WT), heterozygous 
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SMN2+/+,SMNΔ7+/+,smn+/- (defined as carrier or HET) and SMN2+/+, 
SMNΔ7+/+,smn-/- (defined as SMNΔ7 or KO). RNA and protein were extracted 
from tissue, and Pls3 expression was measured by western blot and qPCR.  
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Figure 3.1. Pls3 protein levels in postnatal day 1 SMNΔ7 mice 
(A) Representative image of Western blot showing pls3 protein expression in brain, spinal 
cord and muscle tissues from wild type (WT), heterozygous (HET), and SMNΔ7 (KO) P1 
neonate mouse pups. The membrane was probed with mouse anti-PLS3 antibody; GAPDH 
was used as the house keeping control (n=3). (B) Densitometry for Pls3 fold change: brain, 
spinal cord and muscle (left to right panels). WT, HET and KO pups (n=3). Error bars 
represent (SEM)    
 
At postnatal day 1 there was no statistically significant difference between genotypes 
for Pls3 protein levels in the brain, spinal cord or in thigh muscle (Figure.3.1B). 
None of the genotypes showed detectable Pls3 protein in muscle and only low 
detection in the spinal cord (Figure.3.1A). This suggests that Smn levels do not 
appear to affect Pls3 levels at P1. There was no discernible difference between 
protein levels in any of the genotypes at this age, which correlates with the lack of 
phenotype in P1 pups. The KO pups were phenotypically indistinguishable from 
their WT littermates in the first 48 hours after birth. 
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Figure 3.2. Pls3 protein levels in postnatal day 5 SMNΔ7 mice  
(A) Representative image of Western blot showing Pls3 expression in brain, spinal cord, and 
muscle tissues from postnatal day 5 wild type (WT), heterozygous (HET), and SMNΔ7 
(KO) neonate mouse pups. The membrane was probed with mouse anti- Pls3 antibody, 
GAPDH is the house keeping control. (B) Densitometry for Pls3 fold change: brain, spinal 
cord and muscle (left to right panels). WT, HET and KO pups (n=3). A value of one-way 
ANOVA (*p <0.05 ) was considered to be statistically significant. Error bars represent (SEM)    
 
Pls3 was detected and showed no significant difference in the P5 brains of all 
genotypes (Figure. 3.2A). However, the current analysis revealed that Pls3 protein 
levels were significantly lower in P5 spinal cord of KO and HET when compared to 
WT (p<0.05, n=3) (Figure 3.2). Pls3 was undetectable in muscle of the 3 groups 
tested (Figure 3.2).  
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Figure 3.3. Pls3 protein levels in P10 SMNΔ7 mice 
(A) Western blot showing pls3 expression in brain, spinal cord and muscle tissues from P10 
wild type (WT), heterozygous (HET), and SMNΔ7 neonates (KO) (n=3). The membrane 
was probed with mouse anti-pls3 antibody, GAPDH is the house keeping control. (B) 
Densitometry for Pls3 fold change: brain, spinal cord and muscle (left to right panels). WT, 
HET and KO pups (n=3).  A value of one-way ANOVA (*p <0.05, **p<0.01, ***p <0.001) 
was considered to be statistically significant. Error bars represent (SEM)    
 
Western blot analysis performed at postnatal day 10 revealed a significant decline of 
Pls3 protein levels in the KO brain and spinal cord compared to previous time points 
(P1 and P5) and the same tissues in HET and WT (Figure 3.3), suggesting that SMN 
levels did affect Pls3 expression at P10 in the CNS and muscles. It is also 
noteworthy to state the significant reduction of Pls3 protein in spinal cord of HET 
pups (Figure 3.3). Surprisingly Pls3 levels were higher in HET compared to WT 
brains (Figure 3.3).   
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3.3.2 Pls3 mRNA expression over time 
mRNA expression was examined to see how the pattern of expression changes for 
each of the genotypes as the disease progresses, and whether this correlated with the 
protein.  
 
Figure 3.4  Pls3 mRNA levels over time in the brain, spinal cord and muscle of SMNΔ7 
mice Time course experiment for Pls3 mRNA expression quantification in brain at three 
different time points (P1, P5 and P10). Wild type (WT), heterozygous (HET), and SMNΔ7 
(KO) neonate mouse pups (n=3). Error bars represent ±SEM. (A) Brain, (B) Spinal cord and 
(C) muscle  
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This data confirmed differential Pls3 expression between SMN knockout mice from 
the SMNΔ7 line and their wild-type littermates in the analysed tissue. At early time 
points (postnatal days 1 and 5) there were no differences in Pls3 mRNA levels 
between any of the genotypes in brain (Figure.3.4A). However, by P10 Pls3 is 
almost undetectable in KO mice (Figure 3.4A). Unexpectedly, there was an 
approximately three-fold upregulation of Pls3 mRNA in HET mice compared to 
wild type mice (Figure 3.4A), the mRNA change that was reflected in the protein 
levels (see Figure 3.3).  
In spinal cord there were no differences in Pls3 mRNA levels at P1 between any of 
the genotypes (Figure 3.4B). By postnatal day 5 there was almost similar decrease in 
Pls3 mRNA in HET and KO, however, a steady increase in WT. By P10 
upregulation of Pls3 in WT, while HET Pls3 levelled off, and KO animals showed 
reduction in Pls3 expression to almost undetectable levels.  
In muscle, Pls3 mRNA was almost absent for all at P1 and showed a significant 
increase in WT up to p10 (Figure 3.4C). By P5 Pls3 expression peaks in HET and 
KO to around 3 times the level of WT Pls3. By postnatal day 10 Pls3 mRNA levels 
in both HET and KO declined, however, HET Pls3 was as WT level whilst KO was 
undetectable (Figure 3.4C).  
3.3.3 Localisation of Pls3 in SMNΔ7 mice  
Following the quantification of plastin 3 expression in brain, spinal cord and muscle 
tissues in SMNΔ7 mice at both mRNA and protein levels, qualitative histological 
analysis of the protein localisation was carried out in order to confirm the difference 
between the genotypes, with specific interest in whether Pls3 was enriched in 
specific cell types in brain and spinal cord. PLS3 staining was assessed qualitatively 
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by immunohistochemistry to address its cellular expression by probing tissue with 
anti-PLS3 antibody (n=3 per group).   
Tissue sections were taken from the brain and spinal cord of P10 KO and WT mice. 
Motor neurons were identified morphologically by size and shape within the ventral 
horn of the cervical and lumbar spinal cord sections.  
DAB staining was performed on spinal cord and brain sections (Figures 3.5 and 
3.6), followed by co-immunostaining for PLS3 and NeuN, in brain (Figure. 3.7). In 
addition, SMI32 and CGRP served as motor neuron markers for the spinal cord 
sections (Fig. 3.8, 3.9 and 3.10).  Due to technical challenges processing tissues 
from P1 and P5 animals this was only carried out in P10 pups. 
 
 
Figure 3.5. Pls3 immunostaining in the brain cortical sections of WT and KO P10 pups     
Immunohistochemical staining showing Pls3 expression in brain from P10 wild type (WT) 
and SMNΔ7 mice (KO) (n=3 per group). Brain sections from WT showing immune 
reactivity of Pls3 associated with a large number of neurons in the brain cortex (brown) 
(arrows). SMNΔ7 mice (KO) brain sections showed minimal reactivity of Pls3 associated 
with neurons (arrows). Negative control (no primary antibody) showed purple neuronal 
staining (arrows) (reflecting haematoxylin counter stain) with no Pls3 positive cell staining. 
Scale bar (scale = 50µm) 
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Immunostaining for Pls3 on WT and KO brain sections at P10 indicated a reduction 
in Pls3 signal intensity in brain tissue in KO animals compared to WT group (Figure. 
3.5), consistent with western blotting data (Figure. 3.3) and mRNA analyses 
(Figure.3.4) described earlier in this chapter. Pls3 reactivity was associated with the 
nucleus as well as cytoplasm of cells with long processes, resembling neuronal 
morphology (Figure 3.5).  
To confirm that brain neurons express Pls3 WT brain sections were stained with Pls3 
and neuronal marker NeuN to identify their co-localisation in neurons. Using WT 
brain sections NeuN-positive cells were seen to express Pls3 as reported in Figure. 
3.6A. Pls3 was found in the cytoplasm of cell bodies and excluded from the nucleus. 
The NeuN neuronal marker co-localised with the nuclear stain, DAPI.  
KO brain sections were stained with Pls3 and NeuN to identify their localisation 
(Figure. 3.6B). Examination of KO brain section confirmed low levels of Pls3 
protein in NeuN-positive neurons. This observation is in agreement with Western 
blot findings described above. These data, alongside the WT data, show that Pls3 is 
detectable in WT neurons but is depleted in KO brain. 
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Figure 3.6. Co-localisation of Pls3 protein levels in the brain of WT / KO at P10 of age 
with NeuN 
(A) WT brain section showing co-localisation of Pls3 with the neuronal marker NeuN of 
P10. (B) Brain section from SMNΔ7 mice (KO) demonstrating very weak co-localisation 
between NeuN and the Pls3, (n=3). The nucleus stained with DAPI. The sections were 
stained for DAPI- Diamidino-2-phenylindole  (blue), NeuN- Neuronal nuclei (green) 
and Pls3- Plastin3  (red). A: WT, B: KO, (scale = 50µm) 
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Figure 3.7. Pls3 Immunoreactivity in cervical (A) and lumbar (B) spinal cord of P10 
WT and KO SMNΔ7 mice 
Immunohistochemical staining showing Pls3 expression in the spinal cord from P10 wild 
type (WT) and SMNΔ7 mice (KO) (n=3). WT spinal cord sections showing Pls3 immuno-
reactivity in large number of MNs in the anterior horn of the spinal cord (brown) (arrows), 
when compared to sections from SMNΔ7 mice KO section, which showed minimal 
reactivity of Pls3 associated with MNs (arrows). Negative control (no primary antibody) 
showed purple neuronal staining (arrows) (reflecting haematoxylin counter stain) with no 
Pls3 positivity. Scale bar (scale = 50µm), (A) Cervical spinal cord sections, (B) Lumbar 
spinal cord sections   
 
Investigating Pls3 protein expression in spinal motor neurons is relevant to SMA, 
therefore markers such as SMI32 and CGRP were used to explore localisation of 
Pls3 in spinal motor neurons. Pls3 immuno-reactivity on spinal cord sections in P10 
pups revealed a reduction in Pls3 signal intensity in both cervical and lumbar spinal 
cord of KO animals compared to WT group (Figure. 3.7).  
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Figure 3.8. Double labeling with Pls3 and SMI32 antibodies in the spinal cord sections 
of P10 WT pups  
Wild type spinal cord section showing double labelling with Pls3 and the neuronal marker 
SMI32 in P10 wild type (WT) (n=3). The sections were stained for DAPI- Diamidino-2-
phenylindole (blue), SMI32 (green) and Pls3- Plastin3  (red). A: Scale bar = 200 µm, B: 
Scale bar = 50 µm, C: Scale bar = 20 µm  
 
 
WT spinal cord sections were stained with Pls3 and SMI32 to identify their co-
localisation in neurons (Figure. 3.8). SMI32 detects cytoplasmic neurofilament 
protein, which is predominantly expected in motor neurons. Pls3 signal was detected 
in white matter regions, suggesting that Pls3 expression can be found either in the 
myelinated axons or other cells such as glial cells (astrocytes and microglia) or 
oligodendrocytes. Labelling with neuronal marker SMI32 showed no co-localisation 
with Pls3.   
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Figure 3.9. Double labeling Pls3 and SMI32 in the Spinal Cord sections from 
SMNΔ7 mice (KO) at P10 of age 
SMNΔ7 mice (KO) spinal cord section showing absence of co-localisation of Pls3 with the 
neuronal marker SMI32 (n=3). The sections were stained for DAPI- Diamidino-2-
phenylindole (blue), SMI32- nonphosphorylated neurofilament marker (green) and Pls3- 
Plastin3  (red). A: Scale bar = 200 µm, B: Scale bar = 50 µm, C: Scale bar = 20 µm  
 
Spinal cord sections collected from KO were stained with Pls3 and SMI32 
antibodies to identify possible localisation of Pls3 in motor neurons. No cells were 
found to express Pls3, and therefore no co-localisation with SMI32 staining was 
observed (Figure. 3.9).  
Another MN marker, CGRP, was used to perform co-immunostaining with Pls3 in 
spinal cord (Figure. 3.10). WT and KO spinal cord sections were co-stained with 
Pls3 and CGRP to identify their co-localisation in MNs. 
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Figure 3.10. Co-localization of Pls3 protein levels in the spinal cord of WT / KO at P10 of age 
with CGRP  
(A) Wild type (WT) spinal cord section showing co-localisation of Pls3 with the motor 
neuronal marker CGRP from P10, (n=3). (B) Spinal cord section from SMNΔ7 mice (KO) 
showing no co-localisation between CGRP and the Pls3,(n=3). The sections were stained for 
DAPI- Diamidino-2-phenylindole (blue), Pls3- Plastin3  (green) and CGRP- Calcitonin 
Gene-Related Peptide (red). A: WT, B: KO, (scale = 20 µm) 
 
In the WT spinal cord, MNs were found to express Pls3, which co-localised with 
CGRP staining (Figure. 3.10A). Pls3 was found in the cytoplasm of large cell bodies 
and nucleus. KO spinal cord sections were also stained with Pls3 and CGRP to 
identify the co-localisation in MNs. No cells however were found to express Pls3; 
and subsequently no co-localisation with CGRP staining was seen (Figure. 3.10B), 
suggesting depletion of Pls3 protein levels in KO MNs. 
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3.4 Discussion 
In this chapter, it was shown that Pls3 is expressed in the brain, spinal cord and 
muscle of the SMNΔ7 mice and their non-transgenic littermates, consistent with 
human and other studies on SMA animal models such as zebrafish (De Arruda et al., 
1990, Oprea et al., 2008, Bowerman et al., 2009, Hao et al., 2011). When Smn is 
depleted, however, Pls3 levels are decreased over time as the disease progresses in a 
tissue specific pattern. This study revealed that Smn depletion in KO pups was 
associated with near complete ablation of Pls3 levels in spinal cord and brain by the 
end stage of disease progression (P10) in all tissue types analysed. Given that it is 
believed that Smn and Pls3 interact and function to promote axon growth and motor 
neuron survival (Hao et al., 2012), the decrease in Pls3 may contribute to neuronal 
death in SMA.  
3.4.1 Pls3 expression variations in the CNS of SMNΔ7 mice 
A downregulation of Pls3 mRNA or Pls3 protein expression in brain, spinal cord and 
muscle of the SMNΔ7 mouse model at early stages of development was observed. 
There were no significant differences in Pls3 levels between any of the genotypes at 
postnatal day 1 in any tissues (Figure. 3.1, Figure. 3.4); however, by postnatal day 10 
there was little or no detectable mRNA or protein in the CNS of Smn knockout mice 
(Figure. 3.3, Figure. 3.4). Similar findings have been reported by two independent 
studies in different SMA mouse and zebrafish models, where Pls3 was reduced in 
brain and spinal cord of animals lacking Smn (Oprea et al., 2008, Hao et al., 2011). 
The similarities in Pls3 expression between human SMA patients in previous studies 
and SMNΔ7 mice in the current study indicate that SMNΔ7 mice are a good model 
for testing potential PLS3-based therapeutics for human SMA. The discrepancy 
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between the WB results (Figure. 3.3) and the immunostaining (Figure 3.5 and 3.7) in 
Pls3 reduction in KO mice may simply be by-product of having fewer cells present. 
Another study in an intermediate mouse model supports the same findings where the 
levels of Pls3 were reduced in the brain and spinal cord of Smn2B/− mice at P21 
compared to their wild type littermates (Bowerman et al., 2009).  Previous studies in 
human SMA patients showed that PLS3 was expressed at a very low level in blood 
cells (Oprea et al., 2008, Stratigopoulos et al., 2010, Yanyan et al., 2013).  
The role of PLS3 in motor neuron development is unknown, and its association with 
SMN in developing MNs has not been investigated.  PLS3 overexpression stabilised 
axons, reduced axon pruning, and ameliorated poor connectivity seen in SMA model 
NMJs (Oprea et al., 2008, Boon et al., 2009, Ackermann et al., 2012). Therefore, 
PLS3 deficient MNs are more likely to have shorter axons, poor connectivity at 
NMJs and axon instability. SMN loss is also known to cause the same defects in 
MNs (Rossoll et al., 2003, Simic et al., 2008, Bowerman et al., 2009). This suggests 
that both SMN and PLS3 interact and function to promote axon growth and motor 
neuron survival (Oprea et al., 2008, Bowerman et al., 2009). Therefore, the loss of 
one of these proteins may contribute to the cause of neuronal death and may 
accelerate the disease progression.  
Overexpressing both SMN and PLS3 might provide a better therapeutic effect for 
SMA and other neuromuscular diseases, since previous studies have shown that 
PLS3 managed to rescue axonal defects associated with reduced SMN protein levels 
in MNs (Oprea et al., 2008).  
In the current study, the down regulation of Pls3 levels (Figure. 3.4) was consistent 
with Smn depletion, which may contribute to the modification of SMA phenotype. 
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Both mRNA and protein levels showed the same pattern of down regulation, 
indicating a transcriptional and not a translational effect. This suggests that the 
decrease in Pls3 protein is caused by a decrease in mRNA levels. On the other hand, 
a recent study of Pls3 in zebrafish smn -/- mutants showed that pls3 RNA levels were 
unaffected by Smn levels (Hao et al., 2012). This discrepancy may be due to 
different mechanisms of Pls3 regulation in the different species. There are 2 
possibilities for a mechanism by which SMN reduces PLS3. Firstly, SMN is 
responsible for shuttling molecules along the axon to the synapse. PLS3 mRNA may 
rely on SMN to deliver it to the nerve terminals and a loss of SMN leads to a build-
up of PLS3 in the cell body and eventual degradation without translation. Secondly, 
SMN is also involved in a splicing complex. Loss of SMN may affect PLS3 mRNA 
levels due to the loss of splicing complexes in these models. However, zebrafish smn 
-/- mutants (Hao et al., 2012) do not show any alterations in the splicing of 
endogenous pls3, which indicates that Smn does not affect pls3 transcription, pls3 
RNA or Pls3 protein stability. Moreover, another study in mice (Ackermann et al., 
2012) showed that Pls3 overexpression had no effect on smn expression. In addition, 
one study in PC12 (human cells) (Oprea et al., 2008) reported that the 
overexpression of PLS3 has no influence on SMN levels. Therefore, we could 
conclude that in mammals plastin3 seems to exert its modifying effects 
independently of SMN (Ackermann et al., 2012). These findings suggest that PLS3 
has mechanisms of neuronal protection that are independent of SMN. 
3.4.2 Pls3 levels in the muscle 
Unexpectedly, in muscle at postnatal days 5 up regulation of Pls3 mRNA was 
observed in both carrier (HET) and knockout (KO) mice. By day 10, Pls3 mRNA 
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was almost undetectable in KO mice and decreased to WT levels in HET mice 
(Figure. 3.4). One explanation for the elevated level of Pls3 in early stages of the KO 
mice is that Pls3 could be derived from the maternal RNA. In a published study 
(Boon et al., 2009) to understand the relationship between SMN and PLS3, both 
Smn and Pls3 protein levels in zebrafish smn mutant (smnY262stop−/− zebrafish) 
larvae were analysed. Interestingly, it was reported that Smn protein was present at 
high levels until approximately 4 days post fertilization (dpf) due to maternal 
contribution of RNA and protein in the yolk (Boon et al., 2009). Then, these levels 
decreased gradually – reaching low levels by ≈7 dpf until the mutants died at ≈12 
dpf.  It should be also noted that these zebrafish mutants do not mimic the human 
situation for SMA patients. However, similar findings have been reported in blood of 
SMA children, where their PLS3 expression was higher at early stages of 
development (3 years), and gradually the levels decreased with age (Yanyan et al., 
2013). In our study the peak observed in Pls3 mRNA was not seen in the 
corresponding protein analysis (Fig. 3.2), which may be due to the detection limit of 
western blots; protein levels may be very low, and therefore undetectable. This 
difference may also be due to a delay in translation from RNA to protein. The 
protein peak may fall after day 5 but proteins have reduced again by day 10 (Figure. 
3.2).   
3.4.3 Pls3 levels in SMN heterozygote mice 
In heterozygotes, where SMN is reduced but not ablated, Pls3 decreased to similar 
levels as KOs in spinal cord at day 5 but stayed at a steady level up to day 10 
(Figure. 3.4). Since HET mice have the same life span as WT mice, it was expected 
that half the amount of SMN would be sufficient for neuronal survival. A 50% 
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reduction in SMN does not appear to have an effect on PLS3 in muscle but shows 
changes in PLS3 levels in the CNS, suggesting that the interaction between SMN 
and PLS3 is different and/or less important in muscle than CNS.  Muscle tissue is 
rich in actin filaments, therefore PLS3 may be regulated preferentially by proteins 
other than SMN in this tissue, and so PLS3 levels may be unaffected by the loss of 
SMN in muscle. 
In brain tissue, at P5 pls3 mRNA in HET mice increased above WT levels (Figure. 
3.4). One possible reason could be a compensation of PLS3 after day 5 to help with 
axonal outgrowth in a bid to overcome the reduction of SMN.   
3.4.4 Localisation of Pls3 in P10 SMNΔ7 mice 
Pls3 is decreased at a tissue level, but it is not known whether it is enriched in 
specific cell types or whether the lack of SMN is targeted to specific cells. Pls3 
expression was assessed qualitatively by immunohistochemistry (IHC) to address its 
cellular expression.  Due to the technical challenges and size of spinal cord at P1 and 
P5 only P10 mice could be reliably analysed by IHC. Examination of tissues from 
SMNΔ7 mice at P10 by IHC confirmed reduced Pls3 signal in both the spinal cord 
and brain of KO mice (Figure. 3.5, 3.6, 3.7, 3.8, 3.9 and 3.10).  
Cellular localisation was firstly observed with DAB staining and Pls3 appeared to 
localise in cells with neuronal morphology in WT mice (Figure. 3.5 and 3.6). 
Fluorescent immunohistochemistry was then carried out to allow neuronal markers 
to be used to confirm cell types. NeuN is a pan-neuronal marker commonly staining 
the nucleus and to a lesser extent the cytoplasm. A large number of neuronal cells 
were found to express Pls3, which was co-expressed with NeuN staining in the WT 
brain (Figure. 3.7A). Co-expression of Pls3 in brain with NeuN also revealed a 
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decrease of Pls3 levels in KO SMNΔ7 SMA mice compared to WT littermates, in 
agreement with Bowerman et al. (2009), who reported decreased level of Pls3 in the 
brain of an intermediate SMA mouse model (Bowerman et al., 2009).  
Pls3 did not appear to co-localise with the neuronal marker, SMI32 in spinal cord. 
SMI32 detects cytoplasmic neurofilament protein, which predominantly expressed 
by MNs. Co-localistion of Pls3 with the MN marker CGRP was detected in spinal 
cord lumbar sections. CGRP is specific for calcitonin gene related peptide, a 
neuropeptide that is expressed in the MNs mainly in the peri-nuclear location and 
sensory neurons in dorsal root ganglia (DRG).  
In spinal cord Psl3 distribution was as expected, being expressed in the white matter 
where mostly glial cells and myelinated axons are located. A strong Pls3 signal was 
detected in the white matter regions in the spinal cord indicating that Pls3 may be 
localised to either axons or oligodendrocytes (Figure. 3.8). Double labelling with 
CGRP confirmed localisation of Pls3 to motor neuron cell bodies (Figure. 3.10) but 
did not label axons.  
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3.4.5 Summary 
To sum up, this chapter characterized Pls3 localisation and Pls3 expression and 
protein levels in an intermediate SMA mouse model (SMNΔ7 SMA mouse model) at 
different stages of the disease. Our study has shown down regulation of Pls3 over 
time when Smn is depleted. Early Pls3 depletion may affect the development of 
motor neuron axons in these models and may affect motor neuron survival, 
contributing to the SMA phenotype. This chapter raises many interesting questions 
that need addressing with regards to the expression of Pls3 such as: What is the 
mechanism by which Smn deficiency reduces Pls3 levels? Does Pls3 feedback and 
self-regulate transcription of its own mRNA? Moreover, further evidence is required 
to support the role of Pls3 down regulation in the pathology of spinal muscular 
atrophy, and to demonstrate whether the restoration of Pls3 expression can rescue the 
axonal phenotype in spinal motor neurons cultured from a clinically relevant mouse 
model of SMA. In addition to furthering understanding of the function of Pls3, a 
potential use for Pls3 in gene therapy for SMA can be proposed.  
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4.1 Aims 
Chapter 3 showed that when Smn is depleted Pls3 is also down regulated, suggesting 
an important role of Pls3 in axonal outgrowth and neuronal survival in SMA. This 
chapter aims to test whether overexpression of PLS3 would slow or prevent MN 
loss. The present study aims to evaluate the neuroprotective effect of lentiviral –
mediated gene transfer of PLS3 in an in vitro model of SMA.      
4.2 Introduction 
The identification of PLS3 as a modifier for SMA (Oprea et al., 2008) opened new 
opportunities towards understanding the mechanisms of SMA pathology in this 
childhood condition (Ackermann et al., 2012) and identifying potential therapies. 
Neuroprotection is considered to be an effective treatment option for many CNS 
disorders including neurodegenerative diseases (Azzouz et al., 2004b).  
PLS3 is an actin-binding protein that can influence F-actin levels and rescue 
neuronal axon growth defects arising from SMN deficiency in cultured primary 
SMA MNs (Oprea et al., 2008, Hao et al., 2012). Triple-label experiments were 
performed with Smn, Pls3, and actin in primary murine MNs, and showed that 
endogenous Smn and Pls3 co-localize in granules throughout the axons of MNs and 
accumulate at F-actin–rich growth cones (Oprea et al., 2008).  It was reported that 
PLS3 would likely act via modification of the actin cytoskeleton in axons, which is 
essential for axonogenesis (Hao et al., 2012). Moreover, further evidence was 
provided for actin dynamics involvement in SMA pathogenesis in Smn-deficient 
cells and SMA mice (Ackermann et al., 2012).  These data suggest that PLS3 may 
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modify SMA pathogenesis through stabilisation of the axon terminals by raising the 
F-actin level.  
Several studies have shown that PLS3 overexpression can rescue MN deficits in 
SMA models. MNs lacking Smn showed no alteration in survival but showed 
reduced axonal length and reduced growth cone area, most likely due to disturbed 
distribution of actin in the distal axon and growth cone (Rossoll et al., 2003). A 
Taiwanese SMA mouse model conditionally overexpressing PLS3 showed that PLS3 
overexpression stabilised axons, reduced axon pruning, and enhanced poor 
connectivity seen in SMA NMJs, albeit without ameliorating motor impairment or 
the survival phenotype (Ackermann et al., 2012). In SMN-depleted neuronal PC12 
cells and primary mouse MN cultures derived from SMA null mice, PLS3 
overexpression was able to rescue axon outgrowth defects (Oprea et al., 2008) 
without changing SMN expression levels (Oprea et al., 2008, Stratigopoulos et al., 
2010). This rescue of axon length and outgrowth defects in MNs associated with 
Smn deficiency suggests that PLS3 is a therapeutic target for SMA. It would be 
expected that overexpression of PLS3 in the SMNΔ7 mice would be able to rescue 
the SMA phenotype by increasing axonal length and dendrite branching; therefore, 
in this study axonal length will be used as a measurement of efficacy. 
It can be hypothesised that overexpression of PLS3 in SMNΔ7 mice would have a 
similar effect to SMN and subsequently ameliorate their SMA phenotype. In order to 
test this hypothesis, lentiviral vectors (LV) expressing PLS3 were generated as an in 
vitro gene transfer strategy.  
In this study, LV was selected as a gene delivery vector because of its ability to 
efficiently transfer genes to the central nervous system cells both in vitro and in vivo, 
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which is essential for treatment of SMA. LVs are opening up new treatment 
approaches for many neurological disorders such as motor neuron diseases (MND), 
Huntington’s disease (HD) and Parkinson’s disease (PD). LVs can transduce both 
dividing and non-dividing cells, including neurons (Azzouz et al., 2002). It has been 
reported that lentiviruses were able to deliver the genes efficiently into different 
types of primary neurons from a broad range of different species including man, 
resulting in long-term gene expression (Azzouz et al., 2002, Bienemann et al., 2003). 
LV can produce stable expression of the target gene which allows a single-dose 
therapy rather than the need for repeated treatments, making it even more appealing 
(Azzouz et al., 2002). In addition, these vectors have been developed to a very high 
level in order to be produced safely for clinical trials (Sinn et al., 2005).     
In this chapter, a LV mediating expression of PLS3 has been generated and produced 
at high titres. Three cell types were used for viral validation (HEK293T, NSC34 and 
spinal motor neurons) in order to assess the LV transduction efficiency in different 
cell types. HEK293T cells are widely used in cell biology research and are well 
characterised; they are easy to grow, transfect and transduce very readily. NSC34 are 
a neuronal cell line and are more relevant than HEK293T cells because they are 
motoneuron-like cells. However, both cell lines have endogenous PLS3 and SMN 
proteins. Spinal motor neurons derived from SMNΔ7 embryos will also be used to 
validate the LV-PLS3 as they are derived from the same mouse model used for in 
vivo proof-of-concept (chapter 5 of this thesis), therefore they lack Smn but express 
murine Pls3. Using different cell lines gives power to the study and also allows us to 
see whether there is a cell-specific effect of the virus.  
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Prior to testing the efficacy of the virus in vivo, it is crucial to determine the gene 
transfer efficiency of our vector and whether the transgene is biologically active.  
The main purpose of this chapter is to investigate the neuroprotective effect of LV-
PLS3 in MNs isolated from the SMNΔ7 SMA mouse model. To successfully 
achieve this aim, LV expressing PLS3 has been generated, titred, and then validated 
in cell such as HEK293T, NSC34 and primary MNs. A second function for SMN in 
axonal mRNA transport has also been proposed that may likewise contribute to 
axonal defect in MNs with smn deficiency (See et al., 2014). 
The impact of LV-PLS3 treatment on axonal length was assessed to see whether the 
axonal deficits caused by lack of Smn can be reversed by overexpression of PLS3.  
4.3  Results  
4.3.1 Construction of LV-PLS3  
Gene transfer mediated by viral vectors can achieve a stable and efficient 
transduction of non-dividing cells such as neurons (Azzouz et al., 2002). Lentiviral 
vectors were the first choice for attempting delivery of SMN to motor neurons in 
vitro due to: i) high transduction efficiency in vitro and ii) easy and short production 
protocol compared to other vector systems like AAV. The current chapter 
summarises LV-PLS3 vector design, titration, validation in cell lines, and assessment 
of its ability to enhance axonal length in purified Smn-deficient motor neurons.   
4.3.1.1 Subcloning of PLS3 into lentiviral vector.  
 
The lentiviral vector expressing PLS3 was generated by extracting the PLS3 gene 
from pcDNA3.1-PLS3-V5/His6 plasmid, provided by Prof. Dr. Brunhilde Wirth, 
(Institute of Human Genetics, University Hospital of Cologne, Germany) and cloned 
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into the lentiviral backbone SIN-PGK-cPPT-GDNF-WHV. Figure 4.1a shows the 
plasmid-map of LV-PLS3 vector contains PGK promoter. PLS3 was cloned between 
BamHI and XhoI restriction sites; several clones were generated and assessed by 
restriction digestion (Figure. 4.1b). The LV-PLS3 plasmid’s ability to express PLS3 
was validated in HEK239T and NSC34 cells.  
   
Figure. 4.1. Insertion of PLS3 into the Lentiviral vector 
A) Plasmid map of LV-PLS3 containing PGK promoter showing unique restriction sites. B) 
The gel picture shows BamHI - XhoI digests of six clones. The larger fragment ~ 8.8 kbp 
represents LV plasmid backbone while the smaller ~ 2 kbp represents the PLS3 insert. 
Lanes; 1-6: six clones, M Hyperladder 1 DNA marker.  
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Screening of the samples by digesting the plasmid DNA with the BamHI and XhoI 
restriction enzymes confirmed the presence of the insert and control vector (plasmid 
only) (Figure. 4.1b). Two bands are present: the size of the upper band is about 8.8 
kbp corresponding to the plasmid backbone, and the lower band about 2 kbp 
corresponding to the insert (PLS3). This digestion resulted in the correct band size 
confirming that the PLS3 DNA was successfully cloned into the LV vector. 
Sequencing of the plasmid has confirmed that the correct orientation of the PLS3 
gene without any mutations had been obtained (see appendix3).  
4.3.1.2 Validation of LV-PLS3 plasmid in HEK293T cells by Western blot 
In order to confirm that the PLS3 gene was expressed by the newly generated LV-
PLS3 plasmid, 1x105 HEK293T cells were transfected with 3 µg of the LV-PLS3 
plasmid using the PEI transfection method. Cells were harvested 72 hours post 
transfection and the PLS3 protein levels were assessed by western blot. PLS3 was 
detected using rabbit anti-PLS3 primary antibody. The un-transfected cells were 
considered to be a negative control. 
 
   
 
Figure 4.2. Validation of LV-PLS3 plasmid 72 hours following transfection of 
HEK293T cells 
The western blot shows the presence of a 70 kDa band representing the PLS3 protein. 20µg 
of protein was loaded as indicated. Un-transfected cells show endogenous PLS3 protein 
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level. The membrane was probed with anti-PLS3 antibody. α-Tubulin was the loading 
control 
 
Anti-PLS3 antibody detected a band at 70 kDa, which corresponds to the expected 
molecular weight of PLS3 protein. Western blot analysis revealed overexpression of 
PLS3 protein in cells transfected with LV-PLS3 plasmid when compared to un-
transfected controls (Figure. 4.2), showing that the LV-PLS3 construct is functional. 
Low level of endogenous PLS3 could be seen in un-transfected cells (Figure. 4.2). 
Following successful validation of LV-PLS3 plasmid, it was decided to proceed with 
lentiviral production.  
4.3.2 Lentiviruses mediate efficient overexpression of PLS3 in cell lines 
LV-PLS3 virus was produced using the four-plasmid transfection method, in which 
the cells were transfected with the lentivirus vector plasmid expressing PLS3, one 
envelope plasmid and two packaging plasmids (see M & M Chapter 2). The virus 
was then collected from the media, filtered from cellular debris and concentrated 
using ultracentrifugation. A titre of 2.55 × 108 TU/ml was confirmed using a p24 
ELISA kit as detailed in Materials and Methods (chapter 2). The p24 ELISA kit used 
to determine the titre cannot exclude empty viral particles, therefore it was necessary 
to validate the efficiency of the viral packaging prior to undertaking further studies 
using LV-PLS3.  
4.3.2.1 Validation of LV-PLS3 by Western blot 
To validate the efficiency of the virus, transduction of HEK293T cells was 
performed using the LV-PLS3 virus at different MOIs (1, 10, and 50) (see section 
2.2.4.11 for MOI calculations). The cells were harvested 5 days post transduction for 
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protein analysis. A negative control of un-transduced cells was also included. An 
antibody specific for human PLS3 protein was used. 
  
                                
 
 
Figure 4.3. Validation of LV-PLS3 virus transduction efficiency in HEK293T by 
western blot  
(A) Western blot showing PLS3 protein expression in HEK293T cells transduced with LV-
PLS3 at MOIs 1, 10, and 50 un-transduced cells (UT) was considered as negative control for 
this experiment. The membrane was probed with anti- human PLS3 antibody. α-Tubulin was 
the loading control. (B). Densitometry analysis of PLS3 levels in transduced cells with 
different MOIs of LV-PLS3 (1, 10, and 50) normalized to untransduced control cells (UT).  
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The virus was able to overexpress PLS3 (Figure. 4.3). The western blot (Figure. 
4.3A) revealed the presence of a 70 kDa band representing the PLS3 protein and 50 
kDa band for α-tubulin as a house keeping control. In un-transduced cells the 
endogenous PLS3 showed low expression levels. The densitometry analysis 
indicated correlation between the increased expression levels of transgene PLS3 with 
the increase in MOI used.  Densitometry analysis of PLS3 (Figure. 4.3B) shows 6 -
fold increases in PLS3 expression with MOI10 at day 5 post-transduction as 
compared to un-transduced (UT) cells. There were no signs of toxicity or obvious 
difference in growth rate even at higher MOI.  
4.3.2.2 Validation of LV-PLS3 plasmid by immunofluorescence 
Immunofluorescence was used to assess the expression and localisation of PLS3 in 
HEK293T cells at 72 hours after transduction with LV-PLS3 at MOI 5 and 10, 
compared to the un-transduced HEK293T cells as a control (Figure. 4.4).  
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Figure 4.4. Validation of LV-PLS3 virus in HEK293T cells by immunofluorescence 
HEK293T cells were transduced with LV-PLS3 at MOI 5 or 10. Un-transduced cells were 
considered as negative control. PLS3 (red) and the nucleus stained with DAPI- Diamidino-
2-phenylindole (blue). The arrows white arrows in B indicate PLS3 expression in both 
nucleolus and cytoplasm. (A) Scale bar 100 µm and (B) scale bar 20 µm 
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The results summarised in Figure. 4.4. show overexpression of human PLS3 with 
around 80 % of cells transduced with an MOI of 10. An antibody specific for human 
PLS3 protein was used. The PLS3 localization was observed in a pattern of granular 
staining covering an area within the cytoplasm and nucleus. This experiment 
confirmed that the LV-PLS3 vector is capable of mediating PLS3 gene delivery and 
expression in vitro.  
4.3.2.3 Validation of LV-PLS3 virus in NSC34 cells 
To examine transduction in a neuronal-like cell line, NSC34 cells were transduced 
with LV-PLS3 vector at different MOIs 5, 10, 20, 40 and 80.  
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Figure 4.5. Validation of LV-PLS3 virus in NSC34 cells 
(A) Western blot showing NSC34 cells transduced with LV-PLS3 at MOI 5,10,20,40 or 80 
and probed with anti- human PLS3 antibody, α-Tubulin was the loading control (n=3). Un-
transduced (UT) cells were considered as negative control. (B) A dose response curve of 
LV-PLS3 at 5 days after transduction, along with the western blot data at each multiplicity 
of infection (MOI) used 
 
The western blot revealed the presence of a 70 kDa band representing the PLS3 
protein and 50 kDa band for α-tubulin as a loading control (Figure. 4.5A). The 
densitometry analysis indicated a positive correlation between PLS3 expression and 
the MOI (Figure.4.5B). The transduced cells showed no overt signs of toxicity 
(indicated by a change in cell morphology, reduced adherence or presence of dead 
cells) or obvious difference in growth rate even when the viral vector was used at 
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higher MOI. The treated cells showed no difference in confluence at any of the daily 
checks from untransduced controls.  
Immunofluorescence was used to assess the expression of PLS3, 5 days after 
transduction with different MOIs (20, 40 and 80) of LV-PLS3 compared to the un-
transduced NSC34 cells.    
 
 
Figure 4.6. LV-mediated PLS3 expression in NSC34 assessed by immunofluorescence 
NSC34 cells were transduced with LV-PLS3 at MOIs 20, 40 and 80. Un-transduced cells 
(UT) were used as a negative control. PLS3 (red) and the nucleus stained with DAPI- 
Diamidino-2-phenylindole (blue). Scale bar 20 µm. 
 
The PLS3 localisation was observed throughout the NSC34 cells, which was 
associated with cytoplasm and nucleus. However, the staining pattern was different 
compared to HEK cells that showed a granular reactivity of PLS3 (see Figure 4.4). 
This observation may be due to cell type differences. This experiment confirmed that 
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the LV-PLS3 vector is functional and able to mediate PLS3 expression in motor 
neuron-like cells.  
 
4.3.2.4 PLS3 overexpression promotes motor neuron axonal growth 
The effect of PLS3 overexpression was examined within diseased cells, using 
purified motor neurons from the SMNΔ7 mouse model. This mouse model 
resembles severe SMA carrying two human SMN2 copies on a null Smn background 
(Le et al., 2005). The rationale behind using this particular model in our studies is 
that previous report revealed that purified motor neurons from SMNΔ7 embryos 
exhibit truncated axons with smaller growth cones (Monani et al., 2000, Rossoll et 
al., 2003, Jablonka et al., 2004). To test for potential neuroprotective ability of LV-
PLS3, primary motor neurons were isolated at day E13 from WT (SMN2+/+, 
SMNΔ7+/+, Smn+/+), HET (SMN2+/+, SMNΔ7+/+, Smn+/-), and KO (SMN2+/+, 
SMNΔ7+/+, Smn-/-) embryos. After 24 hrs in culture, MNs were transduced with a 
lentivirus expressing either PLS3 or a green fluorescent protein (GFP) as control 
virus. A second control group of MNs were left un-transduced. MNs were 4%PFA 
fixed after 7 days in culture and immunostained with an anti-tubulin antibody to 
assess axonal length measurements (Figure. 4.7).  
 
Neurons were visualised down the microscope and axons chosen if the entire axon 
length could be seen in a single field. Neurons with tangled axons or lots of branches 
were excluded as the main axon couldn’t easily be identified and measured. 100 
neurones were imaged for each genotype and ImageJ was used to draw a line from 
the start of the axon at the cell body to the tip of the axon. In the case of axons with 
branches (see figure 4.7, wt neuron with no virus) the main axon was chosen as the 
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thickest and longest branch and other branches were excluded from length 
calculations.  
 
A 
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B 
 
 
Figure 4.7. LV-mediated PLS3 neuroprotection in SMNΔ7 purified motor neurons  
Motor neurons isolated from E13 wild type (WT), heterozygous (HET), and SMNΔ7 (KO) 
embryos were transduced with LV-PLS3 or LV-GFP at MOI 80. (A) axon length 
differences between all the genotypes ,(B) axonal localisation of PLS3. PLS3-Plastin3 
(blue), tubulin (red) and GFP (green).  Scale bars: 20µm 
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A weak PLS3 signal was detected in untreated HET and WT MNs but not in 
untreated KO, suggesting that endogenous PLS3 can be detected. After transduction 
of MNs with LV-PLS3 virus, all genotypes showed PLS3 expression. Visually, the 
KO has very short axons except when treated with LV-PLS3 virus. The LV-PLS3-
treated MN axon lengths appear comparable to un-transduced or PLS3-transduced 
MNs from heterozygous and WT embryos (Figure. 4.7). Cytoplasmic hair-like 
projections were seen in 30% of MNs. KO MNs treated by LV-GFP showed no 
changes in axon length, supporting that the changes in PLS3-treated KO cells were 
due to PLS3 and not the LV virus. 
4.3.2.5 Axonal length statistical analysis 
To explore whether lentiviral mediated expression of PLS3 controls axonal growth 
in purified MNs, the axon length was measured using the ImageJ plugin NeuronJ. 
Values from four independent experiments (n=4) were pooled together and the 
results were expressed as the standard error of mean (± SEM).  
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Figure 4.8. Impact of LV-PLS3 treatement on axon length in Smn deficient motor 
neurons 
The bar chart shows the effect of LV-PLS3 treatment on axon length in wild type, 
heterozygous (HET), and SMA knockout (KO) embryos. Y-axis represents axon length in 
µM. A value of one-way ANOVA (*=p <0.05, ***=p <0.001) was considered to be 
statistically significant, average neurite lengths (N = 100 neurites) 
 
In agreement with previous reports (Rossoll et al., 2003, Oprea et al., 2008), our in 
vitro study showed a significant reduction in axon length of Smn-deficient MNs 
when compared to cells from either WT or heterozygous embryos (One way 
ANOVA, p <0.001). Our studies revealed that overexpression of PLS3 through LV-
PLS3 led to a highly significant rescue (ANOVA, P <0.001) of average axon length 
and outgrowth defects associated with Smn down-regulation (N=100 axons) (Figure. 
4.8). Expression of PLS3 in heterozygotes and wild type neurons also significantly 
increased axon length (ANOVA, P<0.05). As expected, the GFP virus showed no 
effect on axon length in any genotype.  
This data provides evidence that PLS3 is important for axonogenesis. The in vitro 
data revealed that PLS3 can rescue MN axon deficits existing in SMNΔ7 primary 
cultures. 
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4.4 Discussion 
The data described in this part of the thesis revealed that modulation of PLS3 
expression may play an important role in promoting axonal growth in healthy and 
diseased MNs. The detrimental effect of low Smn levels on axonal length was 
significantly rescued (P < 0.001) by PLS3 overexpression (Figure. 4.8). Previously 
generated data demonstrated reduced levels of Pls3 expression in various tissues of 
the SMNΔ7 mouse model at early stages of development (Chapter 3). A similar 
finding was seen in purified Smn-deficient MNs from SMNΔ7 mouse model (Sleigh 
et al., 2011). Therefore, spinal MNs from SMNΔ7 mouse embryos were cultured for 
in vitro analysis to study the impact of lentiviral-mediated expression of PLS3 on 
axonal morphology. Spinal MNs cultured from SMNΔ7 mice at E13 showed 
significantly impaired axon growth when compared to WT and HET.  To evaluate 
the neuroprotective effect of PLS3 in an in vitro SMA model, a lentiviral vector 
containing a PLS3 expression cassette was generated, and used to look at its ability 
to rescue axonal growth deficit in Smn-depleted MNs. 
4.4.1 PLS3 staining pattern of different cell types 
The LV-PLS3 virus showed a significant overexpression of PLS3 in 3 different cell 
types, with up to 7 fold increase, leading to the use of this vector for neuroprotection 
in MNs.  
PLS3 expression was observed throughout the NSC34 cells, and was associated with 
the cytoplasm and nucleus. This was similar to PC12 cells, where endogenous PLS3 
and Smn showed diffuse staining in the cytoplasm (Oprea et al., 2008). However, the 
staining pattern was different in HEK cells, which showed a granular reactivity of 
PLS3. It has also been shown in primary murine MNs that Pls3 and Smn co-localise 
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in granules (Oprea et al., 2008). The reason behind this difference in Pls3 expression 
pattern in the cells mentioned above is unknown.  
4.4.2 PLS3 is involved in axonogenesis and rescues the axon length in SMNΔ7 
MNs. 
The LV-mediated overexpression of PLS3 in spinal MNs cultured from SMNΔ7 
mice rescued the observed axonal defects, with no apparent toxicity. There was a 
significant increase in axonal length (P<0.001) in SMNΔ7 MNs when treated with 
LV-PLS3. Notably, the axon length of the treated MNs was similar to that seen in 
wild type PLS3-treated neurons, and greater than in untreated wild type neurons, 
suggesting that LV encoding PLS3 compensate Smn-deficiency. This demonstrates 
that the LV-PLS3 virus was efficient at upregulating PLS3, and suggests a 
neuroprotective effect of PLS3 on MNs isolated from SMNΔ7 mice. It has been 
shown in a previous study that overexpression of PLS3 rescued the outgrowth 
defects and axon length in MNs associated with Smn down-regulation in SMA 
models using  zebrafish and mouse embryos (Oprea et al., 2008). However, this 
study has shown that a novel and more clinically relevant method of gene therapy 
can be used to successfully rescue MN defects.  
Interestingly, further emerging evidence supports the role of PLS3 in axonogenesis. 
It has been demonstrated that knockdown of PLS3 in primary mouse MNs reduced 
axonal length, reproducing the effects of SMN deficiency (Bäumer et al., 2010, Hao 
et al., 2012). This was replicated in zebrafish, where injection of morpholinos 
targeting Pls3 caused shortening of axons and increased axon branching, again 
mimicking the effect of silencing Smn (Hao et al., 2012). Further supporting a 
similar functional role between Smn and Pls3, SMN over-expression in 
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differentiated PC12 cells increases axon length in a similar way to over-expression 
of PLS3 (Oprea et al., 2008). This suggests that PLS3 could potentially modify SMA 
axon phenotypes through SMN and mRNA binding, since the reduced axon growth 
resulting from SMN protein deficiency in MNs was correlated with reduced β-actin 
protein and mRNA levels in growth cones (Rossoll et al., 2003).  
These findings support the involvement of PLS3 down regulation in SMA 
pathology. An important role in promoting axonal outgrowth in both healthy and 
Smn-deficient motor neurons can be proposed. It is worth highlighting that the most 
significant increase in axonal length after LV-PLS3 transduction was reported in 
Smn-/- MNs, in comparison to other genotypes (heterozygous and wild type). Thus, 
enhancing PLS3 expression represents an important therapeutic strategy to improve 
the health of the MN axons in SMA. 
The molecular mechanisms for PLS3 involvement in SMA are unclear. 
Understanding the molecular mechanisms by which PLS3 act as a genetic modifier 
for SMA will be important in understanding the mechanisms of disease 
pathogenesis. PLS3 overexpression has been demonstrated to increase levels of F-
actin, and it has been suggested that its role in stabilising actin filaments is crucial to 
axon development and therefore rescue of SMA pathology (Bowerman et al., 2009). 
However, the expression of a set of partial PLS3 molecules in zebrafish support a 
mechanism for PLS3 in SMA beyond that of actin binding (Lyon et al., 2013). PLS3 
mutants lacking the actin binding domains were able to partially rescue SMA 
phenotype whereas mutants lacking the calcium binding were unable to rescue 
phenotype. This suggests that calcium binding, independent from actin binding, may 
also play a role in SMA disease. 
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This suggests that PLS3 might have an additional function unrelated to its interaction 
with actin (Bowerman et al., 2009). 
4.4.3 Summary  
The neuroprotective property of gene therapy mediated PLS3 expression has been 
shown to increase axonal length in both healthy and diseased Smn-deficient MNs, 
but it is not known whether it would improve mouse survival or disease phenotype in 
vivo. In this current study, only axonal length was assessed, but MN survival, NMJ 
and neuronal health could also be determined to see whether PLS3 also improves the 
quality of the MNs. It is important to test viral vector-mediated PLS3 gene therapy in 
vivo in a mouse model of SMA. The aim of the next chapter was to generate in vivo 
gene therapy proof-of-concept in SMNΔ7 mouse model. 
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5.1 Aims  
In chapter 4, it was reported that lentiviral delivery of the PLS3 gene  led to 
significant transgene expression and rescued axonal length in primary Smn-deficient 
motor neurons. The neuroprotective ability of a viral vector encoding PLS3 has 
never been tested in a mouse model of SMA, therefore the work described in the 
present chapter will evaluate a gene therapy approach using viral vectors encoding 
PLS3 in SMNΔ7 mouse model. This in vivo proof-of-concept study will assess the 
survival of SMNΔ7 mice following delivery of adeno-associated virus serotype 9 
vectors encoding PLS3 (AAV9-PLS3) into the cisterna magna.  
5.2 Introduction 
Chapter 4 demonstrated that PLS3 overexpression in cultured Smn-deficient motor 
neurons ameliorates axon outgrowth defects and restores axon length; suggesting 
that restoration of PLS3 may rescue early lethality in a well-characterised mouse 
model of SMA. Early postnatal delivery of PLS3 may ameliorate SMA phenotype 
via delayed axon pruning and improvement of motor function. Since PLS3 is an 
actin-binding protein, its restoration may regulate actin dynamics, which may 
prevent muscular atrophy due to MN degeneration and therefore SMA pathogenesis.  
This chapter aims to establish the impact of PLS3 modulation in an SMA mouse 
model in vivo. With a clinical application in mind, an AAV-based vector will be 
used, due to its improved safety profile over lentivirus vectors. In this chapter, two 
different types of AAV backbones will be tested: single stranded AAV (ssAAV) and 
self-complimentary AAV (scAAV). ssAAV consist of a single-stranded DNA 
genome, which requires a cellular stress or a helper virus to promote the production 
of the complementary strand and replication, resulting in slow onset of transgene 
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expression (Davidson and Breakefield, 2003). In order to overcome this problem, 
scAAV was generated, in which the DNA contains two complementary sequences 
that produce an intra-molecular double strand upon release from the viral particles 
(McCarty et al., 2001, Davidson and Breakefield, 2003, McCarty et al., 2003). The 
advantage of using scAAV compared to the conventional ssAAV is that it allows a 
faster expression of the transgene in vivo (McCarty et al., 2001, McCarty et al., 2003, 
Wang et al., 2003, Duque et al., 2009, Valori et al., 2010, Gray et al., 2011, Aschauer 
et al., 2013) However, the need for two complementary sequences in the scAAV 
genome limits the packaging capacity with the maximum size of the target gene 
being 2.2kb. Conventional AAV is required for larger inserts up to 4.4kb. The size of 
the PLS3 insert is on the limit of virus packaging capability for scAAV (Hermonat et 
al., 1997); therefore, it wasn’t clear whether a functional scAAV9 virus could be 
made. 
One of the main obstacles of gene therapy in neurodegenerative diseases is the 
difficulty in crossing the blood brain barrier (BBB) to gain access to the cells of 
interest and allow wide dissemination throughout the CNS. AAV serotype 9 (AAV9) 
has been shown to infect a broad range of cells in the CNS and has been shown to be 
able to cross the BBB (Foust et al., 2010, Valori et al., 2010, Aschauer et al., 2013). 
A previous study post intracranial delivery of AAV virus showed high transduction 
efficiency as a result of axonal transport of viral particles to sites distal to the vector 
injection site (Cearley and Wolfe, 2006), revealing its ability to mediate wide spread 
transduction in the CNS.  
 
AAV9 has been chosen for in vivo experiments based on previous studies showing 
high gene transfer to the CNS following intravenous (IV) delivery of this vector into 
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neonatal mice (Valori et al., 2010). Different serotypes of AAV have different capsid 
protein sequences and these variations greatly influence the ability of each serotype 
to transduce particular cell types and brain regions (Miyake et al., 2011). Following 
intravenous (IV) administration of various AAV serotypes AAV1, 5, 6, 8, 7 and 9 in 
adult mice, bioluminescence analysis revealed that three expression levels were 
achieved; low expression (AAV2, 3, 4, and 5), moderate expression (AAV1, 6, and 
8) and high expression (AAV7 and 9) (Zincarelli et al., 2008). Numerous AAV 
serotypes appear to efficiently transduce basal and lateral amygdala (BLA) neurons; 
however, AAV8 and AAV9 appeared to be ideal serotypes to use when targeting 
BLA neurons, as both achieved high titres and transduced BLA neurons well 
(Holehonnur et al., 2014). Another study tested the ability of several single-stranded 
adeno-associated viral (ssAAV) serotypes to deliver transgenes to the brain and 
spinal cord in neonatal mice. Following jugular vein injection of ssAAV vectors 
(serotypes 1, 8 and 9) in neonate mice, all three serotypes were detected in both the 
brain and spinal cord; however, ssAAV9 was the most efficient (Miyake et al., 
2011). AAV9 can strongly transduce MNs in the CNS following intravenous 
administration, as well as other tissues such as cardiac tissue and skeletal muscle 
(Benkhelifa-Ziyyat et al., 2013), making it an ideal candidate for SMA therapy. 
In addition, several studies have shown that scAAV9 virus is able to cross the BBB 
and transduce cells of the CNS safely, with high efficiency and long-term transgene 
expression, demonstrated even in well-developed adult animal models (Kaspar et al., 
2003, Foust et al., 2009, Foust et al., 2010, Valori et al., 2010, Gray et al., 2011, 
Aschauer et al., 2013, Benkhelifa-Ziyyat et al., 2013). Moreover, it was reported that 
after intravenous injection of scAAV9 vector expressing SMN, the virus was able to 
cross the BBB and transduce motor neurons, upregulate SMN protein expression, 
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and improve the survival of SMA mice, cats and non-human primates (Duque et al., 
2009, Foust et al., 2010, Valori et al., 2010). This means it can be introduced to the 
CNS using relatively non-invasive techniques, which is essential for patients to 
improve their quality of life. Furthermore, Benkelifa-Ziyyat et al. (2013) reported 
that upon intramuscular injection of scAAV9-SMN virus, it was able to travel in a 
retrograde manner via axonal transport and transduce cells of the CNS, and 
significantly improve the survival rate of the SMN mouse model (Benkhelifa-Ziyyat 
et al., 2013).   
5.3 Results  
5.3.1 Construction of AAV-PLS3 vectors 
The viral vectors were generated and produced in-house. To produce a viral vector 
expressing the gene of interest, PLS3 was subcloned into the backbone of the AAV 
viral genome. The human PLS3 gene was transferred from pcDNA3.1-PLS3-
V5/His6 into the self-complementary AAV vector (scAAV-CMV-GFP), and the 
conventional AAV vector (pAAV CMV MCS). The maps of the resulting vectors are 
described in Figure 5.3 and in appendix 2.  
5.3.1.1 scAAV vectors encoding PLS3 
A comparison was made between two scAAV viral vectors expressing PLS3 under 
the control of either the CMV full or minimal promoter. This was done in order to 
achieve a virus that successfully expressed PLS3, within the size limit of the vector 
packaging capacity.  
The full CMV promoter is around 650bp, and the minimal promoter is the 3' 120bp-
long fraction of it. Full CMV promoter gives the strongest level of expression, the 
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minimal is also fairly strong in transfection assays and is supposed to be the minimal 
sequence required to initiate gene expression (Doll et al., 1996, Hermonat et al., 
1997). 
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Figure 5.1. Insertion of PLS3 into the scAAV backbone 
(A) PCR product amplified from digested pcDNA3.1-PLS3-V5/His6 shows human 
PLS3 fragment at 2 kb. (B) scAAV-CMV-GFP (Full and Minimal) plasmids were cut by 
BamHI – XbaI. The larger fragment ~ 4 kbp represents the plasmid backbone scAAV-CMV 
while the smaller ~0.7kbp represents the excised GFP. (C) scAAV-CMV-PLS3 (Full/ 
Minimal) plasmids digested by BamHI – XbaI. The larger fragment ~ 4 kbp represents the 
plasmid backbone scAAV-CMV while the smaller ~2kbp represents PLS3. Lanes; 1-5: five 
clones analysed. 
 
The PLS3 gene that was used in viral subcloning for all viruses was amplified by 
PCR (Figure. 5.1A). The scAAV-CMV-GFP Full/Minimal promoter plasmids were 
digested with the restriction enzymes BamHI – XbaI to remove the GFP cassette 
(Figure. 5.1B) and replaced with the desired PLS3 insert; the correct band size after 
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digestion confirmed that the gene was successfully cloned into all vectors (Figure. 
5.1C). In addition, sequencing of the plasmid confirmed the correct orientation of the 
insert and that no spontaneous mutations have occurred (see appendix 3).  
HEK293T cells were transfected with the generated plasmids in order to confirm the 
efficiency of PLS3 expression prior to viral production. Western blot confirmed 
successful overexpression of PLS3 with both vector plasmids (Figure. 5.2A, Figure. 
5.2B). The un-transfected cells have a low endogenous level of PLS3 and were used 
as control. Densitometry showed that the overexpression of the plasmid using the 
minimal promoter plasmid was almost double that of the full promoter plasmid 
(Figure. 5.2C). 
 
 
 
Figure 5.2. Validation of the scAAV-based plasmids expressing PLS3 
Western blots showing scAAV-PLS3 mediated transgene expression in HEK293T cells. (A) 
scAAV-PLS3 with the minimal CMV promotore, (B) scAAV-PLS3 with the full CMV 
promotore. The membrane was probed with the primary anti-PLS3 antibody, and α-Tubulin 
was used as the loading control. PLS3 was detected at 70 kDa. Un-transduced cells were 
considered as negative control for this experiment and had a low levels of endogenous PLS3.  
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Following successful validation of both scAAV plasmids, scAAV-PLS3 with 
minimal CMV promoter was chosen to make a virus. The minimal promoter allowed 
a larger packaging capacity, which was important as the PLS3 gene size is 
considered close to the maximum packaging capacity of scAAV vector.  
5.3.1.2 ssAAV encoding PLS3 
The pAAV CMV MCS (ssAAV) vector was digested with the restriction enzymes 
EcoRI and XbaI to remove the MCS cassette and replaced with the desired insert, 
PLS3 (Figure 5.3).The map of the AAV9-PLS3 vector is presented in Figure 5.3A 
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Figure 5.3. PLS3 cloning into ssAAV backbone 
(A) Plasmid map represents the AAV9-PLS3 sequence with unique restriction sites. (B) 
EcoRI – XbaI digest of four clones. The 4 kbp fragment represents the plasmid backbone 
AAV-CMV while the 2 kbp one represents the PLS3 insert 
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The plasmid showed successful double digestion of AAV9-PLS3, giving the 
expected size for the insert PLS3 (2 kbp) and the AAV-CMV backbone (4 kbp) 
(Figure. 5.3B). The orientation of the insert and the sequence of AAV9-PLS3 
plasmid were validated by sequencing (see appendix 2).  HEK293T cells were 
transfected with AAV9-PLS3 plasmid in order to confirm the efficiency of the 
plasmid prior to viral production.  
 
 
 
 
 
 
 
 
 
Figure 5.4. Validation of the ssAAV-based plasmid expressing PLS3.  
Western blot using protein extracts from HEK293T cells transfected with the AAV-PLS3 
using the PEI transfection method. The membrane was probed with the primary anti-PLS3 
antibody, GAPDH was the loading control. Un-transfected cells were considered a negative 
control for this experiment. PLS3 was detected at ~70 kDa  
 
Overexpression of PLS3 was confirmed by western blot (Figure 5.4). A low level of 
endogenous PLS3 was seen in un-transfected cells and a much stronger band was 
seen in transfected cells (Figure 5.4) suggesting the generated plasmid is functional 
and produces the desired transgene. 
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5.3.2 Virus production and purification 
Following the validation of the plasmids, scAAV-PLS3 (with minimal CMV 
promoter) virus and ssAAV-PLS3 were produced (see Chapter 2 for details). In 
order to assess the purity of the viral preparation, samples of the viral fractions were 
collected and run on an SDS-PAGE gel and stained with SYBRO RUBY. Fractions 
were pooled and western blot analysis was performed on the high quality fraction to 
detect viral proteins by using an antibody against the AAV capsid proteins VP1, VP2 
and VP3.  
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Figure 5.5. Production of high quality AAV9 viruses  
SDS-PAGE gel stained with SYPRO-Ruby showing the purity of the different viral 
fractions. Fractions within the red box were pooled, concentrated and used as high quality 
virus. (A) scAAV9 fractions 6-17 showing three capsid bands are the high quality (HQ) 
preparations. (B) ssAAV9 fractions 4-15 showing three capsid bands are the high quality 
(HQ) preparations. (C) SDS-PAGE gel showing high quality preparations stained with 
SYPRO-Ruby. The three viral capsid proteins bands are present for the HQ preparation; 
VP1 at 87 kDa, VP2 at 72 kDa and VP3 at 62 kDa reflecting the purity of the viral 
preparations. 
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Fractions containing pure virus (red boxes in Figure 5.5) were pooled together and 
considered as high quality virus prep (Figure. 5.5A, Figure. 5.5B). Both viruses had 
clean fractions for pure virus, and the poled high quality virus showed all 3 viral 
capsid proteins (Figure 5.5C). The viral titre was determined by qPCR (Table 5-1). 
Primers for determining titres were designed to detect the transgene, therefore empty 
viral vectors were not detected and did not interfere with the viral titre measurements 
obtained. 
Table 5-1 Viral titres of high quality fractions (viral genomes per ml) 
scAAV-PLS3 ssAAV-PLS3 
7.9x1013 vg/ml 3.9x1013 vg/ml 
 
Both viruses were validated in vitro for overexpression of PLS3 by transduction in 
HEK293T cells. Two different doses of virus (Table 5-2) were used for transduction 
in order to check for toxicity with a high dose of virus before it was tested in vivo.  
Table 5-2 Viral concentrations used for transduction of HEK293T cells 
Virus Low dose High dose 
scAAV-PLS3 3.65E+10 4.9E+11 
AAV-PLS3 3.95E+10 7.9E+11 
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Figure 5.6.  Validation of scAAV9-PLS3 and ssAAV9-PLS3 viruses  
Western blot showing HEK293T cells transduced with two different concentrations of high 
quality virus. The membrane was probed with the primary anti-PLS3 antibody, GAPDH was 
used as a loading control. Un-transduced cells were considered as negative control for this 
experiment. (A) scAAV-PLS3 (B) ssAAV-PLS3 
 
Both scAAV-PLS3 and ssAAV-PLS3 viruses were able to overexpress PLS3 in a 
human cell line (Figure. 5.6A, Figure. 5.6B). In both cases, the high doses showed 
stronger PLS3 protein levels when compared to low doses, suggesting dose-
dependent overexpression (Figure. 5.6).  
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5.3.3 scAAV-PLS3 gene transfer in vivo  
Self-complimentary AAV vectors are preferred to ssAAV due to faster gene 
expression. Following scAAV9-PLS3 production and validation in vitro, this vector 
was chosen to perform a pilot study to test whether the virus can overexpress PLS3 
in vivo. The scAAV9-PLS3 virus, or scAAV-GFP control virus, were administered 
by facial vein injection into WT mice at P1 (25 µl of 1x1010 vg/ml). Three mice were 
injected with each virus, (Figure 5.7) represent extracts from each animal.   
No adverse effects were seen in the mice injected intravenously, revealing that the 
virus is not toxic and it is safe to be used for any further in vivo studies. After 21 
days, mice were culled and protein extracts from spinal cord, brain and muscle were 
assessed for PLS3 expression.  
 
 
 
Figure 5.7. Postnatal day 21 PLS3 protein levels following scAAV9-PLS3 IV delivery in 
P1 mice   
PLS3 protein levels at P21 in WT. Western blot showing PLS3 expression in (A) brain, (B) 
spinal cord and (C) muscle tissues .The membrane was probed with the primary anti-PLS3 
antibody, α -tubulin is the house keeping control (n=3). Lanes 1-3 mice injected with 
scAAV9-PLS3, Lanes 4-6 mice injected with scAAV9-GFP 
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Tissues analysed by western blot at postnatal day 21 revealed no apparent difference 
between the two groups for PLS3 protein levels in the CNS (Figure. 5.7A, Figure. 
5.7B) or muscles (Figure 5.7C). This suggests that there was no overexpression of 
PLS3 at P21 in these tissues. The reason for weak scAAV9-PLS3 expression could 
be due to the size of the insert at the limit of packaging capacity of scAAV 
backbone. Based upon the lack of expression of PLS3 seen with scAAV9-PLS3, it 
was decided not to proceed to in vivo proof-of-concept using this virus.  
5.3.4 Gene transfer efficiency of ssAAV9-delivered via cisterna magna 
Based on the outcome of the pilot study with scAAV9-PLS3 (see above) we decided 
to adopt a new strategy. ssAAV9-PLS3 showed promise in term of PLS3 expression 
when validated in HEK293T cells. The advantage of conventional ssAAV is the 
large cloning capacity (4.4 kb) compared to scAAV. The only issue for conventional 
ssAAV9 is the low ability of crossing BBB when delivered IV, therefore cisterna 
magna was adopted as delivery route for ssAAV9-PLS3. 
At 29 days, the carrier littermate (HET) pups injected with ssAAV9-GFP or 
ssAAV9-PLS3 respectively were culled and spinal cord was collected for Western 
blot assessment. The spinal cord was separated into the three different regions; 
cervical, thoracic and lumbar; and human PLS3 protein was measured to determine 
the efficacy of ssAAV9-PLS3 in mediating PLS3 overexpression.  
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Figure 5.8. WB analysis of the spinal cord following cisterna magna delivery of 
ssAAV9-PLS3 
The figure showing three parts of the spinal cord; cervical, thoracic and lumbar of HET 
SMNΔ7 pups injected with ssAAV9-GFP or ssAAV9-PLS3 respectively. The membrane 
was incubated with anti-hPLS3 antibody. 
 
The analysis summarised in Figure 5.8 demonstrates clear PLS3 overexpression in 
ssAAV9-PLS3 treated spinal cord compared to controls. A very weak band was seen 
in the control group injected with ssAAV9-GFP indicating cross-species reactivity 
between the human anti PLS3 antibody and the endogenous mouse PLS3; however, 
this was used as the baseline of PLS3 when measuring overexpression.   
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5.3.5 Efficacy study  
In vivo pilot study using ssAAV9-PLS3 yielded good levels of PLS3 overexpression 
in the spinal cord. Therefore it was decided to proceed with cisterna magna as route 
of delivery to test the efficacy of ssAAV9-PLS3 in SMNΔ7 mice.  
P1 SMNΔ7 pups were injected with 1µl of ssAAV9-PLS3 containing 2x1013 vg 
(n=7) into the cisterna magna. As a control, SMNΔ7 mice were injected with 
ssAAV9-GFP (1x1010 vg) (n=7) and a third group injected with PBS as a non-treated 
group (n=7). The carrier littermates (SMN2+/+, SMNΔ7+/+, smn+/-) (N=3) were 
also injected with AAV-PLS3, AAV-GFP or PBS as further controls. Daily 
assessment of the mice was performed throughout their life to determine whether 
there was any effect on SMNΔ7 phenotype. All the statistical analysis depending on 
the number of variables was performed by either one-way or two-way ANOVA. 
5.3.6 Body Weight 
Slow growth and loss of body weight from postnatal day 8 is considered to be major 
feature of SMNΔ7 mice phenotype El-Khodor et al, (2008), therefore the weight of 
all mice was monitored daily and changes of body weight were recorded throughout 
the study (El-Khodor et al., 2008).  
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Figure 5.9 Body weight assessment of SMNΔ7 mice 
A: Images showing the same SMNΔ7 pups at different ages, as indicated. A gender-matched 
carrier littermate is included in each picture for reference. The pups were injected at 
postnatal day 1 with either ssAAV9- PLS3 or ssAAV9-GFP or PBS. B: Body weight growth 
in SMNΔ7 injected with PBS (n=7) or ssAAV9-GFP (n=7). C: Body weight growth in 
SMNΔ7 injected with ssAAV9-PLS3 (n=7) or PBS (n=7).  Untreated (injected with PBS) 
were included as controls. *p<0.05, ** p<0.01, *** p<0.001 , **** p<0.0001 for AAV-
PLS3 vs. PBS, #p<0.05, # # p<0.01, ###  p<0.001 , ####  p<0.0001  for AAV-GFP vs, two-
way ANOVA with Dunnett's multiple comparisons test'. ssAAV9 – single stranded adeno-
associated virus serotype 9; GFP – Green fluorescent protein; PLS3-Plastin3; PBS 
Phosphate-buffered saline. 
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There was a significant difference in body weight between ssAAV9-PLS3 treated, 
ssAAV9-GFP controls and PBS injected controls (two-way ANOVA, with Dunnett's 
multiple comparisons test, p < 0.001). Initially, as expected, a weight gain was 
shown with the untreated SMNΔ7 mice, which was then followed by gradual weight 
loss from day 8 to death (Figure. 5.9). SMNΔ7 mice treated with ssAAV9-PLS3 
virus displayed a similar slow weight gain initially, however the body weight decline 
was noticed only after postnatal day 12. Interestingly, the body weight at death was 
similar in all control groups, irrespective of lifespan (Figure. 5.9), suggesting that the 
ssAAV9-PLS3 gene transfer cannot fully compensate for loss of SMN.  
The ssAAV-PLS3-treated mice showed lower body weights than PBS untreated 
mice at 5-8 days of age (p<0.05 at each time point), while at 11-14 days of age, 
PLS3 treated mice had higher body weight compared to PBS (p < 0.001). Notably 
there was a delayed peak of ssAAV9-PLS3 treated group in body weight compared 
to PBS by approximately 4 days. 
Unexpectedly, there was a significant difference between the two control groups 
(PBS and AAV9-GFP treated) at days 5-11 of age (p < 0.001). The ssAAV9-GFP 
group showed a much slower gain in body weight. It has been shown that GFP is 
toxic and causes stress in neurons (Comley et al., 2011). The extra stress from 
producing GFP is putting a strain on already sick mice, slowing down weight gain 
further from the untreated control mice.  
5.3.7 Effect of ssAAV9-PLS3 on mouse life span                            
The expected average lifespan of SMNΔ7 mice is 12 days, therefore survival was 
monitored to assess whether PLS3 gene transfer could extend mouse survival. 
Heterozygous carriers have a normal life expectancy so survival was only monitored 
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for SMNΔ7 mice. 
	  	  	  	  	  	  	  
	  
 
Figure 5.10 Survival curve and disease duration of SMNΔ7 mice     
(A) Kaplan-Meier plot to compare lifespan between all experimental groups of mice (N = 7 
per group; overall Log-rank test p < 0.05 between all three groups; pairwise comparisons 
with Bonferroni correction *p < 0.05 between PLS3 and PBS and #p < 0.05 between PLS3 
and GFP). AAV9 – Adeno-associated virus serotype 9; GFP – Green fluorescent protein; 
PLS3 - Plastin3; PBS Phosphate-buffered saline. (B) Comparison of mean survival across 
the 2 groups (p<0.01, t-test, between AAV-PLS3-treated and PBS mice). 
 
Chapter 5: In vivo Experiments 
145 
 
The mean survival age for ssAAV9-PLS3 treated SMNΔ7 mice was 17 days (± 1.54 
days). The mean survival age of the PBS-treated group was 11 days (± 2.56 days) 
(Figure. 5.10B), and the mean survival age of the control group injected with 
ssAAV9-GFP was 12 days (± 1.52 days). Kaplan-Meier analysis was performed and 
showed that PLS3 treated mice had a longer survival time compared to both 
untreated and GFP treated groups (Log-rank test, p < 0.05 for PLS3 vs PBS and GFP 
vs PBS, pairwise comparison with Bonferroni corrections). Furthermore, the oldest 
mouse lived for 18 days after treatment with AAV9-PLS3 whereas the longest 
surviving mouse after treatment with AAV9-GFP lived for 15 days (Figure. 5.10). 
Overall, this study revealed an increase in survival of PLS3 treated mice compared to 
controls however, the effect on life span was small or marginal. We hypothesis that 
an increase in the dose of ssAAV9-PLS3 could yield a better impact on survival but 
this still needs testing in future studies. 
5.3.8 The power calculation  
Power calculations were carried out post-hoc. The G*Power version 3.03 software 
was used to calculate the statistical power using a T test between PBS and PLS3 
groups. The minimum detectable difference was 1.63 x standard deviation of the 
control group, therefore 4.89. The control groups have an average survival of 11 
days, therefore a survival of 15.89 days needed to be seen in the treated group to get 
a significant effect 80% of the time. This was confirmed through these experiments. 
5.1.1.1 Disease onset and phenotype 
Throughout the study as a measure of overall health, different parameters were 
monitored daily such as percentage weight loss from peak body weight, provoked 
behaviour, weakness of the hind limbs and general appearance (Figure 5.9). 
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ssAAV9-PLS3 treated SMNΔ7 mice showed no difference in severity or onset of 
disease phenotype by the above observations. There was no difference between 
untreated or GFP treated controls. 
5.1.1.1 Transduction efficiency 
Due to the absence of phenotype improvement and lack of change in disease onset, 
transduction efficiency was checked to ensure that this was not due to inefficient 
viral vector delivery to the CNS, in particular to MNs. Immunofluorescence was 
performed on ssAAV-GFP-treated mice to assess the transduction yield of MNs. 
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Figure 5.11 Transduction of spinal motor neurons in SMNΔ7
 
mice  
Heterozygous (carrier) mice were injected at postnatal day 1 with ssAAV9-GFP, spinal 
cords were extracted at 4 weeks post-injection. The cervical and Lumbar spinal cord sections 
were fixed and double labelled with anti-CGRP as a motor neuronal marker and anti-PLS3 
antibodies. DAP1 was used for visualization of nuclei. Transduced MNs pictures were taken 
using x63 magnification. AAV9 – Adeno-associated virus serotype 9; CGRP- Calcitonin 
Gene-Related Peptide; GFP – Green fluorescent protein and DAPI- Diamidino-2-
phenylindole (blue) 
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The total number of motor neurons and the number of GFP positive motor neurons 
(Figure 5.11) were counted to calculate the percentage of transduced neurons. The 
transduction efficiency for GFP was around 24 % of total MNs (Table 5.3).   
Table 5-3 Transduction efficiency of lumbar spinal motor neurons (GFP) 
Mouse Total motor 
neurons CGRP+ 
GFP Transduced 
motor neurons 
Transduction 
efficiency 
1 100 24 24% 
2 100 20 20% 
3 100 28 28% 
Average  24% 
 
5.1.1.2 ssAAV-mediated PLS3 expression in the spinal cord 
 
Western blot analysis confirmed ssAAV9-PLS3 mediated PLS3 protein 
overexpression in whole tissue but did not identify the cell types producing the 
transgene from the virus, therefore immunohistochemistry was performed to identify 
whether the MNs have been targeted efficiently as this does not exclude targeting of 
other cell types. Cervical and lumbar spinal cord sections were double-labelled for 
PLS3 (green) and CGRP (red), and the sections analysed under a confocal 
microscope (Figure. 5.12). 
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Figure 5.12 Transduction efficiency of spinal motor neurons in SMNΔ7
 
mice in 
ssAAV9-PLS3 treated mice  
Heterozygous pups were injected at postnatal day 1 with ssAAV9-PLS3, spinal cords were 
extracted at 4 weeks post-injection. The cervical and lumbar spinal cord sections were fixed 
and labelled with CGRP antibody as a motor neuronal marker (red), PLS3 antibody as an 
indicator of transduction (green), and DAP1 for visualization of nuclei. Transduced MN 
pictures were taken using x63 magnification (scale bar 20 µm). AAV9 – Adeno-associated 
virus serotype 9; CGRP- Calcitonin Gene-Related Peptide; PLS3- Plastin3 and DAPI- 
Diamidino-2-phenylindole (blue). 
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PLS3 was detected in motor neurons and some neuronal axons, showing that the 
virus is targeting motor neurons in the spinal cord (Figure. 5.12). Other cell 
morphologies were identified as PLS3-positive, however without further staining 
these aren’t confirmed. This indicates that the virus has a higher affinity for, but not 
exclusively targeting MNs (Figure 5.12). The PLS3-positive MNs were counted and 
transduction efficiency calculated as the percentage of total CGRP-positive MNs 
(Table 5.4). (Table 5.4). Not all CGRP+ motor neurons expressed PLS3, instead 
quantification revealed around 29% of motor neurons were PLS3 positive. 
 
Table 5-4 Transduction efficiency of lumbar spinal motor neurons (PLS3) 
Mouse Total motor 
neurons CGRP+ 
PLS3 Transduced 
motor neurons 
Transduction 
efficiency 
1 100 29 29%  
2 100 32 32%  
3 100 27 27%  
Average  29.33%  
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5.4 Discussion  
5.4.1 ssAAV9-mediated gene transfer to the CNS 
Histological analysis of CNS showed that cisterna magna administered ssAAV9-
GFP or ssAAV9-PLS3 could mediate significant transduction efficiency (Figure. 
5.12) correlating with an overexpression of PLS3 or GFP in spinal cord MNs. A 
single injection of AAV9 expressing PLS3 or GFP was sufficient to mediate wide 
spread gene transfer in both cervical and lumbar spinal cord MNs. This shows that 
cisterna magna injection can disseminate virus effectively around the CNS, reaching 
cells in the lumbar spinal cord. This finding is in agreement with a previous study 
reporting that AAV9 can transduce both neurons and astrocytes following direct 
injection of this vector system to the CNS (Foust et al., 2010). This is an important 
consideration when designing therapies for neurodegenerative diseases. In neonates, 
AAV9 may target motor neurons efficiently, suggesting that the AAV vector was a 
suitable vector for PLS3 gene delivery.  
Quantification of transduced MNs showed 29% transduction efficiency. In 
comparison, a previous study showed 68% and 51% of spinal motor neurons 
transduced by scAAV, which showed a significant improvement in disease in 
SMNΔ7 mice (Foust et al., 2010, Valori et al., 2010). However, this does not 
necessarily indicate that a higher transduction rate with AAV-PLS3 would improve 
disease, as different serotypes and gene targets were used in these previous studies. 
Improvement of transduction efficiency may be addressed by increasing the dose of 
the virus, which may increase transgene expression levels. The issue of the dose has 
been a limitation because the Home Office licencing and regulation insists on a 
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maximum volume for cisterna magna delivery is around 1µl/g of body weight. Note 
that the body weight of a P1 mouse pup is around 1g. 
PLS3 expression appears to be predominantly neuronal in the spinal cord when 
injected at P1, as glial cells were very rarely transduced. The importance of non-
neuronal cells in disease is not fully understood. There is increasing evidence from 
different SMA mouse models and human patients that alongside MN dysfunction, 
defects in various other tissue types strongly contribute to the lethal phenotype 
indicating that other cell types also play a role in disease pathogenesis (Rindt et al., 
2015). Expression may need to be restored in other cell types such as astrocyte and 
or even in different organs as well as MNs to improve the phenotype and survival.  
5.4.2 ssAAV9-PLS3 mediate marginal increased in the life span of SMNΔ7 
AAV9-PLS3 treatment showed a small or marginal but significant effect on survival 
of SMNΔ7 mice. Kaplan-Meier survival analysis showed mean survival of 17 ± 1.54 
days, 12 ± 1.52 days and 11 ± 2.56 days for AAV9-PLS3, AAV9-GFP and PBS 
treated mice respectively. This shows an increase of a maximum lifespan of 57.14 %, 
with a median increase in lifespan of 154%.  The finding is in agreement with 
previous reports by Ackermann et al. (2012) when PLS3 was over-expressed in a 
milder model of SMA. This study reported moderate increase in survival, but 
significant improvement of motor ability and improved NMJ function. This is in 
contrast to a similar study by the same group which did not detect any survival or 
phenotypic improvements in severely affected SMAPLS3 mice (a conditional PLS3-
over-expressing mouse and bred into an SMA background) (Ackermann et al., 
2012).  
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In the current study, there was mouse-to-mouse variability seen in lifespan of PLS3 
treated mice. This may be due to inefficient gene transfer as previously reported 
(Valori et al., 2010) or technical failure during cisterna magna injection of the 
vector; the small size of mice at P1 can be challenging for efficient viral delivery. 
Thus, it is necessary to determine biodistribution of the virus to assess whether each 
mouse has a good delivery of virus to all tissues.  
The small/marginal extension of lifespan in ssAAV9-PLS3 treated SMNΔ7 mice 
could be explained further by: i) the dose used (2 x 1010vg) is low to transduce a 
significant number of MNs and other cells in the CNS. The choice of the dose was 
based on the maximum volume allowed for cisterna magna delivery under the Home 
Office licencing and regulations; ii) conventional ssAAV9 needs to form double 
stranded DNA upon transduction of cells delaying the start of transgene expression. 
Early start of transgene expression is crucial for SMNΔ7 mice rescue because of fast 
and severe phenotype of this animal model. 
5.4.3 PLS3 does not rescue disease phenotype 
Although this study has shown successful overexpression of PLS3 and a small 
increase in lifespan, there was no delay in onset of disease or improvement of 
disease phenotype. This suggests that PLS3 is an important modulator of disease but 
is not the only factor affected by the loss of SMN. It is not known whether there was 
any rescue of neuromuscular junctions but it can be predicted from the phenotype of 
the mice that there is still neuronal death and dysfunction despite PLS3 
overexpression. However, it is important to bear in mind that this study has not 
tested different doses or optimised gene delivery and expression. The number of 
MNs (29%) targeted by the delivered dose of ssAAV9-PLS3 may simply not be high 
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enough to fully rescue disease phenotype. In addition this study used AAV9, which 
primarily targets neuronal cells over other cell types in the CNS of neonates, such as 
glial cells, which may also have an important role in the disease process. 
Analysis of body weight showed significant difference between groups (Figure. 5.8). 
The weight gain pattern is the same for PLS3 treated and PBS treated mice but the 
decline in weight is delayed by 4 days in PLS3 treated mice. PLS3 treated mice body 
weight increased above the controls after 8 days, before weight loss began. This 
suggests that the overexpression of PLS3 achieved in this study was sufficient to 
rescue weight loss, but only for a short period of time, suggesting that PLS3 can 
overcome disease phenotype to a certain extent but is not enough to exert long-term 
effects. Interestingly, all groups reached the same body weight at death, irrespective 
of peak weight, however, is not known whether this is a significant finding or just a 
coincidence.  
5.4.4 Expression of PLS3 in different vectors 
Two different viral vectors were tested in vivo, a conventional ssAAV and  scAAV. 
ssAAV-PLS3 virus showed good but not optimal overexpression of PLS3 in vivo. 
However, although the viral titre was high for scAAV9-PLS3, there was no 
overexpression of PLS3 three weeks post-IV injection. scAAV9 is the favoured 
vector for gene therapy due to its stability and faster gene transcription. It has been 
reported that scAAV9 achieves maximal expression levels within 48–72 h post-
transduction (Gray et al., 2011). Moreover, the transduction efficiency of scAAV9 in 
some instances is 10- to 100-fold higher than conventional ssAAV (McCarty et al., 
2003, Gray et al., 2011). An alternative study demonstrated the benefits of using 
scAAV compared with ssAAV (McCarty et al., 2001). ICV injection of ssAAV8 
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expressing human full-length SMN into SMNΔ7 mouse model, has shown extended 
life up to ~50 days (Passini et al., 2010). The same study using scAAV8 through the 
same route of delivery showed a better survival up to 157 days (Passini et al., 2010). 
There are a number of possible reasons for why scAAV did not overexpress PLS3. 
Improper packaging of the insert is a problem for transgenes close to or over the 
packaging limit (Chen et al., 2010); the PLS3 gene is very close this packaging 
capacity limit.  Large genomes may result in partial genomes packaged into virions, 
so even if the virus gets to its destination the genome is not complete. Long genomes 
might get packaged intact, but their large size can distort the capsid and make the 
overall virion less stable/efficient. Unstable virus could lead to low or no expression 
of PLS3.  
5.4.5 Summary  
In conclusion, these studies provide the first in vivo gene therapy proof-of-concept 
of PLS3-mediated protection against SMA in SMNΔ7 mouse model, emphasizing 
the impact of PLS3 as a potential therapeutic target in SMA therapy. Both in vitro 
and in vivo data are promising however because of the marginal effect observed in 
SMNΔ7mice, in vivo set up would need further optimisation to assess in more detail 
the impact of PLS3 in SMA.  
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SMA is a debilitating fatal childhood neuromuscular disease, characterized by the 
degeneration of the anterior horn cells of the spinal cord due to reduced expression 
of the SMN protein (Stratigopoulos et al., 2010). Finding a treatment for SMA has 
been challenging, and despite enormous research on SMA there is no effective 
treatment available. Gene therapy is considered to be an attractive approach for SMN 
replacement in this disease (Lefebvre et al., 1995, Foust et al., 2010, Passini et al., 
2010, Valori et al., 2010, Dominguez et al., 2011, Benkhelifa-Ziyyat et al., 2013, 
Little et al., 2014).  
Previous studies have reported other disease-modifying genes, which could also be 
targeted for gene therapy-mediated treatment for SMA, including PLS3, PTEN and 
hnRNP-R (Rossoll et al., 2003, Oprea et al., 2008, Ning et al., 2010, Little et al., 
2014). Stratified analysis of blood samples from SMA type I, II and III patients 
demonstrated that post-pubertal females show an inverse correlation between 
circulating PLS3 and SMA severity (Stratigopoulos et al., 2010). Investigation into 
the function of PLS3 has begun to shed light on its interaction with SMN and its role 
in neuroprotection against SMA. This project aimed to test whether overexpression 
of PLS3 by viral-mediated gene therapy could rescue neuronal loss and increase 
survival of an SMA mouse model and whether it could ultimately be developed into 
a potential clinical therapy. 
6.1 PLS3 levels in the SMNΔ7 SMA mouse model 
In WT mice Pls3 is expressed in neuronal cells in the brain stem and in MNs in the 
spinal cord. Its distribution was as expected in the spinal cord, being expressed in 
cell bodies of MNs and the white matter where the axons of the neurons are located. 
This aligns with previous observations that Pls3 co-localizes with Smn in granules 
Chapter 6: General Discussion 
158 
 
throughout motor neuron axons (Oprea et al. 2008). If both proteins are co-localised 
they may have the ability to interact. They could influence each other stability, 
which has also been suggested by other groups (Dimitriadi et al., 2010). 
The data in chapter 3 of this thesis confirmed differential Pls3 expression between 
Smn knockout mice from the SMNΔ7 line and their wild type littermates. At birth 
there was no difference in Pls3 expression between the genotypes, however by end 
stage of the disease the KO animals showed significantly reduced or absent Pls3 
expression in both CNS and muscles, relative to wild types. Heterozygote SMNΔ7 
mice also showed lower Pls3 levels in the spinal cord, although not in brain or 
muscles, suggesting that Smn protein is influencing Pls3 levels in some tissues. This 
supports previous reports of Pls3 down regulation in the brain and spinal cord of 
other animal models and in human patients (Hao et al., 2011). This report provides 
evidence that the SMNΔ7 mouse is a good model for testing whether modulation of 
PLS3 can be used as a gene therapy for SMA. 
The molecular mechanisms for PLS3’s involvement in SMA are unclear; there are 
no structural or sequence similarities between SMN and PLS3 that may suggest they 
are functionally related, but several theories have been proposed. PLS3 
overexpression has been demonstrated to increase levels of F-actin, and it has been 
suggested that its role in stabilising actin filaments is crucial to axon development 
and therefore rescue of SMA pathology. However, the effects of expressing a set of 
partial Pls3 molecules in zebrafish support a mechanism for PLS3 in SMA beyond 
that of actin binding (Lyon, 2013).   
The crucial role of Ca2+ ions for both SMN and PLS3 proteins were demonstrated in 
two different studies for SMA disease, which may explain the role in neuro-
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maintenance and protection (Jablonka et al., 2007). Interestingly, it was reported that 
calcium dysregulation has been associated with the pathogenesis of SMA (Jablonka 
et al., 2007, McGivern et al., 2013). A novel role for Ca2+ regulation in PLS3 
function in MN development was defined recently (Lyon et al., 2013). The Ca2+ 
binding to the EF hand motifs is essential for PLS3 function in MN development. 
Also of interest was that the mutation of the residues that interact with Ca2+ ions 
within the EF hands resulted in a complete loss of PLS3 rescue (Lyon et al., 2013). 
Moreover, defective Ca2+ channel clustering in axon terminals disturbs excitability in 
MNs in SMA (Jablonka et al., 2007). On the other hand, Smn-deficient MNs exhibit 
defects in spontaneous excitability. These defects correlate with reduced integration 
of voltage-gated Ca2+ channels (VGCCs) in growth cones, which is responsible for 
reduced axon elongation (Lyon et al., 2013). Moreover, these defects could lead to 
disturbances of the presynaptic active zones, causing reduced transmitter release at 
the motor endplate which may contribute to MN malfunction and degeneration in 
SMA (Jablonka et al., 2007). This suggests that enhancing motor neuron survival 
could be achieved through restoration of growth cone excitability and function (Lyon 
et al., 2013).   
6.2 Overexpression of PLS3 by viral vectors 
This study has demonstrated that successful cloning of PLS3 gene into LV or ssAAV 
viral vectors was able to significantly overexpress PLS3 protein by at least five fold, 
in vitro (Chapter 4) and in vivo (Chapter 5). This suggests that overexpression of 
PLS3 by a viral vector is feasible. In vitro, PLS3 doesn’t appear to be toxic to cells; 
cells overexpressing PLS3 did not die and wild type cells treated with PLS3 showed 
no difference in cell death but slightly longer axons than untreated cells. On the 
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contrary, overexpression of PLS3 in cells lacking Smn rescued the axonal length 
deficit. The same is mirrored in vivo; there was no obvious toxicity associated with 
viral injection or PLS3 expression and it was demonstrated that ssAAV9-mediated 
overexpression of PLS3 improved the survival of SMNΔ7 mice when injected into 
the cisterna magna at P1. 
Administration of ssAAV9-PLS3 to the CNS (via cisterna magna) in postnatal day 1 
SMAΔ7 mice led to significant spinal MN transduction efficiency. Although PLS3 
overexpression induced small but significant extension in SMAΔ7 mouse survival 
this gene transfer strategy did not ameliorate the SMA phenotype nor delay disease 
onset. It is worth highlighting that  ssAAV9 showed neuronal tropism and this study 
revealed that other cell type such as glial. Previous studies have shown that 
astrocytes from SMA-induced pluripotent stem cells and in SMNΔ7 mouse spinal 
cord exhibit cellular and morphological changes as an indicator of activation before 
obvious MN loss (Yamanaka et al., 2008, McGivern et al., 2013). The late report 
indicates that early disruption of astrocytes may contribute to SMA disease 
pathology, which suggests that targeting of both MNs and glial cells may be needed 
for an effective therapy in SMA. 
The function of spinal MNs is dramatically affected by motor neuron diseases or 
injuries. Glial cells support and interact with neurons, including MNs. Astrocytes are 
a particular subset of glial cells that produce neuronal survival factors that modulate 
the way neurons talk to each other. Recently it was reported that the mutations in 
genetic disorders affecting the spinal cord, such as SMA, also disable astrocytes. 
Astrocytes actively contribute to the progression of SMA disease, and could 
therefore be therapeutic targets themselves (Yamanaka et al., 2008).  
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The key feature of SMA is the loss of SMN, which is not addressed by 
overexpression of PLS3.  PLS3 may be able to rescue some SMN functions but not 
all, such as calcium dysregulation, snRNP assembly and neuronal development 
which has been observed to be affected in SMA (McGivern et al., 2013). This along 
with the previous observation in humans, where PLS3 provides full protection 
against SMA only in SMN1-deleted individuals carrying three to four SMN2 copies, 
but not in those with only two SMN2 copies or less, suggests that a certain amount 
of SMN is required in order to benefit from PLS3 overexpression in individuals 
lacking SMN1.  
6.3 Considerations for clinical studies 
Although PLS3 can be successfully overexpressed in vivo and is a potential gene 
therapy for SMA, there are several considerations that will need to be addressed 
before this can be taken to clinical trials in humans, such as early delivery of the 
treatment to the SMA patient immediately after birth. 
Recent preclinical trial data suggests that due to the developmental nature of the 
disease it’s crucial for rescuing mechanisms to act right after birth in order to have 
any efficacy in preventing neuronal loss, especially in severe SMA. The therapeutic 
vectors must be introduced during this developmental stage in order to achieve the 
maximal therapeutic benefits. The data in the current thesis has demonstrated an 
increase in survival after P1 administration but did not look at any other time points 
for treatment. A study using scAAV9 expressing SMN protein strongly supports the 
view that only early administration between P0–P3 of recombinant viruses is able to 
rescue the SMA phenotype in mice (Foust et al., 2009, Gray et al., 2011). Systemic 
injection at postnatal day 2 of scAAV9-SMN leads to ~250 days of survival, 
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however, after P5 injection only ~15 days increase in survival and no increase after 
P10 injection was observed (Foust et al., 2010). In a severe SMA mouse model, 
weak effects or no effects have been observed with postsymptomatic administration 
(after P6) (Foust et al., 2010). Interestingly, P2 injection resulted in high-level MN 
transduction, while P10 injection led mostly to glial transduction. However, whether 
the lack of rescue in P10-injected mice is due to this pattern of transduction remains 
to be elucidated. The previous studies concluded that transduction could be altered in 
the CNS depending on the time of injection (Foust et al., 2010). This poses a 
problem as SMA children are often asymptomatic at birth and diagnosis is usually 
made months later, potentially missing the window of opportunity for treatment. 
This highlights the need for pre-natal or newborn screening if treatment is to be 
successful. Screening tests are being developed to detect SMA in newborns, 
supporting the possibility of delivering therapeutics including gene therapy based 
interventions to the affected children immediately after birth (Pyatt et al., 2007).  
Another consideration is the treatment route. This study carried out injections into 
the cisterna magna, which would involve major surgery under general anaesthesia 
for newborns.  This study also used IV injection, although the level of transduction 
in the CNS was not evaluated due to the lack of PLS3 expression. scAAV serotype 9 
has previously been demonstrated to cross the BBB and show preferential 
transduction of neurons (Foust et al., 2009). In addition, IV injection of AAV9 has 
previously shown good transgene expression and viral spread around the CNS and 
other organs following facial vein injection in neonates, and tail vein injection in 
older animals (Benkhelifa-Ziyyat et al., 2013).  
The delivery route makes a difference to where the virus ends up. Injecting into the 
CNS reduces the amount of virus found in the peripheral tissues but increases the 
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amount of MNs targeted (Shababi et al., 2015). However, some evidence suggests 
that in severe cases of disease the rescue of peripheral organs in addition to MNs is 
necessary for the complete rescue of SMA phenotype (Hua et al., 2011, Schreml et 
al., 2013, Shababi et al., 2015). Therefore, transduction of the peripheral organs after 
systemic injection may benefit SMA gene therapy. 
Based on the recent findings in SMA mouse models of heart defects (Bevan et al., 
2010, Shababi et al., 2010a, Valori et al., 2010), it was suggested that intravenous 
(IV) injection leads to better survival compared to ICV injection, which is possibly 
due to its direct cardiac transduction that protects the heart (Passini and Cheng, 
2011). However, direct comparison of the two injection methods in the previous 
study is not advisable, since it requires all parameters to be identical, and in this case, 
the titre and the AAV serotypes were different. 
Identifying the most efficient delivery route for SMA clinical trials will eliminate the 
requirement for introducing an enormous amount of the viral vector to achieve a 
great level of rescue. This needs more optimization by testing different routes in 
different SMA models in nonhuman primates. 
6.4 Future work 
There are various points that need to be addressed to further build upon the data from 
these experiments. This thesis explored PLS3 overexpression in vivo and generated 
promising preliminary data but did not assess the optimal dose or route of delivery 
with AAV-PLS3. Further studies should be carried out with different doses of virus 
to assess whether higher expression of PLS3 would improve phenotype or increase 
transduction levels. It is apparent that in the CNS the transduction efficiency 
achieved in this project was not high, while it was shown by others that at least more 
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than 50% of MNs needs to be transduced to show significant therapeutic effect 
(Little et al., 2014).  
We provide evidence that PLS3 can improve MN axonal length in vitro, as has been 
shown previously (Oprea et al., 2008), (Oprea et al., 2008), however the lack of 
improvement of disease phenotype suggests that the expression of PLS3 was not 
enough to improve the disease phenotype. Another key element in SMA therapy 
development using viral vectors is the early start of gene transfer. This was not the 
case when using ssAAV9. Future efforts could look at reducing the size of PLS3 to 
fit the packaging capacity of scAAV.  
Furthermore as mentioned above it would be useful to use AAV9 to assess the effect 
of overexpressing of other genes such as hnRNP R on SMNΔ7 mice. The in vitro 
data shown from our group suggests that hnRNP R can modify the SMA phenotype. 
Therefore with the level of transduction generated by AAV9 it would be possible to 
assess how well hnRNP R overexpression can compensate for SMN deficiency in 
vivo. It would be interesting to see whether hnRNP would complement PLS3 
treatment and provide a synergistic therapy to the MNs.  
 
Since SMA is a multi-system disorder it would be interesting to see whether other 
cell types or even organs are important as a therapeutic target. Targeting more than 
just motor neurons in order to successfully provide therapy for SMA would be 
possible with AAV9 as it is able to enter the spinal cord through retrograde transport 
but also transduces multiple organs in peripheral tissues. It would therefore be 
interesting to study the efficiency of motor neuron transduction following 
intramuscular injection of AAV9. 
 
Chapter 6: General Discussion 
165 
 
Gene therapy approaches are highly promising, using AAV9-SMN vectors have 
entered a Phase I clinical trial. However, analysis of SMA patients and animal 
models has revealed some limitations that need to be taken into consideration, 
including: i) neonatal screening of SMA due to limited time-window for successful 
therapy delivery; ii) multi-organ damage, requiring systemic therapeutic delivery; iii) 
Combined therapies that both target pathways that rescue motor neuron function  and 
increase SMN levels. Instead of only ameliorating symptoms of SMA, meeting these 
challenges will likely be essential to cure SMA, particularly in its most severe cases. 
 
6.5 Final conclusions 
In summary, evidence has been provided supporting the role of PLS3 
downregulation in the pathology of spinal muscular atrophy, and that restoration of 
PLS3 expression using a lentiviral vector can rescue the axonal phenotype in spinal 
motor neurons cultured from a clinically relevant mouse model of SMA. It has been 
shown that ssAAV9-mediated PLS3 overexpression can improve the survival of 
SMNΔ7 mouse model of SMA. The use of PLS3 overexpression to extend their 
lifespan demonstrates that PLS3 is a disease modifier of SMA and a good potential 
therapeutic target for SMA. PLS3 is a good therapeutic target and can be used in a 
gene therapy approach but may be required to be delivered in combination with other 
disease modulators to give meaningful rescue to motor neurons and alleviate the 
disease phenotype sufficiently.  
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Appendix 1: Lab equipment 
Equipment  Manufacture  
G: Box gel imaging system Syngene 
NanoDrop 1000  Labtech 
Optima L-100K Ultracentrifuge  Beckman Coulter  
GENi imaging machine Syngene  
FLUOstar Omega plate reader BMG Labtech 
MX3000-P Real-time PCR system BIO-RAD 
Confocal microscope Leica SP5 microscope system 
Nikon microscope Nikon  
CFX96 Touch Real-time PCR detection 
system 
BIO-RAD  
Ultracentrifuge  Beckman Coulter  
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Appendix 2: Vector maps. 
 Maps of the LV and AAV Plasmids  
 
(A) Map of SIN-PGK-cPPT-GDNF-WHV 
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 (B) Map of PAAV CMV MCS (conventional AAV) 
 
 
 
Figure 8.1: Expression AAV viral plasmids used in this project 
The lentiviral vector (A.) SIN-PGK-cPPT-GDNF-WHV was used for all tissue culture 
experimental work, whereas the AAV vector (B.) was used for all the in vivo experimental 
work. Abbreviations: AAV – adeno-associated virus, amp – ampicillin, CMV – 
cytomegalovirus, cPPT – central polypurine tract, eGFP – enhanced green fluorescent 
protein, GDNF – glial cell linederived neurotrophic factor, LTR – long terminal repeat, LV – 
lentivirus, PGK – 3- phosphoglycerate kinase, poly-A – polyadenylation signal, RRE – Rev 
responsive element, SIN – self-inactivating, TR – terminal repeat, WHV – Woodchuck 
hepatitis virus, WT – wild type. The maps were Produced by PlasMapper version 2.0 
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Map of the LV-PLS3 
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Map of the AAV-PLS3 
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Appendix 3: Sequence. 
 
PLS3 INSERT 
 
GCCACCATGGATGAGATGGCTACCACTCAGATTTCCAAAGATGAGCTTGATGAACTCAAAGAGGCCTT
TGCAAAAGTTGATCTCAACAGCAACGGATTCATTTGTGACTATGAACTTCATGAGCTCTTCAAGGAAG
CTAATATGCCATTACCAGGATATAAAGTGAGAGAAATTATTCAGAAACTCATGCTGGATGGTGACAGG
AATAAAGATGGGAAAATAAGTTTTGACGAATTTGTTTATATTTTTCAAGAGGTAAAAAGTAGTGATAT
TGCCAAGACCTTCCGCAAAGCAATCAACAGGAAAGAAGGTATTTGTGCTCTGGGTGGAACTTCAGAGT
TGTCCAGCGAAGGAACACAGCATTCTTACTCAGAGGAAGAAAAATATGCTTTTGTTAACTGGATAAAC
AAAGCTTTGGAAAATGATCCTGATTGTAGACATGTTATACCAATGAACCCTAACACCGATGACCTGTT
CAAAGCTGTTGGTGATGGAATTGTGCTTTGTAAAATGATTAACCTTTCAGTTCCTGATACCATTGATG
AAAGAGCAATCAACAAGAAGAAACTTACACCCTTCATCATTCAGGAAAACTTGAACTTGGCACTGAAC
TCTGCTTCTGCCATTGGGTGTCATGTTGTGAACATTGGTGCAGAAGATTTGAGGGCTGGGAAACCTCA
TCTGGTTTTGGGACTGCTTTGGCAGATCATTAAGATCGGTTTGTTCGCTGACATTGAATTAAGCAGGA
ATGAAGCCTTGGCTGCTTTACTCCGAGATGGTGAGACTTTGGAGGAACTTATGAAATTGTCTCCAGAA
GAGCTTCTGCTTAGATGGGCAAACTTTCATTTGGAAAACTCGGGCTGGCAAAAAATTAACAACTTTAG
TGCTGACATCAAGGATTCCAAAGCCTATTTCCATCTTCTCAATCAAATCGCACCAAAAGGACAAAAGG
AAGGTGAACCACGGATAGATATTAACATGTCAGGTTTCAATGAAACAGATGATTTGAAGAGAGCTGAG
AGTATGCTTCAACAAGCAGATAAATTAGGTTGCAGACAGTTTGTTACCCCTGCTGATGTTGTCAGTGG
AAACCCCAAACTCAACTTAGCTTTCGTGGCTAACCTGTTTAATAAATACCCAGCACTAACTAAGCCAG
AGAACCAGGATATTGACTGGACTCTATTAGAAGGAGAAACTCGTGAAGAAAGAACCTTCCGTAACTGG
ATGAACTCTCTTGGTGTCAATCCTCACGTAAACCATCTCTATGCTGACCTGCAAGATGCCCTGGTAAT
CTTACAGTTATATGAACGAATTAAAGTTCCTGTTGACTGGAGTAAGGTTAATAAACCTCCATACCCGA
AACTGGGAGCCAACATGAAAAAGCTAGAAAACTGCAACTATGCTGTTGAATTAGGGAAGCATCCTGCT
AAATTCTCCCTGGTTGGCATTGGAGGGCAAGACCTGAATGATGGGAACCAAACCCTGACTTTAGCTTT
AGTCTGGCAGCTGATGAGAAGATATACCCTCAATGTCCTGGAAGATCTTGGAGATGGTCAGAAAGCCA
ATGACGACATCATTGTGAACTGGGTGAACAGAACGTTGAGTGAAGCTGGAAAATCAACTTCCATTCAG
AGTTTTAAGGACAAGACGATCAGCTCCAGTTTGGCAGTTGTGGATTTAATTGATGCCATCCAGCCAGG
CTGTATAAACTATGACCTTGTGAAGAGTGGCAATCTAACAGAAGATGACAAGCACAATAATGCCAAGT
ATGCAGTGTCAATGGCTAGAAGAATCGGAGCCAGAGTGTATGCTCTCCCTGAAGACCTTGTGGAAGTA
AAGCCCAAGATGGTCATGACTGTGTTTGCATGTTTGATGGGCAGGGGAATGAAGAGAGTGTAA 
 
 
SIN-PGK-cPPT-GDNF-WHV 
 
TGGAAGGGCTAATTCACTCCCAAAGAAGACAAGATATCCTTGATCTGTGGATCTACCACACACAAGGC
TACTTCCCTGATTAGCAGAACTACACACCAGGGCCAGGGGTCAGATATCCACTGACCTTTGGATGGTG
CTACAAGCTAGTACCAGTTGAGCCAGATAAGGTAGAAGAGGCCAATAAAGGAGAGAACACCAGCTTGT
TACACCCTGTGAGCCTGCATGGGATGGATGACCCGGAGAGAGAAGTGTTAGAGTGGAGGTTTGACAGC
CGCCTAGCATTTCATCACGTGGCCCGAGAGCTGCATCCGGAGTACTTCAAGAACTGCTGATATCGAGC
TTGCTACAAGGGACTTTCCGCTGGGGACTTTCCAGGGAGGCGTGGCCTGGGCGGGACTGGGGAGTGGC
GAGCCCTCAGATCCTGCATATAAGCAGCTGCTTTTTGCCTGTACTGGGTCTCTCTGGTTAGACCAGAT
CTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAG
TGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAG
TCAGTGTGGAAAATCTCTAGCAGTGGCGCCCGAACAGGGACCTGAAAGCGAAAGGGAAACCAGAGCTC
TCTCGACGCAGGACTCGGCTTGCTGAAGCGCGCGCACGGCAAGAGGCGAGGGGCGGCGACTGGTGAGT
ACGCCAAAAATTTTGACTAGCGGAGGCTAGAAGGAGAGAGATGGGTGCGAGAGCGTCAGTATTAAGCG
GGGGAGAATTAGATCGCGATGGGAAAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAATTAA
AACATATAGTATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTAATCCTGGCCTGTTAGAAACATCA
GAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACAGGATCAGAAGAACTTAGATC
ATTATATAATACAGTAGCAACCCTCTATTGTGTGCATCAAAGGATAGAGATAAAAGACACCAAGGAAG
CTTTAGACAAGATAGAGGAAGAGCAAAACAAAAGTAAGACCACCGCACAGCAAGCGGCCGCTGATCTT
CAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTAGTAAAAA
TTGAACCATTAGGAGTAGCACCCACCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTG
GGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCCTCAATGAC
GCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTA
TTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAATCCTG
GCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGAAAACTCATTTG
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CACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTGGAATCACACGAC
CTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGCTTAATACACTCCTTAATTGAAGAATCGC
AAAACCAGCAAGAAAAGAATGAACAAGAATTATTGGAATTAGATAAATGGGCAAGTTTGTGGAATTGG
TTTAACATAACAAATTGGCTGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTGGTAGGTTT
AAGAATAGTTTTTGCTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATATTCACCATTATCGTTTC
AGACCCACCTCCCAACCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAGAGAGA
GACAGAGACAGATCCATTCGATTAGTGAACGGATCTCGACGGTATCGGTTAACTTTTAAAAGAAAAGG
GGGGATTGGGGGGTACAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAGACATACAAACTAAAG
AATTACAAAAACAAATTACAAAAATTCAAAATTTTATCGATGGTCGAGTACCGGGTAGGGGAGGCGCT
TTTCCCAAGGCAGTCTGGAGCATGCGCTTTAGCAGCCCCGCTGGGCACTTGGCGCTACACAAGTGGCC
TCTGGCCTCGCACACATTCCACATCCACCGGTAGGCGCCAACCGGCTCCGTTCTTTGGTGGCCCCTTC
GCGCCACCTTCTACTCCTCCCCTAGTCAGGAAGTTCCCCCCCGCCCCGCAGCTCGCGTCGTGCAGGAC
GTGACAAATGGAAGTAGCACGTCTCACTAGTCTCGTGCAGATGGACAGCACCGCTGAGCAATGGAAGC
GGGTAGGCCTTTGGGGCAGCGGCCAATAGCAGCTTTGCTCCTTCGCTTTCTGGGCTCAGAGGCTGGGA
AGGGGTGGGTCCGGGGGCGGGCTCAGGGGCGGGCTCAGGGGCGGGGCGGGCGCCCGAAGGTCCTCCGG
AGGCCCGGCATTCTGCACGCTTCAAAAGCGCACGTCTGCCGCGCTGTTCTCCTCTTCCTCATCTCCGG
GCCTTTCGACCTCTAGGATCCCGTCGAGAATTAGCTTCGCCACCATGAAGTTATGGGATGTCGTGGCT
GTCTGCCTGGTGCTGCTCCACACCGCGTCCGCCTTCCCGCTGCCCGCCGGTAAGAGGCCTCCCGAGGC
GCCCGCCGAAGACCGCTCCCTCGGCCGCCGCCGCGCGCCCTTCGCGCTGAGCAGTGACTCAAATATGC
CAGAGGATTATCCTGATCAGTTCGATGATGTCATGGATTTTATTCAAGCCACCATTAAAAGACTGAAA
AGGTCACCAGATAAACAAATGGCAGTGCTTCCTAGAAGAGAGCGGAATCGGCAGGCTGCAGCTGCCAA
CCCAGAGAATTCCAGAGGAAAAGGTCGGAGAGGCCAGAGGGGCAAAAACCGGGGTTGTGTCTTAACTG
CAATACATTTAAATGTCACTGACTTGGGTCTGGGCTATGAAACCAAGGAGGAACTGATTTTTAGGTAC
TGCAGCGGCTCTTGCGATGCAGCTGAGACAACGTACGACAAAATATTGAAAAACTTATCCAGAAATAG
AAGGCTGGTGAGTGACAAAGTAGGGCAGGCATGTTGCAGACCCATCGCCTTTGATGATGACCTGTCGT
TTTTAGATGATAACCTGGTTTACCATATTCTAAGAAAGCATTCCGCTAAAAGGTGTGGATGTATCTGA
GGATCAATTCACGCGTGGTACCTCTAGAGTCGACCCCCCTCGAGGGAATTCCGATAATCAACCTCTGG
ATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGCTCCTTTTACGCTATGTGGATAC
GCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCCCGTATGGCTTTCATTTTCTCCTCCTTGTATAA
ATCCTGGTTGCTGTCTCTTTATGAGGAGTTGTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTG
TGTTTGCTGACGCAACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGGACTTTC
GCTTTCCCCCTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGGGC
TCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCTGCTCG
CCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCCCTCAATCCAGCG
GACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGAC
GAGTCGGATCTCCCTTTGGGCCGCCTCCCCGCATCGGGAATTCGAGCTCGGTACCTTTAAAACCAATG
ACTTACAAGGCAGCTGTAAATCTTAGCCACTTTTTAAAAGAAAAGGGGGGACTGGAAGGGCTAATTCA
CTCCCAACGAAAACAAAATCTGCTTTTTGCTTGTACTGGGTCTCTCTGGTTAGACCAAATCTGAGCCT
GGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAA
GTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTCAAACCCTTTTAGTCAGTGTG
GAAAATCTCTAGCAGCATCTAGAATTAATTCCGTGTATTCTATAGTGTCACCTAAATCGTATGTGTAT
GATACATAAGGTTATGTATTAATTGTAGCCGCGTTCTAACGACAATATGTACAAGCCTAATTGTGTAG
CATCTGGCTTACTGAAGCAGACCCTATCATCTCTCTCGTAAACTGCCGTCAGAGTCGGTTTGGTTGGA
CGAACCTTCTGAGTTTCTGGTAACGCCGTCCCGCACCCGGAAATGGTCAGCGAACCAATCAGCAGGGT
CATCGCTAGCCAGATCCTCTACGCCGGACGCATCGTGGCCGGCATCACCGGCGCCACAGGTGCGGTTG
CTGGCGCCTATATCGCCGACATCACCGATGGGGAAGATCGGGCTCGCCACTTCGGGCTCATGAGCGCT
TGTTTCGGCGTGGGTATGGTGGCAGGCCCCGTGGCCGGGGGACTGTTGGGCGCCATCTCCTTGCATGC
ACCATTCCTTGCGGCGGCGGTGCTCAACGGCCTCAACCTACTACTGGGCTGCTTCCTAATGCAGGAGT
CGCATAAGGGAGAGCGTCGATATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCC
AGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTAC
AGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAAACGCGC
GAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGA
CGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCA
AATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTAT
GAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTC
ACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAA
CTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCAC
TTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCC
GCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGC
ATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCT
GACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCC
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TTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTA
GCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATT
AATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGT
TTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGAT
GGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAG
ACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATA
TACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAAT
CTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAA
AGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTAC
CAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGA
GCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGC
ACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTC
TTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCG
TGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGA
AAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAG
AGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTC
TGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGC
GGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTG
ATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAG
CGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTG
GCCGATTCATTAATGCAGCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGC
AGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCC
CAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCG
CCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTAT
TTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAG
GCCTAGGCTTTTGCAAAAAGCTTGGACACAAGACAGGCTTGCGAGATATGTTTGAGAATACCACTTTA
TCCCGCGTCAGGGAGAGGCAGTGCGTAAAAAGACGCGGACTCATGTGAAATACTGGTTTTTAGTGCGC
CAGATCTCTATAATCTCGCGCAACCTATTTTCCCCTCGAACACTTTTTAAGCCGTAGATAAACAGGCT
GGGACACTTCACATGAGCGAAAAATACATCGTCACCTGGGACATGTTGCAGATCCATGCACGTAAACT
CGCAAGCCGACTGATGCCTTCTGAACAATGGAAAGGCATTATTGCCGTAAGCCGTGGCGGTCTGTACC
GGGTGCGTTACTGGCGCGTGAACTGGGTATTCGTCATGTCGATACCGTTTGTATTTCCAGCTACGATC
ACGACAACCAGCGCGAGCTTAAAGTGCTGAAACGCGCAGAAGGCGATGGCGAAGGCTTCATCGTTATT
GATGACCTGGTGGATACCGGTGGTACTGCGGTTGCGATTCGTGAAATGTATCCAAAAGCGCACTTTGT
CACCATCTTCGCAAAACCGGCTGGTCGTCCGCTGGTTGATGACTATGTTGTTGATATCCCGCAAGATA
CCTGGATTGAACAGCCGTGGGATATGGGCGTCGTATTCGTCCCGCCAATCTCCGGTCGCTAATCTTTT
CAACGCCTGGCACTGCCGGGCGTTGTTCTTTTTAACTTCAGGCGGGTTACAATAGTTTCCAGTAAGTA
TTCTGGAGGCTGCATCCATGACACAGGCAAACCTGAGCGAAACCCTGTTCAAACCCCGCTTTAAACAT
CCTGAAACCTCGACGCTAGTCCGCCGCTTTAATCACGGCGCACAACCGCCTGTGCAGTCGGCCCTTGA
TGGTAAAACCATCCCTCACTGGTATCGCATGATTAACCGTCTGATGTGGATCTGGCGCGGCATTGACC
CACGCGAAATCCTCGACGTCCAGGCACGTATTGTGATGAGCGATGCCGAACGTACCGACGATGATTTA
TACGATACGGTGATTGGCTACCGTGGCGGCAACTGGATTTATGAGTGGGCCCCGGATCTTTGTGAAGG
AACCTTACTTCTGTGGTGTGACATAATTGGACAAACTACCTACAGAGATTTAAAGCTCTAAGGTAAAT
ATAAAATTTTTAAGTGTATAATGTGTTAAACTACTGATTCTAATTGTTTGTGTATTTTAGATTCCAAC
CTATGGAACTGATGAATGGGAGCAGTGGTGGAATGCCTTTAATGAGGAAAACCTGTTTTGCTCAGAAG
AAATGCCATCTAGTGATGATGAGGCTACTGCTGACTCTCAACATTCTACTCCTCCAAAAAAGAAGAGA
AAGGTAGAAGACCCCAAGGACTTTCCTTCAGAATTGCTAAGTTTTTTGAGTCATGCTGTGTTTAGTAA
TAGAACTCTTGCTTGCTTTGCTATTTACACCACAAAGGAAAAAGCTGCACTGCTATACAAGAAAATTA
TGGAAAAATATTCTGTAACCTTTATAAGTAGGCATAACAGTTATAATCATAACATACTGTTTTTTCTT
ACTCCACACAGGCATAGAGTGTCTGCTATTAATAACTATGCTCAAAAATTGTGTACCTTTAGCTTTTT
AATTTGTAAAGGGGTTAATAAGGAATATTTGATGTATAGTGCCTTGACTAGAGATCATAATCAGCCAT
ACCACATTTGTAGAGCTTTTACTTGCTTTAAAAAACCTCCCACACCTCCCCCTGAACCTGAAACATAA
AATGAATGCAATTGTTGTTGTTAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCA
TCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAAT
GTATCTTATCATGTGTGGATCAACTGGATAACTCAAGCTAACCAAAATCATCCCAAACTTCCCACCCC
ATACCCTATTACCACTGCCAAATTACCTGTGGTTTCATTTACTCTAAACCTGTGATTCCTCTGAATTA
TTTTCATTTTAAAGAAATTGTATTTGTTAAATATGTACTACAAACTTAGTAGT 
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TGGAAGGGCTAATTCACTCCCAAAGAAGACAAGATATCCTTGATCTGTGGATCTACCACACACAAGGC
TACTTCCCTGATTAGCAGAACTACACACCAGGGCCAGGGGTCAGATATCCACTGACCTTTGGATGGTG
CTACAAGCTAGTACCAGTTGAGCCAGATAAGGTAGAAGAGGCCAATAAAGGAGAGAACACCAGCTTGT
TACACCCTGTGAGCCTGCATGGGATGGATGACCCGGAGAGAGAAGTGTTAGAGTGGAGGTTTGACAGC
CGCCTAGCATTTCATCACGTGGCCCGAGAGCTGCATCCGGAGTACTTCAAGAACTGCTGATATCGAGC
TTGCTACAAGGGACTTTCCGCTGGGGACTTTCCAGGGAGGCGTGGCCTGGGCGGGACTGGGGAGTGGC
GAGCCCTCAGATCCTGCATATAAGCAGCTGCTTTTTGCCTGTACTGGGTCTCTCTGGTTAGACCAGAT
CTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAG
TGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAG
TCAGTGTGGAAAATCTCTAGCAGTGGCGCCCGAACAGGGACCTGAAAGCGAAAGGGAAACCAGAGCTC
TCTCGACGCAGGACTCGGCTTGCTGAAGCGCGCGCACGGCAAGAGGCGAGGGGCGGCGACTGGTGAGT
ACGCCAAAAATTTTGACTAGCGGAGGCTAGAAGGAGAGAGATGGGTGCGAGAGCGTCAGTATTAAGCG
GGGGAGAATTAGATCGCGATGGGAAAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAATTAA
AACATATAGTATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTAATCCTGGCCTGTTAGAAACATCA
GAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACAGGATCAGAAGAACTTAGATC
ATTATATAATACAGTAGCAACCCTCTATTGTGTGCATCAAAGGATAGAGATAAAAGACACCAAGGAAG
CTTTAGACAAGATAGAGGAAGAGCAAAACAAAAGTAAGACCACCGCACAGCAAGCGGCCGCTGATCTT
CAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTAGTAAAAA
TTGAACCATTAGGAGTAGCACCCACCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTG
GGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCCTCAATGAC
GCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTA
TTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAATCCTG
GCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGAAAACTCATTTG
CACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTGGAATCACACGAC
CTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGCTTAATACACTCCTTAATTGAAGAATCGC
AAAACCAGCAAGAAAAGAATGAACAAGAATTATTGGAATTAGATAAATGGGCAAGTTTGTGGAATTGG
TTTAACATAACAAATTGGCTGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTGGTAGGTTT
AAGAATAGTTTTTGCTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATATTCACCATTATCGTTTC
AGACCCACCTCCCAACCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAGAGAGA
GACAGAGACAGATCCATTCGATTAGTGAACGGATCTCGACGGTATCGGTTAACTTTTAAAAGAAAAGG
GGGGATTGGGGGGTACAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAGACATACAAACTAAAG
AATTACAAAAACAAATTACAAAAATTCAAAATTTTATCGATGGTCGAGTACCGGGTAGGGGAGGCGCT
TTTCCCAAGGCAGTCTGGAGCATGCGCTTTAGCAGCCCCGCTGGGCACTTGGCGCTACACAAGTGGCC
TCTGGCCTCGCACACATTCCACATCCACCGGTAGGCGCCAACCGGCTCCGTTCTTTGGTGGCCCCTTC
GCGCCACCTTCTACTCCTCCCCTAGTCAGGAAGTTCCCCCCCGCCCCGCAGCTCGCGTCGTGCAGGAC
GTGACAAATGGAAGTAGCACGTCTCACTAGTCTCGTGCAGATGGACAGCACCGCTGAGCAATGGAAGC
GGGTAGGCCTTTGGGGCAGCGGCCAATAGCAGCTTTGCTCCTTCGCTTTCTGGGCTCAGAGGCTGGGA
AGGGGTGGGTCCGGGGGCGGGCTCAGGGGCGGGCTCAGGGGCGGGGCGGGCGCCCGAAGGTCCTCCGG
AGGCCCGGCATTCTGCACGCTTCAAAAGCGCACGTCTGCCGCGCTGTTCTCCTCTTCCTCATCTCCGG
GCCTTTCGACCTCTAGGATCCACTAGTCCAGTGTGGTGGAATTGCCCTTGAGGTGCAGAAGTTGTCTG
AGTGCGTTGGTCGGCGGCAGTCGGGCCAGACCCAGGACTCTGCGACTTTACATCTTTAAATGGATGAG
ATGGCTACCACTCAGATTTCCAAAGATGAGCTTGATGAACTCAAAGAGGCCTTTGCAAAAGTTGATCT
CAACAGCAACGGATTCATTTGTGACTATGAACTTCATGAGCTCTTCAAGGAAGCTAATATGCCATTAC
CAGGATATAAAGTGAGAGAAATTATTCAGAAACTCATGCTGGATGGTGACAGGAATAAAGATGGGAAA
ATAAGTTTTGACGAATTTGTTTATATTTTTCAAGAGGTAAAAAGTAGTGATATTGCCAAGACCTTCCG
CAAAGCAATCAACAGGAAAGAAGGTATTTGTGCTCTGGGTGGAACTTCAGAGTTGTCCAGCGAAGGAA
CACAGCATTCTTACTCAGAGGAAGAAAAATATGCTTTTGTTAACTGGATAAACAAAGCTTTGGAAAAT
GATCCTGATTGTAGACATGTTATACCAATGAACCCTAACACCGATGACCTGTTCAAAGCTGTTGGTGA
TGGAATTGTGCTTTGTAAAATGATTAACCTTTCAGTTCCTGATACCATTGATGAAAGAGCAATCAACA
AGAAGAAACTTACACCCTTCATCATTCAGGAAAACTTGAACTTGGCACTGAACTCTGCTTCTGCCATT
GGGTGTCATGTTGTGAACATTGGTGCAGAAGATTTGAGGGCTGGGAAACCTCATCTGGTTTTGGGACT
GCTTTGGCAGATCATTAAGATCGGTTTGTTCGCTGACATTGAATTAAGCAGGAATGAAGCCTTGGCTG
CTTTACTCCGAGATGGTGAGACTTTGGAGGAACTTATGAAATTGTCTCCAGAAGAGCTTCTGCTTAGA
TGGGCAAACTTTCATTTGGAAAACTCGGGCTGGCAAAAAATTAACAACTTTAGTGCTGACATCAAGGA
TTCCAAAGCCTATTTCCATCTTCTCAATCAAATCGCACCAAAAGGACAAAAGGAAGGTGAACCACGGA
TAGATATTAACATGTCAGGTTTCAATGAAACAGATGATTTGAAGAGAGCTGAGAGTATGCTTCAACAA
GCAGATAAATTAGGTTGCAGACAGTTTGTTACCCCTGCTGATGTTGTCAGTGGAAACCCCAAACTCAA
CTTAGCTTTCGTGGCTAACCTGTTTAATAAATACCCAGCACTAACTAAGCCAGAGAACCAGGATATTG
ACTGGACTCTATTAGAAGGAGAAACTCGTGAAGAAAGAACCTTCCGTAACTGGATGAACTCTCTTGGT
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GTCAATCCTCACGTAAACCATCTCTATGCTGACCTGCAAGATGCCCTGGTAATCTTACAGTTATATGA
ACGAATTAAAGTTCCTGTTGACTGGAGTAAGGTTAATAAACCTCCATACCCGAAACTGGGAGCCAACA
TGAAAAAGCTAGAAAACTGCAACTATGCTGTTGAATTAGGGAAGCATCCTGCTAAATTCTCCCTGGTT
GGCATTGGAGGGCAAGACCTGAATGATGGGAACCAAACCCTGACTTTAGCTTTAGTCTGGCAGCTGAT
GAGAAGATATACCCTCAATGTCCTGGAAGATCTTGGAGATGGTCAGAAAGCCAATGACGACATCATTG
TGAACTGGGTGAACAGAACGTTGAGTGAAGCTGGAAAATCAACTTCCATTCAGAGTTTTAAGGACAAG
ACGATCAGCTCCAGTTTGGCAGTTGTGGATTTAATTGATGCCATCCAGCCAGGCTGTATAAACTATGA
CCTTGTGAAGAGTGGCAATCTAACAGAAGATGACAAGCACAATAATGCCAAGTATGCAGTGTCAATGG
CTAGAAGAATCGGAGCCAGAGTGTATGCTCTCCCTGAAGACCTTGTGGAAGTAAAGCCCAAGATGGTC
ATGACTGTGTTTGCATGTTTGATGGGCAGGGGAATGAAGAGAGTGTAAGGGCAATTCTGCAGATATCC
AGCACAGTGGCGGCCGCTCGAGGGAATTCCGATAATCAACCTCTGGATTACAAAATTTGTGAAAGATT
GACTGGTATTCTTAACTATGTTGCTCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATC
ATGCTATTGCTTCCCGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTAT
GAGGAGTTGTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCTGACGCAACCCCCAC
TGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGGACTTTCGCTTTCCCCCTCCCTATTGCCA
CGGCGGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAAT
TCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCTGCTCGCCTGTGTTGCCACCTGGATTCT
GCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGC
TGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCC
GCCTCCCCGCATCGGGAATTCGAGCTCGGTACCTTTAAAACCAATGACTTACAAGGCAGCTGTAAATC
TTAGCCACTTTTTAAAAGAAAAGGGGGGACTGGAAGGGCTAATTCACTCCCAACGAAAACAAAATCTG
CTTTTTGCTTGTACTGGGTCTCTCTGGTTAGACCAAATCTGAGCCTGGGAGCTCTCTGGCTAACTAGG
GAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGT
GTGACTCTGGTAACTAGAGATCCCTCAAACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGCATCTAG
AATTAATTCCGTGTATTCTATAGTGTCACCTAAATCGTATGTGTATGATACATAAGGTTATGTATTAA
TTGTAGCCGCGTTCTAACGACAATATGTACAAGCCTAATTGTGTAGCATCTGGCTTACTGAAGCAGAC
CCTATCATCTCTCTCGTAAACTGCCGTCAGAGTCGGTTTGGTTGGACGAACCTTCTGAGTTTCTGGTA
ACGCCGTCCCGCACCCGGAAATGGTCAGCGAACCAATCAGCAGGGTCATCGCTAGCCAGATCCTCTAC
GCCGGACGCATCGTGGCCGGCATCACCGGCGCCACAGGTGCGGTTGCTGGCGCCTATATCGCCGACAT
CACCGATGGGGAAGATCGGGCTCGCCACTTCGGGCTCATGAGCGCTTGTTTCGGCGTGGGTATGGTGG
CAGGCCCCGTGGCCGGGGGACTGTTGGGCGCCATCTCCTTGCATGCACCATTCCTTGCGGCGGCGGTG
CTCAACGGCCTCAACCTACTACTGGGCTGCTTCCTAATGCAGGAGTCGCATAAGGGAGAGCGTCGATA
TGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGACACCCGCCAACACC
CGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCG
GGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAAACGCGCGAGACGAAAGGGCCTCGTGATA
CGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGG
AAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGAC
AATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTC
GCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGT
AAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGA
TCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGC
GCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGA
CTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCA
GTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAG
GAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCT
GAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCA
AACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGAT
AAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGC
CGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAG
TTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCC
TCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACT
TCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAAC
GTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTT
TTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGA
TCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCC
TTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTG
CTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACG
ATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGC
GAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGG
AGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGG
GGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGT
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GATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCC
TTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTAC
CGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGG
AAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGT
GGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATG
CATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAG
CATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGC
CCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCC
TCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCT
TGGACACAAGACAGGCTTGCGAGATATGTTTGAGAATACCACTTTATCCCGCGTCAGGGAGAGGCAGT
GCGTAAAAAGACGCGGACTCATGTGAAATACTGGTTTTTAGTGCGCCAGATCTCTATAATCTCGCGCA
ACCTATTTTCCCCTCGAACACTTTTTAAGCCGTAGATAAACAGGCTGGGACACTTCACATGAGCGAAA
AATACATCGTCACCTGGGACATGTTGCAGATCCATGCACGTAAACTCGCAAGCCGACTGATGCCTTCT
GAACAATGGAAAGGCATTATTGCCGTAAGCCGTGGCGGTCTGTACCGGGTGCGTTACTGGCGCGTGAA
CTGGGTATTCGTCATGTCGATACCGTTTGTATTTCCAGCTACGATCACGACAACCAGCGCGAGCTTAA
AGTGCTGAAACGCGCAGAAGGCGATGGCGAAGGCTTCATCGTTATTGATGACCTGGTGGATACCGGTG
GTACTGCGGTTGCGATTCGTGAAATGTATCCAAAAGCGCACTTTGTCACCATCTTCGCAAAACCGGCT
GGTCGTCCGCTGGTTGATGACTATGTTGTTGATATCCCGCAAGATACCTGGATTGAACAGCCGTGGGA
TATGGGCGTCGTATTCGTCCCGCCAATCTCCGGTCGCTAATCTTTTCAACGCCTGGCACTGCCGGGCG
TTGTTCTTTTTAACTTCAGGCGGGTTACAATAGTTTCCAGTAAGTATTCTGGAGGCTGCATCCATGAC
ACAGGCAAACCTGAGCGAAACCCTGTTCAAACCCCGCTTTAAACATCCTGAAACCTCGACGCTAGTCC
GCCGCTTTAATCACGGCGCACAACCGCCTGTGCAGTCGGCCCTTGATGGTAAAACCATCCCTCACTGG
TATCGCATGATTAACCGTCTGATGTGGATCTGGCGCGGCATTGACCCACGCGAAATCCTCGACGTCCA
GGCACGTATTGTGATGAGCGATGCCGAACGTACCGACGATGATTTATACGATACGGTGATTGGCTACC
GTGGCGGCAACTGGATTTATGAGTGGGCCCCGGATCTTTGTGAAGGAACCTTACTTCTGTGGTGTGAC
ATAATTGGACAAACTACCTACAGAGATTTAAAGCTCTAAGGTAAATATAAAATTTTTAAGTGTATAAT
GTGTTAAACTACTGATTCTAATTGTTTGTGTATTTTAGATTCCAACCTATGGAACTGATGAATGGGAG
CAGTGGTGGAATGCCTTTAATGAGGAAAACCTGTTTTGCTCAGAAGAAATGCCATCTAGTGATGATGA
GGCTACTGCTGACTCTCAACATTCTACTCCTCCAAAAAAGAAGAGAAAGGTAGAAGACCCCAAGGACT
TTCCTTCAGAATTGCTAAGTTTTTTGAGTCATGCTGTGTTTAGTAATAGAACTCTTGCTTGCTTTGCT
ATTTACACCACAAAGGAAAAAGCTGCACTGCTATACAAGAAAATTATGGAAAAATATTCTGTAACCTT
TATAAGTAGGCATAACAGTTATAATCATAACATACTGTTTTTTCTTACTCCACACAGGCATAGAGTGT
CTGCTATTAATAACTATGCTCAAAAATTGTGTACCTTTAGCTTTTTAATTTGTAAAGGGGTTAATAAG
GAATATTTGATGTATAGTGCCTTGACTAGAGATCATAATCAGCCATACCACATTTGTAGAGCTTTTAC
TTGCTTTAAAAAACCTCCCACACCTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTT
AACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGC
ATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTGTGGATCA
ACTGGATAACTCAAGCTAACCAAAATCATCCCAAACTTCCCACCCCATACCCTATTACCACTGCCAAA
TTACCTGTGGTTTCATTTACTCTAAACCTGTGATTCCTCTGAATTATTTTCATTTTAAAGAAATTGTA
TTTGTTAAATATGTACTACAAACTTAGTAGT 
 
scAAV-CMV-PLS3 (FULL) 
 
AAAGCTTCCCGGGGGGATCTGGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGAC
CAAAGGTCGCCCGACGCCCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGA
GTGGCCAACTCCATCACTAGGGGTTCCTGGAGGGGTGGAGTCGTGACCCCTAAAATGGGCAAACATTG
CGCTAGCGCGGCCGCGGTACCTACCGATGTACGGGCCAGATATACGCGTTAGTTATTAATAGTAATCA
ATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCC
GCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGC
CAATAGGGACTTTCCATTGACGTCAATGGGTGGACTATTTACGGTAAACTGCCCACTTGGCAGTACAT
CAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTA
TGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTA
CCATGGGAATTCTGCAGTCGACGGTACCGCGGGCCCGGGATCCACCGGTCGCCACCATGGTGAGCAAG
GGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAA
GTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCA
CCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTC
AGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCA
GGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCG
ACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCAC
AAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAA
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GGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGA
ACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTG
AGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCAC
TCTCGGCATGGACGAGCTGTACAAGTAAAGCGGCCGCGACTCTAGAGTCGACCTGCAGGGAAGACCAA
GCTGACCTGACTCGATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAG
CTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGG
AGGTTTTTTAAACTAGTCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGG
TCGCCCGACGCCCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGACAGATC
CGGGCCCGCATGCGTCGACAATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCG
TTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGC
ACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGCGCCTGATGCGGTATTTTCTCCT
TACGCATCTGTGCGGTATTTCACACCGCATATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCAT
AGTTAAGCCAGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCA
TCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACC
GAAACGCGCGAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGG
TTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAA
ATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAG
GAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTG
TTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGT
TACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAAT
GATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAAC
TCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTT
ACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAA
CTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATG
TAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACG
ATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCG
GCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGG
CTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTG
GGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGA
ACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTT
ACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTT
TTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGA
AAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAAC
CACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGC
TTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAA
CTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATA
AGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACG
GGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGA
GCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCG
GAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTT
CGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGC
CAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGT
TATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGA
ACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCC
CGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGC
GCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCT
CGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGC
CAAGCTCTCGAGATCTAG 
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194 
 
scAAV-CMV-PLS3 
 
AAAGCTTCCCGGGGGGATCTGGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGAC
CAAAGGTCGCCCGACGCCCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGA
GTGGCCAACTCCATCACTAGGGGTTCCTGGAGGGGTGGAGTCGTGACCCCTAAAATGGGCAAACATTG
CGCTAGCGCGGCCGCGGTACCTACCGATGTACGGGCCAGATATACGCGTTGACATTGATTATTGACTA
GTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAA
CTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTA
TGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGACTATTTACGGTAAACTG
CCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAA
TGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGT
ATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTG
ACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAA
CGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTG
GGAGGTCTATATAAGCAGAGCTCTCTGGCTAACTAGAGAACCCACTGCTTACTGGCTTATCGAAATTA
ATACGACTCACTATAGGGAGACCCAAGCTGGCTAGCGTTTAAACTTAAGCTTGGTACCGAGCTCGGAT
CCACTAGTCCAGTGTGGTGGAATTGCCCTTGAGGTGCAGAAGTTGTCTGAGTGCGTTGGTCGGCGGCA
GTCGGGCCAGACCCAGGACTCTGCGACTTTACATCTTTAAATGGATGAGATGGCTACCACTCAGATTT
CCAAAGATGAGCTTGATGAACTCAAAGAGGCCTTTGCAAAAGTTGATCTCAACAGCAACGGATTCATT
TGTGACTATGAACTTCATGAGCTCTTCAAGGAAGCTAATATGCCATTACCAGGATATAAAGTGAGAGA
AATTATTCAGAAACTCATGCTGGATGGTGACAGGAATAAAGATGGGAAAATAAGTTTTGACGAATTTG
TTTATATTTTTCAAGAGGTAAAAAGTAGTGATATTGCCAAGACCTTCCGCAAAGCAATCAACAGGAAA
GAAGGTATTTGTGCTCTGGGTGGAACTTCAGAGTTGTCCAGCGAAGGAACACAGCATTCTTACTCAGA
GGAAGAAAAATATGCTTTTGTTAACTGGATAAACAAAGCTTTGGAAAATGATCCTGATTGTAGACATG
TTATACCAATGAACCCTAACACCGATGACCTGTTCAAAGCTGTTGGTGATGGAATTGTGCTTTGTAAA
ATGATTAACCTTTCAGTTCCTGATACCATTGATGAAAGAGCAATCAACAAGAAGAAACTTACACCCTT
CATCATTCAGGAAAACTTGAACTTGGCACTGAACTCTGCTTCTGCCATTGGGTGTCATGTTGTGAACA
TTGGTGCAGAAGATTTGAGGGCTGGGAAACCTCATCTGGTTTTGGGACTGCTTTGGCAGATCATTAAG
ATCGGTTTGTTCGCTGACATTGAATTAAGCAGGAATGAAGCCTTGGCTGCTTTACTCCGAGATGGTGA
GACTTTGGAGGAACTTATGAAATTGTCTCCAGAAGAGCTTCTGCTTAGATGGGCAAACTTTCATTTGG
AAAACTCGGGCTGGCAAAAAATTAACAACTTTAGTGCTGACATCAAGGATTCCAAAGCCTATTTCCAT
CTTCTCAATCAAATCGCACCAAAAGGACAAAAGGAAGGTGAACCACGGATAGATATTAACATGTCAGG
TTTCAATGAAACAGATGATTTGAAGAGAGCTGAGAGTATGCTTCAACAAGCAGATAAATTAGGTTGCA
GACAGTTTGTTACCCCTGCTGATGTTGTCAGTGGAAACCCCAAACTCAACTTAGCTTTCGTGGCTAAC
CTGTTTAATAAATACCCAGCACTAACTAAGCCAGAGAACCAGGATATTGACTGGACTCTATTAGAAGG
AGAAACTCGTGAAGAAAGAACCTTCCGTAACTGGATGAACTCTCTTGGTGTCAATCCTCACGTAAACC
ATCTCTATGCTGACCTGCAAGATGCCCTGGTAATCTTACAGTTATATGAACGAATTAAAGTTCCTGTT
GACTGGAGTAAGGTTAATAAACCTCCATACCCGAAACTGGGAGCCAACATGAAAAAGCTAGAAAACTG
CAACTATGCTGTTGAATTAGGGAAGCATCCTGCTAAATTCTCCCTGGTTGGCATTGGAGGGCAAGACC
TGAATGATGGGAACCAAACCCTGACTTTAGCTTTAGTCTGGCAGCTGATGAGAAGATATACCCTCAAT
GTCCTGGAAGATCTTGGAGATGGTCAGAAAGCCAATGACGACATCATTGTGAACTGGGTGAACAGAAC
GTTGAGTGAAGCTGGAAAATCAACTTCCATTCAGAGTTTTAAGGACAAGACGATCAGCTCCAGTTTGG
CAGTTGTGGATTTAATTGATGCCATCCAGCCAGGCTGTATAAACTATGACCTTGTGAAGAGTGGCAAT
CTAACAGAAGATGACAAGCACAATAATGCCAAGTATGCAGTGTCAATGGCTAGAAGAATCGGAGCCAG
AGTGTATGCTCTCCCTGAAGACCTTGTGGAAGTAAAGCCCAAGATGGTCATGACTGTGTTTGCATGTT
TGATGGGCAGGGGAATGAAGAGAGTGTAAAAGGGCAATTCTGCAGATTAAGCTGCAATAAACAAGTTA
ACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAACTAGT
CCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGC
TTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGACAGATCCGGGCCCGCATGCGTCG
ACAATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGC
CTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCA
ACAGTTGCGCAGCCTGAATGGCGAATGGCGCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTA
TTTCACACCGCATATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGA
CACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGC
TGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAAACGCGCGAGACGAA
AGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGT
GGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTA
TCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTC
AACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAA
ACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCT
CAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAG
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TTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACAC
TATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGT
AAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGA
TCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGT
TGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGC
AACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACT
GGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCT
GATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCC
CTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCG
CTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAG
ATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGAC
CAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTT
CTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTG
GTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGAT
ACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTA
CATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGG
TTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACA
GCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCA
CGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACG
AGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGA
GCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTT
TACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTG
GATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGA
GTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTC
ATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTG
AGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAAT
TGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTCTCGAGATCTA
G 
 
 
PAAV CMV MCS (conventional AAV) 
 
CCTGCAGGCAGCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCAAAGCCCGGGCGTCGGGCGACC
TTTGGTCGCCCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGG
TTCCTGCGGCCGCACGCGTGGAGCTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCC
CATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCC
CGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGTCAATAGGGACTTTCCATTGACGTCA
ATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGC
CCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGAC
TTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTA
CATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATG
GGAGTTTGTTTTGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGC
AAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATC
GCCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGATCCAGCCTCCGCGG
ATTCGAATCCCGGCCGGGAACGGTGCATTGGAACGCGGATTCCCCGTGCCAAGAGTGACGTAAGTACC
GCCTATAGAGTCTATAGGCCCACAAAAAATGCTTTCTTCTTTTAATATACTTTTTTGTTTATCTTATT
TCTAATACTTTCCCTAATCTCTTTCTTTCAGGGCAATAATGATACAATGTATCATGCCTCTTTGCACC
ATTCTAAAGAATAACAGTGATAATTTCTGGGTTAAGGCAATAGCAATATTTCTGCATATAAATATTTC
TGCATATAAATTGTAACTGATGTAAGAGGTTTCATATTGCTAATAGCAGCTACAATCCAGCTACCATT
CTGCTTTTATTTTATGGTTGGGATAAGGCTGGATTATTCTGAGTCCAAGCTAGGCCCTTTTGCTAATC
ATGTTCATACCTCTTATCTTCCTCCCACAGCTCCTGGGCAACGTGCTGGTCTGTGTGCTGGCCCATCA
CTTTGGCAAAGAATTGGGATTCGAACATCGATTGAATTCCCCGGGGATCCTCTAGAGTCGACCTGCAG
AAGCTTGCCTCGAGCAGCGCTGCTCGAGAGATCTACGGGTGGCATCCCTGTGACCCCTCCCCAGTGCC
TCTCCTGGCCCTGGAAGTTGCCACTCCAGTGCCCACCAGCCTTGTCCTAATAAAATTAAGTTGCATCA
TTTTGTCTGACTAGGTGTCCTTCTATAATATTATGGGGTGGAGGGGGGTGGTATGGAGCAAGGGGCAA
GTTGGGAAGACAACCTGTAGGGCCTGCGGGGTCTATTGGGAACCAAGCTGGAGTGCAGTGGCACAATC
TTGGCTCACTGCAATCTCCGCCTCCTGGGTTCAAGCGATTCTCCTGCCTCAGCCTCCCGAGTTGTTGG
GATTCCAGGCATGCATGACCAGGCTCAGCTAATTTTTGTTTTTTTGGTAGAGACGGGGTTTCACCATA
TTGGCCAGGCTGGTCTCCAACTCCTAATCTCAGGTGATCTACCCACCTTGGCCTCCCAAATTGCTGGG
ATTACAGGCGTGAACCACTGCTCCCTTCCCTGTCCTTCTGATTTTGTAGGTAACCACGTGCGGACCGA
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GCGGCCGCAGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGG
CCGGGCGACCAAAGGTCGCCCGACGCCCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGC
AGCTGCCTGCAGGGGCGCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTCACACCGCAT
ACGTCAAAGCAACCATAGTACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCG
CAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCG
CCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCT
TTACGGCACCTCGACCCCAAAAAACTTGATTTGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATA
GACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAA
CAACACTCAACCCTATCTCGGGCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGG
TTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGTTTACAATTTT
ATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGACACCCGCCAACAC
CCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCC
GGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAAACGCGCGAGACGAAAGGGCCTCGTGAT
ACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGG
GAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGA
CAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGT
CGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAG
TAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAG
ATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGG
CGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATG
ACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGC
AGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAA
GGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGC
TGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGC
AAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGA
TAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAG
CCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTA
GTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGC
CTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAAC
TTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAA
CGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTT
TTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGG
ATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTC
CTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCT
GCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGAC
GATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAG
CGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGG
GAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAG
GGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTG
TGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGC
CTTTTGCTGGCCTTTTGCTCACATGT 
 
 
AAV-PLS3 
 
CCTGCAGGCAGCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCAAAGCCCGGGCGTCGGGCGACC
TTTGGTCGCCCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATACTAGGGGT
TCCTGCGGCCGCACGCGTGGAGCTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCC
ATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTACCGCCCAACGACCCCCG
CCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGTCAATAGGGACTTTCCATTGACGTCAAT
GGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATAAGTGTATCATATGCCAAGTACGCCCC
CTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTT
CCTACTTGGCAGTACATCTACGTATTAGTCATGCTATTACCATGGTGATGCGGTTTTGGCAGTACATC
AATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAG
TTTGTTTTGCACCAAAATCAACGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATG
GGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATCGCCTG
GAGACGCCATCCACCTGTTTTGACCTCCATAGAAGACACCGGGACCGATCCAGCCTCCGCGGATTCGA
ATCCCGGCCGGGAACGGTGCATTGGAACGCGGATTCCCCGTGCCAAGAGTGACGTAAGTACCGCCTAT
AGAGTTATAGGCCCACAAAAAATGCTTTCTTCTTTTAATATACTTTTTTGTTTATCTTATTTCTAATA
CTTTCCCTAATCTCTTTCTTTCAGGGCAATAATGATACAATGTATCATGCCTCTTTGCACCATTTAAA
GAATAACAGTGATAATTTCTGGGTTAAGGCAATAGCAATATTTCTGCATATAAATATTTCTGCATATA
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AATTGTAACTGATGTAAGAGGTTTCATATTGCTAATAGCAGCTACAATCCAGCTACATTCTGCTTTTA
TTTTATGGTTGGGATAAGGCTGGATTATTCTGAGTCCAAGCTAGGCCCTTTTGCTAATCATGTTCATA
CCTCTTATCTTCCTCCCACAGCTCCTGGGCAACGTGCTGGTCTGTGGCTGGCCCATCACTTTGGCAAA
GAATTGGGATTCGAACATCGATTGaattcGCCACCATGGATGAGATGGCTACCACTCAGATTTCCAAA
GATGAGCTTGATGAACTCAAAGAGGCCTTTGCAAAAGTTGATCTCAACAGCAACGGATTCATTTGTGA
CTATGAACTTCATGAGCTCTTCAAGGAAGCTAATATGCCATTACCAGGATATAAAGTGAGAGAAATTA
TTCAGAAACTCATGCTGGATGGTGACAGGAATAAAGATGGGAAAATAAGTTTTGACGAATTTGTTTAT
ATTTTTCAAGAGGTAAAAAGTAGTGATATTGCCAAGACCTTCCGCAAAGCAATCAACAGGAAAGAAGG
TATTTGTGCTCTGGGTGGAACTTCAGAGTTGTCCAGCGAAGGAACACAGCATTCTTACTCAGAGGAAG
AAAAATATGCTTTTGTTAACTGGATAAACAAAGCTTTGGAAAATGATCCTGATTGTAGACATGTTATA
CCAATGAACCCTAACACCGATGACCTGTTCAAAGCTGTTGGTGATGGAATTGTGCTTTGTAAAATGAT
TAACCTTTCAGTTCCTGATACCATTGATGAAAGAGCAATCAACAAGAAGAAACTTACACCCTTCATCA
TTCAGGAAAACTTGAACTTGGCACTGAACTCTGCTTCTGCCATTGGGTGTCATGTTGTGAACATTGGT
GCAGAAGATTTGAGGGCTGGGAAACCTCATCTGGTTTTGGGACTGCTTTGGCAGATCATTAAGATCGG
TTTGTTCGCTGACATTGAATTAAGCAGGAATGAAGCCTTGGCTGCTTTACTCCGAGATGGTGAGACTT
TGGAGGAACTTATGAAATTGTCTCCAGAAGAGCTTCTGCTTAGATGGGCAAACTTTCATTTGGAAAAC
TCGGGCTGGCAAAAAATTAACAACTTTAGTGCTGACATCAAGGATTCCAAAGCCTATTTCCATCTTCT
CAATCAAATCGCACCAAAAGGACAAAAGGAAGGTGAACCACGGATAGATATTAACATGTCAGGTTTCA
ATGAAACAGATGATTTGAAGAGAGCTGAGAGTATGCTTCAACAAGCAGATAAATTAGGTTGCAGACAG
TTTGTTACCCCTGCTGATGTTGTCAGTGGAAACCCCAAACTCAACTTAGCTTTCGTGGCTAACCTGTT
TAATAAATACCCAGCACTAACTAAGCCAGAGAACCAGGATATTGACTGGACTCTATTAGAAGGAGAAA
CTCGTGAAGAAAGAACCTTCCGTAACTGGATGAACTCTCTTGGTGTCAATCCTCACGTAAACCATCTC
TATGCTGACCTGCAAGATGCCCTGGTAATCTTACAGTTATATGAACGAATTAAAGTTCCTGTTGACTG
GAGTAAGGTTAATAAACCTCCATACCCGAAACTGGGAGCCAACATGAAAAAGCTAGAAAACTGCAACT
ATGCTGTTGAATTAGGGAAGCATCCTGCTAAATTCTCCCTGGTTGGCATTGGAGGGCAAGACCTGAAT
GATGGGAACCAAACCCTGACTTTAGCTTTAGTCTGGCAGCTGATGAGAAGATATACCCTCAATGTCCT
GGAAGATCTTGGAGATGGTCAGAAAGCCAATGACGACATCATTGTGAACTGGGTGAACAGAACGTTGA
GTGAAGCTGGAAAATCAACTTCCATTCAGAGTTTTAAGGACAAGACGATCAGCTCCAGTTTGGCAGTT
GTGGATTTAATTGATGCCATCCAGCCAGGCTGTATAAACTATGACCTTGTGAAGAGTGGCAATCTAAC
AGAAGATGACAAGCACAATAATGCCAAGTATGCAGTGTCAATGGCTAGAAGAATCGGAGCCAGAGTGT
ATGCTCTCCCTGAAGACCTTGTGGAAGTAAAGCCCAAGATGGTCATGACTGTGTTTGCATGTTTGATG
GGCAGGGGAATGAAGAGAGTGTAAtCTAGAGTCGACCTGCAGAAGCTTGCCTCGAGCAGCGCTGCTCG
AGAGATCTACGGGTGGCATCCTGTGACCCCTCCCCAGTGCCTCTCCTGGCCCTGGAAGTTGCCACTCC
AGTGCCCACCAGCCTTGTCCTAATAAAATTAAGTTGCATCATTTTGTCTGACTAGGTGTCCTTCTATA
ATATTATGGGGTGAGGGGGGTGGTATGGAGCAAGGGGCAAGTTGGGAAGACAACCTGTAGGGCCTGCG
GGGTCTATTGGGAACCAAGCTGGAGTGCAGTGGCACAATCTTGGCTCACTGCAATCTCCGCCTCCTGG
GTTAAGCGATTCTCCTGCCTCAGCCTCCCGAGTTGTTGGGATTCCAGGCATGCATGACCAGGCTCAGC
TAATTTTTGTTTTTTTGGTAGAGACGGGGTTTCACCATATTGGCCAGGCTGGTCTCCAACTCTAATCT
CAGGTGATCTACCCACCTTGGCCTCCCAAATTGCTGGGATTACAGGCGTGAACCACTGCTCCCTTCCC
TGTCCTTCTGATTTTGTAGGTAACCACGTGCGGACCGAGCGGCCGCAGGAACCCTAGTGATGGAGTTG
GCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGG
CTTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCAGCTGCCGCAGGGGCGCCTGATGCGGTATTT
TCTCCTTACGCATCTGTGCGGTATTTCACACCGCATACGTCAAAGCAACCATAGTACGCGCCCTGTAG
CGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCCAGCGTGACCGCTACACTTGCCAGCGCCCTAGC
GCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAA
ATCGGGGGCTCCCTTTAGGGTTCCGATTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTTGG
GTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACG
TTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGGCTATTCTTTTGA
TTTATAAGGGATTTTGCCGATTTGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGC
GAATTTTAACAAAATATTAACGTTTACAATTTTATGGTGCACTCTCAGTACAATCTGCTCTGATGCCG
CATAGTTAAGCCAGCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGG
CATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCA
CCGAACGCGCGAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATG
GTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTCTAA
ATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAG
GAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTGCCTTCCTGT
TTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTT
ACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCGAAGAACGTTTTCCAATGA
TGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTC
GGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGGTACTCACCAGTCACAGAAAAGCATCTTACG
GATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTT
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ACTTCTGACAACGATCGGAGGACCGAAGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAAC
TCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGC
CTGTAGCAATGGCAACAACTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAAC
AATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGC
TGGTTTATTGTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCA
GATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAA
TGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAAGACAGATCGCTGAGATAGGTGCC
TCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACT
TCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTGATAATCTCATGACCAAAATCCCTTAACG
TGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTT
TTCTGCGCGTAATCTGCTGCTTGCAAAAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATC
AAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTT
CTAGTGTAGCCGTAGTTAGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTA
ATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATA
GTTACCGGAAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAAC
GACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAA
GGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAA
ACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTGTGATGCT
CGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGC
TGGCCTTTTGCTCACATGT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
